[
	{
		"amg_number" : "ABP 206",
		"product" : "ABP 206",
		"name" : "5440028.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "PD-1",
		"current_phase" : "Preclinical",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "ABP 206",
		"indication_description" : "CANCER - SOLID TUMORS",
		"business_partner" : "",
		"portfolio_priority" : "Standard",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "ABP 215",
		"product" : "Mvasi",
		"name" : "5289982.03",
		"trade_name" : "MVASI",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "VEGF",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "bevacizumab biosimilar",
		"indication_description" : "ONCOLOGY",
		"business_partner" : "",
		"portfolio_priority" : "Standard",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "ABP 215",
		"product" : "Mvasi",
		"name" : "5289982.02",
		"trade_name" : "MVASI",
		"notepad" : "MVASI® (formerly ABP 215 - biosimilar bevacizumab) is an anti-vascular endothelial growth factor receptor (VEGFR) monoclonal antibody.  The reference product primary conditions are  indications are colorectal cancer (CRC), non-small cell lung cancer (NSCLC), Breast cancer (BC) and renal cell carcinoma (RCC)",
		"modality" : "mAb",
		"target" : "VEGF",
		"current_phase" : "Launch",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "bevacizumab biosimilar",
		"indication_description" : "ONCOLOGY",
		"business_partner" : "",
		"portfolio_priority" : "Standard",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "ABP 215",
		"product" : "bevacizumab biosimilar",
		"name" : "5289028.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "VEGF",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "bevacizumab biosimilar",
		"indication_description" : "CANCER - SOLID TUMORS",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "ABP 234",
		"product" : "ABP 234",
		"name" : "5428982.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "PD-1",
		"current_phase" : "Preclinical",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "ABP 234",
		"indication_description" : "ONCOLOGY",
		"business_partner" : "",
		"portfolio_priority" : "Standard",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "ABP 443",
		"product" : "ABP 443",
		"name" : "5396982.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "HER2",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "ABP 443",
		"indication_description" : "ONCOLOGY",
		"business_partner" : "",
		"portfolio_priority" : "Close Out",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "ABP 494",
		"product" : "ABP 494",
		"name" : "5303982.01",
		"trade_name" : "",
		"notepad" : "ABP 494 (biosimilar cetuximab) is an anti-epidermal growth factor receptor (anti-EGFr) monoclonal antibody. It is in pre-clinical development. The reference product primary conditions are colorectal cancer and head and neck cancer. Amgen is developing ABP 494 in collaboration with Allergan.",
		"modality" : "mAb",
		"target" : "Anti-EGRF (BS Erbitux)",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "ABP 494",
		"indication_description" : "ONCOLOGY",
		"business_partner" : "",
		"portfolio_priority" : "Gated",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "ABP 501",
		"product" : "Amgevita",
		"name" : "5286072.01",
		"trade_name" : "",
		"notepad" : "AMGEVITA (formerly ABP 501 - biosimilar adalimumab) inhibits binding of TNF-alpha to cell surface TNF receptors \/ TNF-alpha.  The reference product primary conditions are Rheumatoid arthritis (RA), Crohns disease, Psoriasis, Arthritis Psoriatic and ulcerative colitis.",
		"modality" : "mAb",
		"target" : "TNF alpha",
		"current_phase" : "Launch",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "adalimumab biosimilar",
		"indication_description" : "RHEUMATOID ARTHRITIS - MUSCULO-SKELETAL",
		"business_partner" : "",
		"portfolio_priority" : "Standard",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "ABP 501",
		"product" : "Amgevita",
		"name" : "5286984.02",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "TNF alpha",
		"current_phase" : "",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "adalimumab biosimilar",
		"indication_description" : "INFLAMMATION",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "ABP 654",
		"product" : "ABP 654",
		"name" : "5397984.01",
		"trade_name" : "",
		"notepad" : "ABP 654 is an investigational biosimilar to STELARA® (ustekinumab), which is a monoclonal antibody that inhibits IL-12 and IL-23. ;;ADDITIONAL INFORMATION;;STELARA is a registered trademark of Johnson & Johnson.",
		"modality" : "mAb",
		"target" : "IL-12\/IL-23",
		"current_phase" : "Phase 3",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "ABP 654",
		"indication_description" : "INFLAMMATION",
		"business_partner" : "",
		"portfolio_priority" : "Standard",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "ABP 692",
		"product" : "ABP 692",
		"name" : "5455080.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "CD-20",
		"current_phase" : "Preclinical",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "ABP 692",
		"indication_description" : "MULTIPLE SCLEROSIS",
		"business_partner" : "",
		"portfolio_priority" : "Standard",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "ABP 710",
		"product" : "AVSOLA",
		"name" : "5301984.01",
		"trade_name" : "AVSOLA",
		"notepad" : "AVSOLA® (formerly ABP 710 - biosimilar infliximab) is an anti-tumour necrosis factor-alpha (anti-TNF) monoclonal antibody. The reference product primary conditions are rheumatoid arthritis, plaque psoriasis, Crohn s disease, ulcerative colitis, psoriatic arthritis, and ankylosing spondylitis.",
		"modality" : "mAb",
		"target" : "TNF alpha",
		"current_phase" : "Launch",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "infliximab biosimilar",
		"indication_description" : "INFLAMMATION",
		"business_partner" : "",
		"portfolio_priority" : "Standard",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "ABP 798",
		"product" : "RIABNI",
		"name" : "5302984.03",
		"trade_name" : "",
		"notepad" : "RIABNI  (formerly ABP 798 (rituximab), a biosimilar candidate to Rituxan®\/MabThera , is an anti-CD20 monoclonal antibody. Amgen is developing ABP 798 in a collaboration with Allergan since 2011. Allergan was acquired by AbbVie in May 2020.;;Additional Information;;Rituxan is a registered trademark of Biogen MA Inc.  MabThera  is a trademark of F. Hoffmann-La Roche Ltd.",
		"modality" : "mAb",
		"target" : "Anti-CD20",
		"current_phase" : "Launch",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "rituximab biosimilar",
		"indication_description" : "INFLAMMATION",
		"business_partner" : "",
		"portfolio_priority" : "Standard",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "ABP 798",
		"product" : "RIABNI",
		"name" : "5302982.01",
		"trade_name" : "",
		"notepad" : "RIABNI  (formerly ABP 798 (rituximab), a biosimilar candidate to Rituxan®\/MabThera , is an anti-CD20 monoclonal antibody. ;;Additional Information;; Amgen is developing ABP 798 in a collaboration with Allergan since 2011. Allergan was acquired by AbbVie in May 2020. Rituxan is a registered trademark of Biogen MA Inc.  MabThera  is a trademark of F. Hoffmann-La Roche Ltd.",
		"modality" : "mAb",
		"target" : "Anti-CD20",
		"current_phase" : "Launch",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "rituximab biosimilar",
		"indication_description" : "ONCOLOGY",
		"business_partner" : "",
		"portfolio_priority" : "Standard",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "ABP 895",
		"product" : "ABP 895",
		"name" : "5361986.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "α4-integrin",
		"current_phase" : "",
		"medical_therapeutic_area" : "Neuroscience",
		"generic_name" : "ABP 895",
		"indication_description" : "NEUROSCIENCE",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "ABP 938",
		"product" : "ABP 938",
		"name" : "5362132.01",
		"trade_name" : "",
		"notepad" : "ABP 938 is an investigational biosimilar to EYLEA® (afibercept), which is a vascular endothelial growth factor receptor (VEGFR) Fc fusion protein.;;Additional Information;;EYLEA is a registered trademark of Regeneron Pharmaceuticals, Inc.",
		"modality" : "PrFc",
		"target" : "VEGF",
		"current_phase" : "Phase 3",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "ABP 938",
		"indication_description" : "OPHTHALMOLOGY",
		"business_partner" : "",
		"portfolio_priority" : "Standard",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "ABP 959",
		"product" : "eculizumab",
		"name" : "5363131.01",
		"trade_name" : "",
		"notepad" : "ABP 959 is an investigational biosimilar to SOLIRIS® (eculizumab), which is a monoclonal antibody that binds to the complement protein C5. ;;Additional Information;;SOLIRIS is a registered trademark of Alexion Pharmaceuticals Inc.",
		"modality" : "mAb",
		"target" : "C5",
		"current_phase" : "Phase 3",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "eculizumab",
		"indication_description" : "HEMATOLOGY",
		"business_partner" : "",
		"portfolio_priority" : "Standard",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "ABP 980",
		"product" : "Kanjinti",
		"name" : "5320982.01",
		"trade_name" : "",
		"notepad" : "KANJINTI® (formerly ABP 980 - biosimilar trastuzumab) is an anti-HER2 monoclonal antibody. The reference product primary conditions are HER2+ breast cancer and HER2+ gastric cancer.",
		"modality" : "mAb",
		"target" : "HER2",
		"current_phase" : "Launch",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "trastuzumab biosimilar",
		"indication_description" : "ONCOLOGY",
		"business_partner" : "",
		"portfolio_priority" : "Standard",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 004",
		"product" : "interferon alfacon-1",
		"name" : "5115950.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "Pr",
		"target" : "INF-alfacon-1",
		"current_phase" : "",
		"medical_therapeutic_area" : "Exploratory",
		"generic_name" : "interferon alfacon-1",
		"indication_description" : "COST OF GOODS MANUFACTURED",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 004",
		"product" : "interferon alfacon-1",
		"name" : "5115950.02",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "Pr",
		"target" : "INF-alfacon-1",
		"current_phase" : "",
		"medical_therapeutic_area" : "Exploratory",
		"generic_name" : "interferon alfacon-1",
		"indication_description" : "COST OF GOODS MANUFACTURED",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Manufacturing Process"
	},
	{
		"amg_number" : "AMG 005",
		"product" : "EPOGEN",
		"name" : "5101006.02",
		"trade_name" : "Epogen",
		"notepad" : "EPOGEN® is a prescription medicine used to treat a lower than normal number of red blood cells (anemia) caused by chronic kidney disease in patients on dialysis to reduce or avoid the need for red blood cell transfusions.",
		"modality" : "Pr",
		"target" : "Erythropoietic Stimulating Protein",
		"current_phase" : "Post-Launch",
		"medical_therapeutic_area" : "Nephrology",
		"generic_name" : "epoetin alfa",
		"indication_description" : "ANEMIA - CHRONIC RENAL FAILURE",
		"business_partner" : "Johnson & Johnson",
		"portfolio_priority" : "Standard",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 005",
		"product" : "EPOGEN",
		"name" : "5101816.01",
		"trade_name" : "Epogen",
		"notepad" : "",
		"modality" : "Pr",
		"target" : "Erythropoietic Stimulating Protein",
		"current_phase" : "",
		"medical_therapeutic_area" : "Nephrology",
		"generic_name" : "epoetin alfa",
		"indication_description" : "DEVICES AND FORMULATIONS-2ND GENERATION",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Formulation \/ Delivery System for a Marketed Active Substance"
	},
	{
		"amg_number" : "AMG 005",
		"product" : "EPOGEN",
		"name" : "5101983.04",
		"trade_name" : "Epogen",
		"notepad" : "",
		"modality" : "Pr",
		"target" : "Erythropoietic Stimulating Protein",
		"current_phase" : "",
		"medical_therapeutic_area" : "Nephrology",
		"generic_name" : "epoetin alfa",
		"indication_description" : "NEPHROLOGY",
		"business_partner" : "Johnson & Johnson",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 006",
		"product" : "NEUPOGEN",
		"name" : "5103130.03",
		"trade_name" : "Neupogen",
		"notepad" : "",
		"modality" : "Pr",
		"target" : "G-CSF",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "filgrastim",
		"indication_description" : "ACUTE RADIATION SYNDROME (ARS)",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 006",
		"product" : "NEUPOGEN",
		"name" : "5103982.02",
		"trade_name" : "Neupogen",
		"notepad" : "",
		"modality" : "Pr",
		"target" : "G-CSF",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "filgrastim",
		"indication_description" : "ONCOLOGY",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 006",
		"product" : "NEUPOGEN",
		"name" : "5103059.01",
		"trade_name" : "Neupogen",
		"notepad" : "NEUPOGEN® is used to treat neutropenia - a condition where the body makes too few neutrophils. Neutrophils are a type of white blood cell important in the bodys fight against infection. NEUPOGEN® helps to reduce the risk of infection (marked by fever) in patients with certain types of cancer who are receiving strong chemotherapy that decreases the number of infection-fighting white blood cells. This type of infection is called febrile neutropenia (neutropenia with fever). Studies have shown that some people have a greater risk of a low white blood cell count or infection when treated with strong chemotherapy.",
		"modality" : "Pr",
		"target" : "G-CSF",
		"current_phase" : "Post-Launch",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "filgrastim",
		"indication_description" : "NEUTROPENIA - CHEMOTHERAPY INDUCED",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 009",
		"product" : "AMG 009",
		"name" : "5116009.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "SM",
		"target" : "CRTH2\/DP",
		"current_phase" : "",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "AMG 009",
		"indication_description" : "ASTHMA",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 011",
		"product" : "Neulasta",
		"name" : "5104982.09",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "PrPEG",
		"target" : "Granulocyte colony-stimulating factor receptor",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "pegfilgrastim",
		"indication_description" : "ONCOLOGY",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 011",
		"product" : "Neulasta",
		"name" : "5104048.05",
		"trade_name" : "Neulasta",
		"notepad" : "",
		"modality" : "PrPEG",
		"target" : "Granulocyte colony-stimulating factor receptor",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "pegfilgrastim",
		"indication_description" : "LEUKEMIA - ACUTE MYELOID (AML)",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 011",
		"product" : "Neulasta",
		"name" : "5104812.11",
		"trade_name" : "",
		"notepad" : "Neulasta® is a prescription medication used to help reduce the chance of infection due to a low white blood cell count in people with certain types of cancer (non-myeloid) who receive anti-cancer medicines (chemotherapy) that can cause fever and low blood cell count.",
		"modality" : "PrPEG",
		"target" : "Granulocyte colony-stimulating factor receptor",
		"current_phase" : "Post-Launch",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "pegfilgrastim",
		"indication_description" : "DEVICES AND FORMULATIONS",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Formulation \/ Delivery System for a Marketed Active Substance"
	},
	{
		"amg_number" : "AMG 011",
		"product" : "Neulasta",
		"name" : "5104059.07",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "PrPEG",
		"target" : "Granulocyte colony-stimulating factor receptor",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "pegfilgrastim",
		"indication_description" : "NEUTROPENIA - CHEMOTHERAPY INDUCED",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Patient Population"
	},
	{
		"amg_number" : "AMG 011",
		"product" : "Neulasta",
		"name" : "5104982.04",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "PrPEG",
		"target" : "Granulocyte colony-stimulating factor receptor",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "pegfilgrastim",
		"indication_description" : "ONCOLOGY",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 011",
		"product" : "Neulasta",
		"name" : "5104067.02",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "PrPEG",
		"target" : "Granulocyte colony-stimulating factor receptor",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "pegfilgrastim",
		"indication_description" : "PBPC MOBILIZATION",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 011",
		"product" : "Neulasta",
		"name" : "5104900.08",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "PrPEG",
		"target" : "Granulocyte colony-stimulating factor receptor",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "pegfilgrastim",
		"indication_description" : "GENERAL (NON-INDICATION SPECIFIC)",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 011",
		"product" : "Neulasta",
		"name" : "5104982.06",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "PrPEG",
		"target" : "Granulocyte colony-stimulating factor receptor",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "pegfilgrastim",
		"indication_description" : "ONCOLOGY",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 011",
		"product" : "Neulasta",
		"name" : "5104812.10",
		"trade_name" : "",
		"notepad" : "Neulasta® is a prescription medication used to help reduce the chance of infection due to a low white blood cell count in people with certain types of cancer (non-myeloid) who receive anti-cancer medicines (chemotherapy) that can cause fever and low blood cell count.",
		"modality" : "PrPEG",
		"target" : "Granulocyte colony-stimulating factor receptor",
		"current_phase" : "Post-Launch",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "pegfilgrastim",
		"indication_description" : "DEVICES AND FORMULATIONS",
		"business_partner" : "",
		"portfolio_priority" : "Standard",
		"project_type" : "New Formulation \/ Delivery System for a Marketed Active Substance"
	},
	{
		"amg_number" : "AMG 011",
		"product" : "Neulasta",
		"name" : "5104059.01",
		"trade_name" : "",
		"notepad" : "Neulasta® is a prescription medication used to help reduce the chance of infection due to a low white blood cell count in people with certain types of cancer (non-myeloid) who receive anti-cancer medicines (chemotherapy) that can cause fever and low blood cell count.",
		"modality" : "PrPEG",
		"target" : "Granulocyte colony-stimulating factor receptor",
		"current_phase" : "Post-Launch",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "pegfilgrastim",
		"indication_description" : "NEUTROPENIA - CHEMOTHERAPY INDUCED",
		"business_partner" : "",
		"portfolio_priority" : "Standard",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 011",
		"product" : "Neulasta",
		"name" : "5104982.03",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "PrPEG",
		"target" : "Granulocyte colony-stimulating factor receptor",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "pegfilgrastim",
		"indication_description" : "ONCOLOGY",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 015",
		"product" : "STEMGEN",
		"name" : "5114003.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "Pr",
		"target" : "SCF",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "ancestim",
		"indication_description" : "ANEMIA - APLASTIC",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 015",
		"product" : "STEMGEN",
		"name" : "5114067.02",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "Pr",
		"target" : "SCF",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "ancestim",
		"indication_description" : "PBPC MOBILIZATION",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 015",
		"product" : "STEMGEN",
		"name" : "5114078.03",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "Pr",
		"target" : "SCF",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "ancestim",
		"indication_description" : "VITILIGO",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 024",
		"product" : "Kepivance",
		"name" : "5107055.02",
		"trade_name" : "Kepivance",
		"notepad" : "",
		"modality" : "Pr",
		"target" : "Keratinocyte growth factor",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "palifermin",
		"indication_description" : "MUCOSITIS - SIDE EFFECT TO CANCER THERAP",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 024",
		"product" : "Kepivance",
		"name" : "5107055.05",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "Pr",
		"target" : "Keratinocyte growth factor",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "palifermin",
		"indication_description" : "MUCOSITIS - SIDE EFFECT TO CANCER THERAP",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 024",
		"product" : "Kepivance",
		"name" : "5107055.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "Pr",
		"target" : "Keratinocyte growth factor",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "palifermin",
		"indication_description" : "MUCOSITIS - SIDE EFFECT TO CANCER THERAP",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 024",
		"product" : "Kepivance",
		"name" : "5107055.04",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "Pr",
		"target" : "Keratinocyte growth factor",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "palifermin",
		"indication_description" : "MUCOSITIS - SIDE EFFECT TO CANCER THERAP",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 024",
		"product" : "Kepivance",
		"name" : "5107055.06",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "Pr",
		"target" : "Keratinocyte growth factor",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "palifermin",
		"indication_description" : "MUCOSITIS - SIDE EFFECT TO CANCER THERAP",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 024",
		"product" : "Kepivance",
		"name" : "5107055.03",
		"trade_name" : "Kepivance",
		"notepad" : "",
		"modality" : "Pr",
		"target" : "Keratinocyte growth factor",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "palifermin",
		"indication_description" : "MUCOSITIS - SIDE EFFECT TO CANCER THERAP",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 025",
		"product" : "anakinra",
		"name" : "5108080.02",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "Pr",
		"target" : "IL-1R Ab",
		"current_phase" : "",
		"medical_therapeutic_area" : "Neuroscience",
		"generic_name" : "anakinra",
		"indication_description" : "MULTIPLE SCLEROSIS",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 025",
		"product" : "anakinra",
		"name" : "5108072.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "Pr",
		"target" : "IL-1R Ab",
		"current_phase" : "Filing",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "anakinra",
		"indication_description" : "RHEUMATOID ARTHRITIS - MUSCULO-SKELETAL",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 025",
		"product" : "anakinra",
		"name" : "5108006.03",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "Pr",
		"target" : "IL-1R Ab",
		"current_phase" : "",
		"medical_therapeutic_area" : "Nephrology",
		"generic_name" : "anakinra",
		"indication_description" : "ANEMIA - CHRONIC RENAL FAILURE",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 028",
		"product" : "liatermin",
		"name" : "5165066.04",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "Pr",
		"target" : "GDNF",
		"current_phase" : "",
		"medical_therapeutic_area" : "Neuroscience",
		"generic_name" : "liatermin",
		"indication_description" : "PARKINSON'S DISEASE",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 028",
		"product" : "liatermin",
		"name" : "5165066.03",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "Pr",
		"target" : "GDNF",
		"current_phase" : "",
		"medical_therapeutic_area" : "Neuroscience",
		"generic_name" : "liatermin",
		"indication_description" : "PARKINSON'S DISEASE",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 028",
		"product" : "liatermin",
		"name" : "5165066.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "Pr",
		"target" : "GDNF",
		"current_phase" : "",
		"medical_therapeutic_area" : "Neuroscience",
		"generic_name" : "liatermin",
		"indication_description" : "PARKINSON'S DISEASE",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 028",
		"product" : "liatermin",
		"name" : "5165066.02",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "Pr",
		"target" : "GDNF",
		"current_phase" : "",
		"medical_therapeutic_area" : "Neuroscience",
		"generic_name" : "liatermin",
		"indication_description" : "PARKINSON'S DISEASE",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 033",
		"product" : "Aranesp",
		"name" : "5105816.05",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "Pr",
		"target" : "Erythropoietic Stimulating Protein",
		"current_phase" : "",
		"medical_therapeutic_area" : "Nephrology",
		"generic_name" : "darbepoetin alfa",
		"indication_description" : "DEVICES AND FORMULATIONS-2ND GENERATION",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 033",
		"product" : "Aranesp",
		"name" : "5105983.13",
		"trade_name" : "",
		"notepad" : "Aranesp® is a recombinant human protein agonist of the erythropoietin receptor. It is being investigated as a treatment for low risk myelodysplastic syndromes.",
		"modality" : "Pr",
		"target" : "Erythropoietic Stimulating Protein",
		"current_phase" : "Post-Launch",
		"medical_therapeutic_area" : "Nephrology",
		"generic_name" : "darbepoetin alfa",
		"indication_description" : "NEPHROLOGY",
		"business_partner" : "Kirin",
		"portfolio_priority" : "Standard",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 033",
		"product" : "Aranesp",
		"name" : "5105004.08",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "Pr",
		"target" : "Erythropoietic Stimulating Protein",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "darbepoetin alfa",
		"indication_description" : "ANEMIA - CANCER INDUCED",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 033",
		"product" : "Aranesp",
		"name" : "5105006.12",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "Pr",
		"target" : "Erythropoietic Stimulating Protein",
		"current_phase" : "",
		"medical_therapeutic_area" : "Nephrology",
		"generic_name" : "darbepoetin alfa",
		"indication_description" : "ANEMIA - CHRONIC RENAL FAILURE",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 033",
		"product" : "Aranesp",
		"name" : "5105007.10",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "Pr",
		"target" : "Erythropoietic Stimulating Protein",
		"current_phase" : "",
		"medical_therapeutic_area" : "Nephrology",
		"generic_name" : "darbepoetin alfa",
		"indication_description" : "ANEMIA - HEART FAILURE",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 033",
		"product" : "Aranesp",
		"name" : "5105006.03",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "Pr",
		"target" : "Erythropoietic Stimulating Protein",
		"current_phase" : "",
		"medical_therapeutic_area" : "Nephrology",
		"generic_name" : "darbepoetin alfa",
		"indication_description" : "ANEMIA - CHRONIC RENAL FAILURE",
		"business_partner" : "Kirin",
		"portfolio_priority" : "",
		"project_type" : "New Patient Population"
	},
	{
		"amg_number" : "AMG 033",
		"product" : "Aranesp",
		"name" : "5105812.04",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "Pr",
		"target" : "Erythropoietic Stimulating Protein",
		"current_phase" : "",
		"medical_therapeutic_area" : "Nephrology",
		"generic_name" : "darbepoetin alfa",
		"indication_description" : "DEVICES AND FORMULATIONS",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 033",
		"product" : "Aranesp",
		"name" : "5105006.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "Pr",
		"target" : "Erythropoietic Stimulating Protein",
		"current_phase" : "",
		"medical_therapeutic_area" : "Nephrology",
		"generic_name" : "darbepoetin alfa",
		"indication_description" : "ANEMIA - CHRONIC RENAL FAILURE",
		"business_partner" : "Kyowa Hakko Kirin",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 033",
		"product" : "Aranesp",
		"name" : "5105006.02",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "Pr",
		"target" : "Erythropoietic Stimulating Protein",
		"current_phase" : "",
		"medical_therapeutic_area" : "Nephrology",
		"generic_name" : "darbepoetin alfa",
		"indication_description" : "ANEMIA - CHRONIC RENAL FAILURE",
		"business_partner" : "Kyowa Hakko Kirin",
		"portfolio_priority" : "",
		"project_type" : "New Dosage Form"
	},
	{
		"amg_number" : "AMG 033",
		"product" : "Aranesp",
		"name" : "5105005.07",
		"trade_name" : "",
		"notepad" : "Aranesp® is a recombinant human protein agonist of the erythropoietin receptor. It is being investigated as a treatment for low risk myelodysplastic syndromes.",
		"modality" : "Pr",
		"target" : "Erythropoietic Stimulating Protein",
		"current_phase" : "Post-Launch",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "darbepoetin alfa",
		"indication_description" : "ANEMIA - CHEMOTHERAPY INDUCED",
		"business_partner" : "Kyowa Hakko Kirin",
		"portfolio_priority" : "Standard",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 033",
		"product" : "Aranesp",
		"name" : "5105006.06",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "Pr",
		"target" : "Erythropoietic Stimulating Protein",
		"current_phase" : "",
		"medical_therapeutic_area" : "Nephrology",
		"generic_name" : "darbepoetin alfa",
		"indication_description" : "ANEMIA - CHRONIC RENAL FAILURE",
		"business_partner" : "Kyowa Hakko Kirin",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 033",
		"product" : "Aranesp",
		"name" : "5105982.11",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "Pr",
		"target" : "Erythropoietic Stimulating Protein",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "darbepoetin alfa",
		"indication_description" : "ONCOLOGY",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 033",
		"product" : "Aranesp",
		"name" : "5105057.09",
		"trade_name" : "",
		"notepad" : "Aranesp® is a recombinant human protein agonist of the erythropoietin receptor. It is being investigated as a treatment for low risk myelodysplastic syndromes.",
		"modality" : "Pr",
		"target" : "Erythropoietic Stimulating Protein",
		"current_phase" : "Post-Launch",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "darbepoetin alfa",
		"indication_description" : "MYELODYSPLASTIC SYNDROME (MDS)",
		"business_partner" : "Kyowa Hakko Kirin",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 036",
		"product" : "pegsunercept",
		"name" : "5110072.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "PrPEG",
		"target" : "sTNF-R1",
		"current_phase" : "",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "pegsunercept",
		"indication_description" : "RHEUMATOID ARTHRITIS - MUSCULO-SKELETAL",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 073",
		"product" : "Sensipar",
		"name" : "5106044.03",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "SM",
		"target" : "CASR",
		"current_phase" : "",
		"medical_therapeutic_area" : "Nephrology",
		"generic_name" : "cinacalcet hcl",
		"indication_description" : "HYPERPARATHYROIDISM (HPT) - SECONDARY",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 073",
		"product" : "Sensipar",
		"name" : "5106079.06",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "SM",
		"target" : "CASR",
		"current_phase" : "",
		"medical_therapeutic_area" : "Nephrology",
		"generic_name" : "cinacalcet hcl",
		"indication_description" : "PARATHYROID CARCINOMA",
		"business_partner" : "NPS Pharmaceuticals",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 073",
		"product" : "Sensipar",
		"name" : "5106043.04",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "SM",
		"target" : "CASR",
		"current_phase" : "",
		"medical_therapeutic_area" : "Nephrology",
		"generic_name" : "cinacalcet hcl",
		"indication_description" : "HYPERPARATHYROIDISM (HPT) - PRIMARY",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 073",
		"product" : "Sensipar",
		"name" : "5106043.10",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "SM",
		"target" : "CASR",
		"current_phase" : "",
		"medical_therapeutic_area" : "Nephrology",
		"generic_name" : "cinacalcet hcl",
		"indication_description" : "HYPERPARATHYROIDISM (HPT) - PRIMARY",
		"business_partner" : "NPS Pharmaceuticals",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 073",
		"product" : "Sensipar",
		"name" : "5106044.09",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "SM",
		"target" : "CASR",
		"current_phase" : "",
		"medical_therapeutic_area" : "Nephrology",
		"generic_name" : "cinacalcet hcl",
		"indication_description" : "HYPERPARATHYROIDISM (HPT) - SECONDARY",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 073",
		"product" : "Sensipar",
		"name" : "5106043.07",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "SM",
		"target" : "CASR",
		"current_phase" : "",
		"medical_therapeutic_area" : "Nephrology",
		"generic_name" : "cinacalcet hcl",
		"indication_description" : "HYPERPARATHYROIDISM (HPT) - PRIMARY",
		"business_partner" : "NPS Pharmaceuticals",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 073",
		"product" : "Sensipar",
		"name" : "5106044.08",
		"trade_name" : "",
		"notepad" : "Sensipar® (cinacalcet) is indicated for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on dialysis.",
		"modality" : "SM",
		"target" : "CASR",
		"current_phase" : "Post-Launch",
		"medical_therapeutic_area" : "Nephrology",
		"generic_name" : "cinacalcet hcl",
		"indication_description" : "HYPERPARATHYROIDISM (HPT) - SECONDARY",
		"business_partner" : "Kyowa Hakko Kirin",
		"portfolio_priority" : "Standard",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 076",
		"product" : "AMG 076",
		"name" : "5118060.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "SM",
		"target" : "MCHR1 B\/U",
		"current_phase" : "",
		"medical_therapeutic_area" : "Metabolic Disorders",
		"generic_name" : "AMG 076",
		"indication_description" : "OBESITY",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 102",
		"product" : "rilotumumab",
		"name" : "5119024.12",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "HFG Ab",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "rilotumumab",
		"indication_description" : "CANCER - PROSTATE",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 102",
		"product" : "rilotumumab",
		"name" : "5119025.03",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "HFG Ab",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "rilotumumab",
		"indication_description" : "CANCER - RENAL CELL",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 102",
		"product" : "rilotumumab",
		"name" : "5119018.14",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "HFG Ab",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "rilotumumab",
		"indication_description" : "CANCER - HEAD AND NECK",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 102",
		"product" : "rilotumumab",
		"name" : "5119016.11",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "HFG Ab",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "rilotumumab",
		"indication_description" : "CANCER - COLORECTAL",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 102",
		"product" : "rilotumumab",
		"name" : "5119020.08",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "HFG Ab",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "rilotumumab",
		"indication_description" : "CANCER - NON SMALL CELL LUNG",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 102",
		"product" : "rilotumumab",
		"name" : "5119019.16",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "HFG Ab",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "rilotumumab",
		"indication_description" : "CANCER - MULTIPLE MYELOMA",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 102",
		"product" : "rilotumumab",
		"name" : "5119037.02",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "HFG Ab",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "rilotumumab",
		"indication_description" : "GLIOBLASTOMA",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 102",
		"product" : "rilotumumab",
		"name" : "5119025.05",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "HFG Ab",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "rilotumumab",
		"indication_description" : "CANCER - RENAL CELL",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 102",
		"product" : "rilotumumab",
		"name" : "5119037.04",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "HFG Ab",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "rilotumumab",
		"indication_description" : "GLIOBLASTOMA",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 102",
		"product" : "rilotumumab",
		"name" : "5119087.07",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "HFG Ab",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "rilotumumab",
		"indication_description" : "CANCER - BLADDER",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 102",
		"product" : "rilotumumab",
		"name" : "5119082.06",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "HFG Ab",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "rilotumumab",
		"indication_description" : "CANCER - GASTRIC",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 102",
		"product" : "rilotumumab",
		"name" : "5119082.17",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "HFG Ab",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "rilotumumab",
		"indication_description" : "CANCER - GASTRIC",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 102",
		"product" : "rilotumumab",
		"name" : "5119022.10",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "HFG Ab",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "rilotumumab",
		"indication_description" : "CANCER - OVARIAN",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 102",
		"product" : "rilotumumab",
		"name" : "5119028.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "HFG Ab",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "rilotumumab",
		"indication_description" : "CANCER - SOLID TUMORS",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 102",
		"product" : "rilotumumab",
		"name" : "5119015.09",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "HFG Ab",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "rilotumumab",
		"indication_description" : "CANCER - BREAST",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 102",
		"product" : "rilotumumab",
		"name" : "5119020.18",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "HFG Ab",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "rilotumumab",
		"indication_description" : "CANCER - NON SMALL CELL LUNG",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 102",
		"product" : "rilotumumab",
		"name" : "5119027.13",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "HFG Ab",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "rilotumumab",
		"indication_description" : "CANCER - SMALL CELL LUNG",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 102",
		"product" : "rilotumumab",
		"name" : "5119103.15",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "HFG Ab",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "rilotumumab",
		"indication_description" : "MESOTHELIOMA",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 103",
		"product" : "BLINCYTO",
		"name" : "5311122.08",
		"trade_name" : "Blincyto",
		"notepad" : "BLINCYTO® is an anti-CD 19 x anti-CD3 BiTE® (bispecific T cell engager) molecule. It is being investigated in subcutaneous administration of Blinatumomab for the treatment of adults with relapsed\/refractory Acute Lymphoblastic Leukemia (ALL) ;;",
		"modality" : "BiTE",
		"target" : "CD19",
		"current_phase" : "Phase 1",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "blinatumomab",
		"indication_description" : "CANCER - LIQUID TUMORS",
		"business_partner" : "",
		"portfolio_priority" : "Standard",
		"project_type" : "New Formulation \/ Delivery System for a Marketed Active Substance"
	},
	{
		"amg_number" : "AMG 103",
		"product" : "BLINCYTO",
		"name" : "5311122.10",
		"trade_name" : "Blincyto",
		"notepad" : "BLINCYTO is an anti-CD19 x anti-CD3 BiTE (bispecific T cell engager) molecule. It is being investigated in newly diagnosed adults with Ph-negative B-cell precursor Acute Lymphoblastic Leukemia (ALL)",
		"modality" : "BiTE",
		"target" : "CD19",
		"current_phase" : "Phase 3",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "blinatumomab",
		"indication_description" : "CANCER - LIQUID TUMORS",
		"business_partner" : "",
		"portfolio_priority" : "Standard",
		"project_type" : "New Patient Population"
	},
	{
		"amg_number" : "AMG 103",
		"product" : "BLINCYTO",
		"name" : "5311122.09",
		"trade_name" : "Blincyto",
		"notepad" : "BLINCYTO® is an anti-CD 19  x anti-CD3 BiTE® (bispecific T cell engager) construct. It is being investigated in combination with AMG 404* for the treatment of adults with relapsed\/refractory Acute Lymphoblastic Leukemia (ALL);;*AMG 404 is a human anti-programmed cell death-1 (PD-1) monoclonal antibody",
		"modality" : "BiTE",
		"target" : "CD19",
		"current_phase" : "Phase 1",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "blinatumomab",
		"indication_description" : "CANCER - LIQUID TUMORS",
		"business_partner" : "",
		"portfolio_priority" : "Standard",
		"project_type" : "New Combination of a Marketed Active Substance"
	},
	{
		"amg_number" : "AMG 103",
		"product" : "BLINCYTO",
		"name" : "5311122.01",
		"trade_name" : "Blincyto",
		"notepad" : "BLINCYTO® is an anti-CD19 x anti-CD3 BiTE® (bispecific T cell engager) molecule indicated for adult, pediatric and young adult patients with relapsed or refractory B-Cell ALL (Acute Lymphoblastic Leukemia) and for the treatment of minimal residual disease (MRD) positive ALL. It is being investigated in frontline ALL.",
		"modality" : "BiTE",
		"target" : "CD19",
		"current_phase" : "Post-Launch",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "blinatumomab",
		"indication_description" : "CANCER - LIQUID TUMORS",
		"business_partner" : "",
		"portfolio_priority" : "Standard",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 103",
		"product" : "BLINCYTO",
		"name" : "5311122.04",
		"trade_name" : "Blincyto",
		"notepad" : "BLINCYTO® is an anti-CD19 x anti-CD3 BiTE® (bispecific T cell engager) construct indicated for adult, pediatric and young adult patients with relapsed or refractory B-Cell ALL (Acute Lymphoblastic Leukemia) and for the treatment of minimal residual disease (MRD) positive ALL. It is being investigated in frontline ALL.",
		"modality" : "BiTE",
		"target" : "CD19",
		"current_phase" : "Launch",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "blinatumomab",
		"indication_description" : "CANCER - LIQUID TUMORS",
		"business_partner" : "",
		"portfolio_priority" : "Standard",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 103",
		"product" : "BLINCYTO",
		"name" : "5311122.06",
		"trade_name" : "Blincyto",
		"notepad" : "BLINCYTO® is an anti-CD19 x anti-CD3 BiTE® (bispecific T cell engager) molecule indicated for adult, pediatric and young adult patients with relapsed or refractory B-Cell ALL (Acute Lymphoblastic Leukemia) and for the treatment of minimal residual disease (MRD) positive ALL. It is being investigated in frontline ALL.",
		"modality" : "BiTE",
		"target" : "CD19",
		"current_phase" : "Phase 2",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "blinatumomab",
		"indication_description" : "CANCER - LIQUID TUMORS",
		"business_partner" : "",
		"portfolio_priority" : "Standard",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 103",
		"product" : "BLINCYTO",
		"name" : "5311122.02",
		"trade_name" : "Blincyto",
		"notepad" : "BLINCYTO® is an anti-CD19 x anti-CD3 BiTE® (bispecific T cell engager) molecule indicated for adult, pediatric and young adult patients with relapsed or refractory B-Cell ALL (Acute Lymphoblastic Leukemia) and for the treatment of minimal residual disease (MRD) positive ALL. It is being investigated in frontline ALL.",
		"modality" : "BiTE",
		"target" : "CD19",
		"current_phase" : "Phase 2",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "blinatumomab",
		"indication_description" : "CANCER - LIQUID TUMORS",
		"business_partner" : "",
		"portfolio_priority" : "Standard",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 103",
		"product" : "BLINCYTO",
		"name" : "5311122.03",
		"trade_name" : "Blincyto",
		"notepad" : "BLINCYTO® is an anti-CD19 x anti-CD3 BiTE® (bispecific T cell engager) construct indicated for adult, pediatric and young adult patients with relapsed or refractory B-Cell ALL (Acute Lymphoblastic Leukemia) and for the treatment of minimal residual disease (MRD) positive ALL. It is being investigated in R\/R Ph+ ALL.",
		"modality" : "BiTE",
		"target" : "CD19",
		"current_phase" : "Launch",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "blinatumomab",
		"indication_description" : "CANCER - LIQUID TUMORS",
		"business_partner" : "",
		"portfolio_priority" : "Standard",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 103",
		"product" : "BLINCYTO",
		"name" : "5311122.05",
		"trade_name" : "Blincyto",
		"notepad" : "BLINCYTO® is an anti-CD19 x anti-CD3 BiTE® (bispecific T cell engager) molecule. It is approved for treatment of pediatric patients with B-cell acute lymphoblastic leukemia (ALL) in first relapse.;;",
		"modality" : "BiTE",
		"target" : "CD19",
		"current_phase" : "Launch",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "blinatumomab",
		"indication_description" : "CANCER - LIQUID TUMORS",
		"business_partner" : "",
		"portfolio_priority" : "Standard",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 103",
		"product" : "BLINCYTO",
		"name" : "5311122.07",
		"trade_name" : "Blincyto",
		"notepad" : "BLINCYTO® is an anti-CD19 x anti-CD3 BiTE® (bispecific T cell engager) construct indicated for adult, pediatric and young adult patients with relapsed or refractory B-Cell ALL (Acute Lymphoblastic Leukemia) and for the treatment of minimal residual disease (MRD) positive ALL. It is being investigated in frontline ALL.",
		"modality" : "BiTE",
		"target" : "CD19",
		"current_phase" : "Phase 1",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "blinatumomab",
		"indication_description" : "CANCER - LIQUID TUMORS",
		"business_partner" : "Merck",
		"portfolio_priority" : "Standard",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 104",
		"product" : "AMG 104",
		"name" : "5475009.01",
		"trade_name" : "",
		"notepad" : "AMG 104 is a human anti-TSLP Fab.;;AMG 104 is being developed in collaboration with AstraZeneca plc.",
		"modality" : "mAb",
		"target" : "TSLP",
		"current_phase" : "Phase 1",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "AMG 104",
		"indication_description" : "ASTHMA",
		"business_partner" : "AstraZeneca\/MedImmune",
		"portfolio_priority" : "Standard",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 108",
		"product" : "AMG 108",
		"name" : "5120061.02",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "IL1R1",
		"current_phase" : "",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "AMG 108",
		"indication_description" : "OSTEOARTHRITIS",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 108",
		"product" : "AMG 108",
		"name" : "5120072.03",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "IL1R1",
		"current_phase" : "",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "AMG 108",
		"indication_description" : "RHEUMATOID ARTHRITIS - MUSCULO-SKELETAL",
		"business_partner" : "Medarex",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 108",
		"product" : "AMG 108",
		"name" : "5120032.04",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "IL1R1",
		"current_phase" : "",
		"medical_therapeutic_area" : "Metabolic Disorders",
		"generic_name" : "AMG 108",
		"indication_description" : "DIABETES - TYPE 2",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 108",
		"product" : "AMG 108",
		"name" : "5120061.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "IL1R1",
		"current_phase" : "",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "AMG 108",
		"indication_description" : "OSTEOARTHRITIS",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 110",
		"product" : "AMG 110",
		"name" : "5308028.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "BiTE",
		"target" : "EPCAM aka MT110",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "AMG 110",
		"indication_description" : "CANCER - SOLID TUMORS",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 114",
		"product" : "AMG 114",
		"name" : "5199005.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "Pr",
		"target" : "HS-NESP",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "AMG 114",
		"indication_description" : "ANEMIA - CHEMOTHERAPY INDUCED",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 119",
		"product" : "AMG 119",
		"name" : "5402027.01",
		"trade_name" : "",
		"notepad" : "AMG 119 is a DLL3 CAR T (chimeric antigen receptor T cell) cellular therapy.  It is being investigated as a treatment for small-cell lung cancer.",
		"modality" : "CAR-T",
		"target" : "DLL3",
		"current_phase" : "Phase 1",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "AMG 119",
		"indication_description" : "CANCER - SMALL CELL LUNG",
		"business_partner" : "",
		"portfolio_priority" : "Gated",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 124",
		"product" : "AMG 124",
		"name" : "5457020.01",
		"trade_name" : "",
		"notepad" : "AMG 124 is a half-life extended anti-Melanoma Antigen Gene (MAGE)-B2 BiTE® (Bispecific T cell Engager) for the treatment of squamous non-small cell lung cancer (NSCLC), head and neck squamous cell cancer (HNSCC) and hepatocellular cancer (HCC).",
		"modality" : "HLE BiTE",
		"target" : "MAGE B2",
		"current_phase" : "Preclinical",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "AMG 124",
		"indication_description" : "CANCER - NON SMALL CELL LUNG",
		"business_partner" : "",
		"portfolio_priority" : "Standard",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 131",
		"product" : "AMG 131",
		"name" : "5121032.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "SM",
		"target" : "PPAR-g",
		"current_phase" : "",
		"medical_therapeutic_area" : "Metabolic Disorders",
		"generic_name" : "AMG 131",
		"indication_description" : "DIABETES - TYPE 2",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 132",
		"product" : "AMG 132",
		"name" : "5188001.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "Anti-Amyloid Ab #1",
		"current_phase" : "",
		"medical_therapeutic_area" : "Neuroscience",
		"generic_name" : "AMG 132",
		"indication_description" : "ALZHEIMER'S DISEASE",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 133",
		"product" : "AMG 133",
		"name" : "5411060.01",
		"trade_name" : "",
		"notepad" : "AMG 133 is a gastric inhibitory polypeptide receptor (GIPR) antagonist and glucagon-like peptide 1 (GLP-1R) agonist. It is being investigated for the treatment of obesity.",
		"modality" : "AbPep",
		"target" : "GIPR",
		"current_phase" : "Phase 1",
		"medical_therapeutic_area" : "Metabolic Disorders",
		"generic_name" : "AMG 133",
		"indication_description" : "OBESITY",
		"business_partner" : "",
		"portfolio_priority" : "Standard",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 138",
		"product" : "AMG 138",
		"name" : "5365001.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "SM",
		"target" : "BACE # 2",
		"current_phase" : "",
		"medical_therapeutic_area" : "Neuroscience",
		"generic_name" : "AMG 138",
		"indication_description" : "ALZHEIMER'S DISEASE",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 139",
		"product" : "AMG 139",
		"name" : "5205031.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "IL-23",
		"current_phase" : "",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "AMG 139",
		"indication_description" : "CROHN'S DISEASE",
		"business_partner" : "AstraZeneca\/MedImmune",
		"portfolio_priority" : "Close Out",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 145",
		"product" : "Repatha",
		"name" : "5193088.12",
		"trade_name" : "Repatha",
		"notepad" : "Repatha® is a PCSK9 inhibitor indicated in adults with cardiovascular disease to reduce the risk of heart attack - stroke and certain types of heart surgery, in adults with primary hyperlipidemia (heterozygous familial hypercholesterolemia) to reduce low-density lipoprotein (LDL), and in homozygous familial hypercholesterolemia (HoFH) when additional lowering of LDL cholesterol is needed.",
		"modality" : "mAb",
		"target" : "PCSK9",
		"current_phase" : "Post-Launch",
		"medical_therapeutic_area" : "Cardiovascular",
		"generic_name" : "evolocumab",
		"indication_description" : "HYPERCHOLESTEROLEMIA",
		"business_partner" : "Astellas",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 145",
		"product" : "Repatha",
		"name" : "5193088.08",
		"trade_name" : "Repatha",
		"notepad" : "Repatha® is a PCSK9 inhibitor indicated in adults with cardiovascular disease to reduce the risk of heart attack - stroke and certain types of heart surgery, in adults with primary hyperlipidemia (heterozygous familial hypercholesterolemia) to reduce low-density lipoprotein (LDL), and in homozygous familial hypercholesterolemia (HoFH) when additional lowering of LDL cholesterol is needed.",
		"modality" : "mAb",
		"target" : "PCSK9",
		"current_phase" : "Phase 3",
		"medical_therapeutic_area" : "Cardiovascular",
		"generic_name" : "evolocumab",
		"indication_description" : "HYPERCHOLESTEROLEMIA",
		"business_partner" : "Astellas",
		"portfolio_priority" : "Standard",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 145",
		"product" : "Repatha",
		"name" : "5193088.05",
		"trade_name" : "Repatha",
		"notepad" : "Repatha® is a human monoclonal antibody that inhibits proprotein convertase subtilisin\/kexin type 9 (PCSK9). It is being investigated in the Phase 3 VESALIUS – CV study in high-risk cardiovascular disease patients without prior heart attack or stroke.",
		"modality" : "mAb",
		"target" : "PCSK9",
		"current_phase" : "Phase 1",
		"medical_therapeutic_area" : "Cardiovascular",
		"generic_name" : "evolocumab",
		"indication_description" : "HYPERCHOLESTEROLEMIA",
		"business_partner" : "Astellas",
		"portfolio_priority" : "Standard",
		"project_type" : "New Formulation \/ Delivery System for a Marketed Active Substance"
	},
	{
		"amg_number" : "AMG 145",
		"product" : "Repatha",
		"name" : "5193088.04",
		"trade_name" : "Repatha",
		"notepad" : "Repatha® is a PCSK9 inhibitor indicated in adults with cardiovascular disease to reduce the risk of heart attack - stroke and certain types of heart surgery, in adults with primary hyperlipidemia (heterozygous familial hypercholesterolemia) to reduce low-density lipoprotein (LDL), and in homozygous familial hypercholesterolemia (HoFH) when additional lowering of LDL cholesterol is needed.",
		"modality" : "mAb",
		"target" : "PCSK9",
		"current_phase" : "Launch",
		"medical_therapeutic_area" : "Cardiovascular",
		"generic_name" : "evolocumab",
		"indication_description" : "HYPERCHOLESTEROLEMIA",
		"business_partner" : "Astellas",
		"portfolio_priority" : "",
		"project_type" : "New Formulation \/ Delivery System for a Marketed Active Substance"
	},
	{
		"amg_number" : "AMG 145",
		"product" : "Repatha",
		"name" : "5193088.03",
		"trade_name" : "Repatha",
		"notepad" : "Repatha® is a PCSK9 inhibitor indicated in adults with cardiovascular disease to reduce the risk of heart attack - stroke and certain types of heart surgery, in adults with primary hyperlipidemia (heterozygous familial hypercholesterolemia) to reduce low-density lipoprotein (LDL), and in homozygous familial hypercholesterolemia (HoFH) when additional lowering of LDL cholesterol is needed.",
		"modality" : "mAb",
		"target" : "PCSK9",
		"current_phase" : "Post-Launch",
		"medical_therapeutic_area" : "Cardiovascular",
		"generic_name" : "evolocumab",
		"indication_description" : "HYPERCHOLESTEROLEMIA",
		"business_partner" : "Astellas",
		"portfolio_priority" : "",
		"project_type" : "New Formulation \/ Delivery System for a Marketed Active Substance"
	},
	{
		"amg_number" : "AMG 145",
		"product" : "Repatha",
		"name" : "5193088.09",
		"trade_name" : "Repatha",
		"notepad" : "Repatha® is a human monoclonal antibody that inhibits proprotein convertase subtilisin\/kexin type 9 (PCSK9). It is being investigated in VESALIUS-CV study in high-risk cardiovascular disease patients without prior heart attack or stroke.",
		"modality" : "mAb",
		"target" : "PCSK9",
		"current_phase" : "Phase 3",
		"medical_therapeutic_area" : "Cardiovascular",
		"generic_name" : "evolocumab",
		"indication_description" : "HYPERCHOLESTEROLEMIA",
		"business_partner" : "Astellas",
		"portfolio_priority" : "Standard",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 145",
		"product" : "Repatha",
		"name" : "5193088.11",
		"trade_name" : "Repatha",
		"notepad" : "Repatha® is a PCSK9 inhibitor indicated in adults with cardiovascular disease to reduce the risk of heart attack - stroke and certain types of heart surgery, in adults with primary hyperlipidemia (heterozygous familial hypercholesterolemia) to reduce low-density lipoprotein (LDL), and in homozygous familial hypercholesterolemia (HoFH) when additional lowering of LDL cholesterol is needed.",
		"modality" : "mAb",
		"target" : "PCSK9",
		"current_phase" : "Post-Launch",
		"medical_therapeutic_area" : "Cardiovascular",
		"generic_name" : "evolocumab",
		"indication_description" : "HYPERCHOLESTEROLEMIA",
		"business_partner" : "Astellas",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 145",
		"product" : "Repatha",
		"name" : "5193088.10",
		"trade_name" : "Repatha",
		"notepad" : "Repatha® is a PCSK9 inhibitor indicated in adults with cardiovascular disease to reduce the risk of heart attack - stroke and certain types of heart surgery, in adults with primary hyperlipidemia (heterozygous familial hypercholesterolemia) to reduce low-density lipoprotein (LDL), and in homozygous familial hypercholesterolemia (HoFH) when additional lowering of LDL cholesterol is needed. Acute Coronary Syndrome was not an approved indication and will not be pursued.",
		"modality" : "mAb",
		"target" : "PCSK9",
		"current_phase" : "Post-Launch",
		"medical_therapeutic_area" : "Cardiovascular",
		"generic_name" : "evolocumab",
		"indication_description" : "HYPERCHOLESTEROLEMIA",
		"business_partner" : "Astellas",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 145",
		"product" : "Repatha",
		"name" : "5193088.06",
		"trade_name" : "Repatha",
		"notepad" : "Repatha® is a PCSK9 inhibitor indicated in adults with cardiovascular disease to reduce the risk of heart attack - stroke and certain types of heart surgery, in adults with primary hyperlipidemia (heterozygous familial hypercholesterolemia) to reduce low-density lipoprotein (LDL), and in homozygous familial hypercholesterolemia (HoFH) when additional lowering of LDL cholesterol is needed.",
		"modality" : "mAb",
		"target" : "PCSK9",
		"current_phase" : "Post-Launch",
		"medical_therapeutic_area" : "Cardiovascular",
		"generic_name" : "evolocumab",
		"indication_description" : "HYPERCHOLESTEROLEMIA",
		"business_partner" : "Astellas",
		"portfolio_priority" : "",
		"project_type" : "New Formulation \/ Delivery System for a Marketed Active Substance"
	},
	{
		"amg_number" : "AMG 145",
		"product" : "Repatha",
		"name" : "5193088.02",
		"trade_name" : "Repatha",
		"notepad" : "Repatha® is a PCSK9 inhibitor indicated in adults with cardiovascular disease to reduce the risk of heart attack - stroke and certain types of heart surgery, in adults with primary hyperlipidemia (heterozygous familial hypercholesterolemia) to reduce low-density lipoprotein (LDL), and in homozygous familial hypercholesterolemia (HoFH) when additional lowering of LDL cholesterol is needed.",
		"modality" : "mAb",
		"target" : "PCSK9",
		"current_phase" : "Post-Launch",
		"medical_therapeutic_area" : "Cardiovascular",
		"generic_name" : "evolocumab",
		"indication_description" : "HYPERCHOLESTEROLEMIA",
		"business_partner" : "Astellas",
		"portfolio_priority" : "",
		"project_type" : "New Formulation \/ Delivery System for a Marketed Active Substance"
	},
	{
		"amg_number" : "AMG 145",
		"product" : "Repatha",
		"name" : "5193088.07",
		"trade_name" : "Repatha",
		"notepad" : "Repatha® is a PCSK9 inhibitor indicated in adults with cardiovascular disease to reduce the risk of heart attack - stroke and certain types of heart surgery, in adults with primary hyperlipidemia (heterozygous familial hypercholesterolemia) to reduce low-density lipoprotein (LDL), and in homozygous familial hypercholesterolemia (HoFH) when additional lowering of LDL cholesterol is needed.",
		"modality" : "mAb",
		"target" : "PCSK9",
		"current_phase" : "Post-Launch",
		"medical_therapeutic_area" : "Cardiovascular",
		"generic_name" : "evolocumab",
		"indication_description" : "HYPERCHOLESTEROLEMIA",
		"business_partner" : "Astellas",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 145",
		"product" : "Repatha",
		"name" : "5193088.01",
		"trade_name" : "Repatha",
		"notepad" : "Repatha® is a human monoclonal antibody that inhibits proprotein convertase subtilisin\/kexin type 9 (PCSK9). It is being investigated in the Phase 3 VESALIUS   CV study in high-risk cardiovascular disease patients without prior heart attack or stroke.",
		"modality" : "mAb",
		"target" : "PCSK9",
		"current_phase" : "Post-Launch",
		"medical_therapeutic_area" : "Cardiovascular",
		"generic_name" : "evolocumab",
		"indication_description" : "HYPERCHOLESTEROLEMIA",
		"business_partner" : "Astellas",
		"portfolio_priority" : "Standard",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 145",
		"product" : "Repatha",
		"name" : "5193088.13",
		"trade_name" : "Repatha",
		"notepad" : "Repatha® is a human monoclonal antibody that inhibits proprotein convertase subtilisin\/kexin type 9 (PCSK9). It is being investigated in pediatric patients with familial hypercholesterolemia (FH).",
		"modality" : "mAb",
		"target" : "PCSK9",
		"current_phase" : "Launch",
		"medical_therapeutic_area" : "Cardiovascular",
		"generic_name" : "evolocumab",
		"indication_description" : "HYPERCHOLESTEROLEMIA",
		"business_partner" : "",
		"portfolio_priority" : "Standard",
		"project_type" : "New Patient Population"
	},
	{
		"amg_number" : "AMG 146",
		"product" : "AMG 146",
		"name" : "5417135.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "Pep",
		"target" : "PAC1",
		"current_phase" : "Preclinical",
		"medical_therapeutic_area" : "Neuroscience",
		"generic_name" : "AMG 146",
		"indication_description" : "ACUTE MIGRAINE",
		"business_partner" : "",
		"portfolio_priority" : "Gated",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 147",
		"product" : "AMG 147",
		"name" : "5351102.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "hIgG",
		"target" : "FM #2",
		"current_phase" : "",
		"medical_therapeutic_area" : "Bone",
		"generic_name" : "AMG 147",
		"indication_description" : "FRACTURE HEALING",
		"business_partner" : "",
		"portfolio_priority" : "Close Out",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 151",
		"product" : "AMG 151",
		"name" : "5218032.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "SM",
		"target" : "GKA #1",
		"current_phase" : "",
		"medical_therapeutic_area" : "Metabolic Disorders",
		"generic_name" : "AMG 151",
		"indication_description" : "DIABETES - TYPE 2",
		"business_partner" : "Array BioPharma",
		"portfolio_priority" : "",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 155",
		"product" : "AMG 155",
		"name" : "5413108.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "PAC1 Ab",
		"current_phase" : "Preclinical",
		"medical_therapeutic_area" : "Neuroscience",
		"generic_name" : "AMG 155",
		"indication_description" : "MIGRAINE",
		"business_partner" : "Novartis",
		"portfolio_priority" : "Gated",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 157",
		"product" : "TEZSPIRE",
		"name" : "5186144.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "TSLP",
		"current_phase" : "Phase 3",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "tezepelumab",
		"indication_description" : "EOSINOPHILIC ESOPHAGITIS",
		"business_partner" : "AstraZeneca\/MedImmune",
		"portfolio_priority" : "Standard",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 157",
		"product" : "TEZSPIRE",
		"name" : "5186009.01",
		"trade_name" : "",
		"notepad" : "Tezspire is a monoclonal antibody that inhibits the action of thymic stromal lymphopoietin (TSLP). It is being investigated for the treatment of severe asthma.;;Following a priority review by the U.S. FDA, Tezspire was approved in December 2021 for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma. Regulatory reviews are underway in the EU, Japan, and other jurisdictions.;;Tezspire is being developed in collaboration with AstraZeneca plc.",
		"modality" : "mAb",
		"target" : "TSLP",
		"current_phase" : "Launch",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "tezepelumab",
		"indication_description" : "ASTHMA",
		"business_partner" : "AstraZeneca\/MedImmune",
		"portfolio_priority" : "Standard",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 157",
		"product" : "TEZSPIRE",
		"name" : "5186109.02",
		"trade_name" : "",
		"notepad" : "Tezepelumab is a human monoclonal antibody that inhibits the action of the thymic stromal lymphopoietin (TSLP). It is being investigated for the treatment of atopic dermatitis. Tezepelumab is being developed in collaboration with AstraZeneca plc.",
		"modality" : "mAb",
		"target" : "TSLP",
		"current_phase" : "Phase 2",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "tezepelumab",
		"indication_description" : "ATOPIC DERMATITIS",
		"business_partner" : "AstraZeneca\/MedImmune",
		"portfolio_priority" : "Gated",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 157",
		"product" : "TEZSPIRE",
		"name" : "5186009.03",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "TSLP",
		"current_phase" : "Phase 1",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "tezepelumab",
		"indication_description" : "ASTHMA",
		"business_partner" : "AstraZeneca\/MedImmune",
		"portfolio_priority" : "Standard",
		"project_type" : "New Patient Population"
	},
	{
		"amg_number" : "AMG 157",
		"product" : "TEZSPIRE",
		"name" : "5186140.01",
		"trade_name" : "",
		"notepad" : "TEZSPIRE is a human monoclonal antibody that inhibits the action of the thymic stromal lymphopoietin (TSLP). It is being investigated for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP).;; TEZSPIRE is being developed in collaboration with AstraZeneca plc.",
		"modality" : "mAb",
		"target" : "TSLP",
		"current_phase" : "Phase 3",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "tezepelumab",
		"indication_description" : "140",
		"business_partner" : "",
		"portfolio_priority" : "Standard",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 157",
		"product" : "TEZSPIRE",
		"name" : "5186030.01",
		"trade_name" : "",
		"notepad" : "Tezspire is a human monoclonal antibody that inhibits the action of the thymic stromal lymphopoietin (TSLP). It is being investigated for the treatment of chronic obstructive pulmonary disease (COPD).;; Tezspire  is being developed in collaboration with AstraZeneca plc.",
		"modality" : "mAb",
		"target" : "TSLP",
		"current_phase" : "Phase 2",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "tezepelumab",
		"indication_description" : "CHRONIC OBSTRUCTIVE PULMONARY DISEASE",
		"business_partner" : "",
		"portfolio_priority" : "Standard",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 157",
		"product" : "TEZSPIRE",
		"name" : "5186107.01",
		"trade_name" : "",
		"notepad" : "Tezspire  is a human monoclonal antibody that inhibits the action of the thymic stromal lymphopoietin (TSLP). It is being investigated for the treatment of chronic spontaneous urticaria (CSU).;; Tezspire is being developed in collaboration with AstraZeneca plc.",
		"modality" : "mAb",
		"target" : "TSLP",
		"current_phase" : "Phase 2",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "tezepelumab",
		"indication_description" : "URTICARIA",
		"business_partner" : "",
		"portfolio_priority" : "Standard",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 160",
		"product" : "acapatamab",
		"name" : "5414024.01",
		"trade_name" : "",
		"notepad" : "Acapatamab (formerly AMG 160) is a half-life extended (HLE) anti- prostate-specific membrane antigen (PSMA) x anti-CD3 bispecific T cell engager (BiTE) molecule. It is being investigated for the treatment of prostate cancer.",
		"modality" : "HLE BiTE",
		"target" : "PSMA",
		"current_phase" : "Phase 1",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "acapatamab",
		"indication_description" : "CANCER - PROSTATE",
		"business_partner" : "",
		"portfolio_priority" : "Standard",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 160",
		"product" : "acapatamab",
		"name" : "5414015.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "HLE BiTE",
		"target" : "PSMA",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "acapatamab",
		"indication_description" : "CANCER - BREAST",
		"business_partner" : "",
		"portfolio_priority" : "Standard",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 160",
		"product" : "acapatamab",
		"name" : "5414028.01",
		"trade_name" : "",
		"notepad" : "Acapatamab (formerly AMG 160) is a half-life extended (HLE) anti- prostate-specific membrane antigen (PSMA) x anti-CD3 bispecific T cell engager (BiTE) molecule. It is being investigated for the treatment of prostate cancer.",
		"modality" : "HLE BiTE",
		"target" : "PSMA",
		"current_phase" : "Preclinical",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "acapatamab",
		"indication_description" : "CANCER - SOLID TUMORS",
		"business_partner" : "",
		"portfolio_priority" : "Standard",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 160",
		"product" : "acapatamab",
		"name" : "5414020.01",
		"trade_name" : "",
		"notepad" : "Acapatamab (formerly AMG 160) is a half-life extended (HLE) anti- prostate-specific membrane antigen (PSMA) x anti-CD3 bispecific T cell engager (BiTE) molecule. It is being investigated for the treatment of non-small cell lung cancer (NSCLC).",
		"modality" : "HLE BiTE",
		"target" : "PSMA",
		"current_phase" : "Phase 1",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "acapatamab",
		"indication_description" : "CANCER - NON SMALL CELL LUNG",
		"business_partner" : "",
		"portfolio_priority" : "Standard",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 162",
		"product" : "denosumab",
		"name" : "13205.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "OPG L Ab",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "denosumab",
		"indication_description" : "ANEMIA - CHEMOTHERAPY INDUCED",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 162",
		"product" : "prolia",
		"name" : "5113062.21",
		"trade_name" : "",
		"notepad" : "Prolia® is a human monoclonal antibody that inhibits RANKL and is indicated: for postmenopausal women with osteoporosis at high risk for fracture, to increase bone mass in men with osteoporosis at high risk for fracture, for glucocorticoid-induced osteoporosis in men and women at high risk of facture, to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer, and to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer.",
		"modality" : "mAb",
		"target" : "OPG L Ab",
		"current_phase" : "Post-Launch",
		"medical_therapeutic_area" : "Bone",
		"generic_name" : "denosumab",
		"indication_description" : "OSTEOPOROSIS",
		"business_partner" : "",
		"portfolio_priority" : "Standard",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 162",
		"product" : "denosumab",
		"name" : "13205.02",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "OPG L Ab",
		"current_phase" : "",
		"medical_therapeutic_area" : "Bone",
		"generic_name" : "denosumab",
		"indication_description" : "ANEMIA - CHEMOTHERAPY INDUCED",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 162",
		"product" : "XGEVA",
		"name" : "5113093.23",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "OPG L Ab",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "denosumab",
		"indication_description" : "CANCER THERAPEUTICS",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 162",
		"product" : "denosumab",
		"name" : "5113900.14",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "OPG L Ab",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "denosumab",
		"indication_description" : "GENERAL (NON-INDICATION SPECIFIC)",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Manufacturing Process"
	},
	{
		"amg_number" : "AMG 162",
		"product" : "XGEVA",
		"name" : "5113020.20",
		"trade_name" : "",
		"notepad" : "XGEVA® is a prescription medicine used to prevent fracture and spinal cord compression or the need for radiation or surgery to bone in patients with multiple myeloma and in patients with bone metastases from solid tumors.;;.",
		"modality" : "mAb",
		"target" : "OPG L Ab",
		"current_phase" : "Phase 3",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "denosumab",
		"indication_description" : "CANCER - NON SMALL CELL LUNG",
		"business_partner" : "Daiichi Sankyo",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 162",
		"product" : "prolia",
		"name" : "5113063.06",
		"trade_name" : "",
		"notepad" : "Prolia® is a human monoclonal antibody that inhibits RANKL and is indicated: for postmenopausal women with osteoporosis at high risk for fracture, to increase bone mass in men with osteoporosis at high risk for fracture, for glucocorticoid-induced osteoporosis in men and women at high risk of facture, to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer, and to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer.",
		"modality" : "mAb",
		"target" : "OPG L Ab",
		"current_phase" : "Post-Launch",
		"medical_therapeutic_area" : "Bone",
		"generic_name" : "denosumab",
		"indication_description" : "OSTEOPOROSIS - POST MENOPAUSAL (PMO)",
		"business_partner" : "Daiichi Sankyo",
		"portfolio_priority" : "Standard",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 162",
		"product" : "prolia",
		"name" : "5113123.16",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "OPG L Ab",
		"current_phase" : "",
		"medical_therapeutic_area" : "Bone",
		"generic_name" : "denosumab",
		"indication_description" : "CP4 PROLIA",
		"business_partner" : "Glaxo Smith-Kline",
		"portfolio_priority" : "",
		"project_type" : "New Manufacturing Process"
	},
	{
		"amg_number" : "AMG 162",
		"product" : "XGEVA",
		"name" : "5113092.02",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "OPG L Ab",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "denosumab",
		"indication_description" : "BONE LOSS ONCOLOGY",
		"business_partner" : "Glaxo Smith-Kline",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 162",
		"product" : "prolia",
		"name" : "5113063.12",
		"trade_name" : "",
		"notepad" : "Prolia® is a human monoclonal antibody that inhibits RANKL and is indicated: for postmenopausal women with osteoporosis at high risk for fracture, to increase bone mass in men with osteoporosis at high risk for fracture, for glucocorticoid-induced osteoporosis in men and women at high risk of facture, to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer, and to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer.",
		"modality" : "mAb",
		"target" : "OPG L Ab",
		"current_phase" : "Post-Launch",
		"medical_therapeutic_area" : "Bone",
		"generic_name" : "denosumab",
		"indication_description" : "OSTEOPOROSIS - POST MENOPAUSAL (PMO)",
		"business_partner" : "",
		"portfolio_priority" : "Standard",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 162",
		"product" : "prolia",
		"name" : "5113063.24",
		"trade_name" : "",
		"notepad" : "Prolia® is a monoclonal antibody that inhibits RANK ligand. It is being investigated for the treatment of glucocorticoid-induced osteoporosis (GIOP) in pediatric patients.",
		"modality" : "mAb",
		"target" : "OPG L Ab",
		"current_phase" : "Phase 3",
		"medical_therapeutic_area" : "Bone",
		"generic_name" : "denosumab",
		"indication_description" : "OSTEOPOROSIS - POST MENOPAUSAL (PMO)",
		"business_partner" : "",
		"portfolio_priority" : "Standard",
		"project_type" : "New Patient Population"
	},
	{
		"amg_number" : "AMG 162",
		"product" : "denosumab",
		"name" : "13205.03",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "OPG L Ab",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "denosumab",
		"indication_description" : "ANEMIA - CHEMOTHERAPY INDUCED",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 162",
		"product" : "denosumab",
		"name" : "13205.04",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "OPG L Ab",
		"current_phase" : "",
		"medical_therapeutic_area" : "Bone",
		"generic_name" : "denosumab",
		"indication_description" : "ANEMIA - CHEMOTHERAPY INDUCED",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 162",
		"product" : "XGEVA",
		"name" : "5113093.05",
		"trade_name" : "",
		"notepad" : "XGEVA® is a prescription medicine used to prevent fracture and spinal cord compression or the need for radiation or surgery to bone in patients with multiple myeloma and in patients with bone metastases from solid tumors.",
		"modality" : "mAb",
		"target" : "OPG L Ab",
		"current_phase" : "Post-Launch",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "denosumab",
		"indication_description" : "CANCER THERAPEUTICS",
		"business_partner" : "Daiichi Sankyo",
		"portfolio_priority" : "Standard",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 162",
		"product" : "denosumab",
		"name" : "5113072.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "OPG L Ab",
		"current_phase" : "",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "denosumab",
		"indication_description" : "RHEUMATOID ARTHRITIS - MUSCULO-SKELETAL",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 162",
		"product" : "prolia",
		"name" : "5113062.22",
		"trade_name" : "",
		"notepad" : "Prolia® is a monoclonal antibody that inhibits RANK ligand. It is being investigated for the treatment of osteogenesis imperfecta in pediatric patients.",
		"modality" : "mAb",
		"target" : "OPG L Ab",
		"current_phase" : "Phase 3",
		"medical_therapeutic_area" : "Bone",
		"generic_name" : "denosumab",
		"indication_description" : "OSTEOPOROSIS",
		"business_partner" : "",
		"portfolio_priority" : "Standard",
		"project_type" : "New Patient Population"
	},
	{
		"amg_number" : "AMG 162",
		"product" : "prolia",
		"name" : "5113063.13",
		"trade_name" : "",
		"notepad" : "Prolia® is a human monoclonal antibody that inhibits RANKL and is indicated: for postmenopausal women with osteoporosis at high risk for fracture, to increase bone mass in men with osteoporosis at high risk for fracture, for glucocorticoid-induced osteoporosis in men and women at high risk of facture, to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer, and to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer.",
		"modality" : "mAb",
		"target" : "OPG L Ab",
		"current_phase" : "Post-Launch",
		"medical_therapeutic_area" : "Bone",
		"generic_name" : "denosumab",
		"indication_description" : "OSTEOPOROSIS - POST MENOPAUSAL (PMO)",
		"business_partner" : "",
		"portfolio_priority" : "Standard",
		"project_type" : "New Manufacturing Process"
	},
	{
		"amg_number" : "AMG 162",
		"product" : "XGEVA",
		"name" : "5113019.19",
		"trade_name" : "",
		"notepad" : "XGEVA® is a prescription medicine used to prevent fracture and spinal cord compression or the need for radiation or surgery to bone in patients with multiple myeloma and in patients with bone metastases from solid tumors.",
		"modality" : "mAb",
		"target" : "OPG L Ab",
		"current_phase" : "Post-Launch",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "denosumab",
		"indication_description" : "CANCER - MULTIPLE MYELOMA",
		"business_partner" : "Daiichi Sankyo",
		"portfolio_priority" : "Standard",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 162",
		"product" : "prolia",
		"name" : "5113984.07",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "OPG L Ab",
		"current_phase" : "",
		"medical_therapeutic_area" : "Bone",
		"generic_name" : "denosumab",
		"indication_description" : "INFLAMMATION",
		"business_partner" : "Daiichi Sankyo",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 162",
		"product" : "XGEVA",
		"name" : "5113124.17",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "OPG L Ab",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "denosumab",
		"indication_description" : "CP4 XGEVA",
		"business_partner" : "Glaxo Smith-Kline",
		"portfolio_priority" : "",
		"project_type" : "New Manufacturing Process"
	},
	{
		"amg_number" : "AMG 162",
		"product" : "XGEVA",
		"name" : "5113013.10",
		"trade_name" : "",
		"notepad" : "XGEVA® is a prescription medicine used to prevent fracture and spinal cord compression or the need for radiation or surgery to bone in patients with multiple myeloma and in patients with bone metastases from solid tumors.",
		"modality" : "mAb",
		"target" : "OPG L Ab",
		"current_phase" : "Post-Launch",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "denosumab",
		"indication_description" : "BONE METASTASIS",
		"business_partner" : "Daiichi Sankyo",
		"portfolio_priority" : "Standard",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 162",
		"product" : "XGEVA",
		"name" : "5113982.15",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "OPG L Ab",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "denosumab",
		"indication_description" : "ONCOLOGY",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 162",
		"product" : "XGEVA",
		"name" : "5113013.22",
		"trade_name" : "",
		"notepad" : "XGEVA® is a prescription medicine used to prevent fracture and spinal cord compression or the need for radiation or surgery to bone in patients with multiple myeloma and in patients with bone metastases from solid tumors.",
		"modality" : "mAb",
		"target" : "OPG L Ab",
		"current_phase" : "Phase 3",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "denosumab",
		"indication_description" : "BONE METASTASIS",
		"business_partner" : "Daiichi Sankyo",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 167",
		"product" : "AMG 167",
		"name" : "5194063.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "Anti-Sclerostin #2",
		"current_phase" : "",
		"medical_therapeutic_area" : "Bone",
		"generic_name" : "AMG 167",
		"indication_description" : "OSTEOPOROSIS - POST MENOPAUSAL (PMO)",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 171",
		"product" : "AMG 171",
		"name" : "5423060.01",
		"trade_name" : "",
		"notepad" : "AMG 171 is a Growth Differential Factor 15 (GDF 15) analog. It is being investigated for the treatment of obesity.",
		"modality" : "PrFc",
		"target" : "GDF15",
		"current_phase" : "Phase 1",
		"medical_therapeutic_area" : "Metabolic Disorders",
		"generic_name" : "AMG 171",
		"indication_description" : "OBESITY",
		"business_partner" : "",
		"portfolio_priority" : "Standard",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 172",
		"product" : "AMG 172",
		"name" : "5213982.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "AbSM",
		"target" : "CD27L",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "AMG 172",
		"indication_description" : "ONCOLOGY",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 172",
		"product" : "AMG 172",
		"name" : "5213028.02",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "AbSM",
		"target" : "CD27L",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "AMG 172",
		"indication_description" : "CANCER - SOLID TUMORS",
		"business_partner" : "Immunogen Inc.",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 173",
		"product" : "AMG 173",
		"name" : "5436048.01",
		"trade_name" : "",
		"notepad" : "AMG 173 is an anti-CD123+FLT3 x anti-CD3 BiTE® (bispecific T cell engager) construct. It is being investigated as a treatment for acute myeloid leukemia.",
		"modality" : "HLE dBiTE-OR",
		"target" : "CD123xFLT3",
		"current_phase" : "Preclinical",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "AMG 173",
		"indication_description" : "LEUKEMIA - ACUTE MYELOID (AML)",
		"business_partner" : "",
		"portfolio_priority" : "Gated",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 176",
		"product" : "AMG 176",
		"name" : "5370982.01",
		"trade_name" : "",
		"notepad" : "AMG 176 is a small molecule inhibitor of myeloid cell leukemia 1 (MCL-1). It is being investigated for the treatment of hematologic malignancies.",
		"modality" : "SM",
		"target" : "Mcl - 1",
		"current_phase" : "Phase 1",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "AMG 176",
		"indication_description" : "ONCOLOGY",
		"business_partner" : "",
		"portfolio_priority" : "Standard",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 176",
		"product" : "AMG 176",
		"name" : "5370048.01",
		"trade_name" : "",
		"notepad" : "AMG 176 is a small molecule inhibitor of myeloid cell leukemia 1 (MCL-1). It is being investigated for the treatment of hematologic malignancies.",
		"modality" : "SM",
		"target" : "Mcl - 1",
		"current_phase" : "Phase 1",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "AMG 176",
		"indication_description" : "LEUKEMIA - ACUTE MYELOID (AML)",
		"business_partner" : "",
		"portfolio_priority" : "Standard",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 176",
		"product" : "AMG 176",
		"name" : "5370057.01",
		"trade_name" : "",
		"notepad" : "AMG 176 is a small molecule inhibitor of myeloid cell leukemia 1 (MCL-1). It is being investigated for the treatment of hematologic malignancies.",
		"modality" : "SM",
		"target" : "Mcl - 1",
		"current_phase" : "Preclinical",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "AMG 176",
		"indication_description" : "MYELODYSPLASTIC SYNDROME (MDS)",
		"business_partner" : "",
		"portfolio_priority" : "Standard",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 181",
		"product" : "AMG 181",
		"name" : "5206031.02",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "a4B7 Ab",
		"current_phase" : "",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "AMG 181",
		"indication_description" : "CROHN'S DISEASE",
		"business_partner" : "AstraZeneca\/MedImmune",
		"portfolio_priority" : "Close Out",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 181",
		"product" : "AMG 181",
		"name" : "5206104.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "a4B7 Ab",
		"current_phase" : "",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "AMG 181",
		"indication_description" : "ULCERATIVE COLITIS",
		"business_partner" : "AstraZeneca\/MedImmune",
		"portfolio_priority" : "Close Out",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 191",
		"product" : "AMG 191",
		"name" : "5169085.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "c-Kit",
		"current_phase" : "",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "AMG 191",
		"indication_description" : "IDIOPATHIC PULMONARY FIBROSIS",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 193",
		"product" : "AMG 193",
		"name" : "5460028.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "SM",
		"target" : "PRMT5",
		"current_phase" : "Phase 1",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "AMG 193",
		"indication_description" : "CANCER - SOLID TUMORS",
		"business_partner" : "",
		"portfolio_priority" : "Fastlane",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 195",
		"product" : "AMG 195",
		"name" : "5172046.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "PepFc",
		"target" : "AMP5 b\/u",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "AMG 195",
		"indication_description" : "IDIOPATHIC THROMBOCYTOPENIA PURPURA-ITP",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 199",
		"product" : "AMG 199",
		"name" : "5419082.01",
		"trade_name" : "",
		"notepad" : "AMG 199 is a half-life extended (HLE) anti-MUC17 x anti-CD3 bispecific T cell engager (BiTE) molecule. It is being investigated for the treatment of MUC17-Positive Solid Tumors including Gastric, Gastroesophageal Junction, Colorectal, and Pancreatic Cancers",
		"modality" : "HLE BiTE",
		"target" : "MUC17",
		"current_phase" : "Phase 1",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "AMG 199",
		"indication_description" : "CANCER - GASTRIC",
		"business_partner" : "",
		"portfolio_priority" : "Standard",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 199",
		"product" : "AMG 199",
		"name" : "5419082.04",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "HLE BiTE",
		"target" : "MUC17",
		"current_phase" : "Preclinical",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "AMG 199",
		"indication_description" : "CANCER - GASTRIC",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Combination of a Pipeline Active Substance"
	},
	{
		"amg_number" : "AMG 199",
		"product" : "AMG 199",
		"name" : "5419023.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "HLE BiTE",
		"target" : "MUC17",
		"current_phase" : "Phase 1",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "AMG 199",
		"indication_description" : "CANCER - PANCREAS",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 199",
		"product" : "AMG 199",
		"name" : "5419982.01",
		"trade_name" : "",
		"notepad" : "AMG 199 LCM Indication: CRC",
		"modality" : "HLE BiTE",
		"target" : "MUC17",
		"current_phase" : "Phase 1",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "AMG 199",
		"indication_description" : "ONCOLOGY",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 204",
		"product" : "AMG 204",
		"name" : "5469028.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "B7-H4",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "AMG 204",
		"indication_description" : "CANCER - SOLID TUMORS",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 208",
		"product" : "AMG 208",
		"name" : "5195028.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "SM",
		"target" : "C-met #2",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "AMG 208",
		"indication_description" : "CANCER - SOLID TUMORS",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 211",
		"product" : "AMG 211",
		"name" : "5310028.01",
		"trade_name" : "",
		"notepad" : "AMG 211 CLINICAL ACTIVITIES HAVE BEEN TERMINATED.  AMG 211 is a BiTE antibody targeting carcinoembryonic antigen (CEA).  It is being investigated in adults with advanced GI adenocarcinomas.  AMG 211 is being developed in collaboration with MedImmune.",
		"modality" : "BiTE",
		"target" : "CEA aka MT111",
		"current_phase" : "Phase 1",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "AMG 211",
		"indication_description" : "CANCER - SOLID TUMORS",
		"business_partner" : "AstraZeneca\/MedImmune",
		"portfolio_priority" : "Close Out",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 212",
		"product" : "AMG 212",
		"name" : "5309020.01",
		"trade_name" : "",
		"notepad" : "AMG 212 is an anti-prostate-specific membrane antigen (PSMA) x anti-CD3 BiTE® (bispecific T cell engager) construct. It is being investigated for the treatment of prostate cancer.",
		"modality" : "BiTE",
		"target" : "PSMA",
		"current_phase" : "Preclinical",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "AMG 212",
		"indication_description" : "CANCER - NON SMALL CELL LUNG",
		"business_partner" : "",
		"portfolio_priority" : "Close Out",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 212",
		"product" : "AMG 212",
		"name" : "5309028.01",
		"trade_name" : "",
		"notepad" : "AMG 212 is an anti-prostate-specific membrane antigen (PSMA) x anti-CD3 BiTE® (bispecific T cell engager) construct. It is being investigated for the treatment of prostate cancer.",
		"modality" : "BiTE",
		"target" : "PSMA",
		"current_phase" : "Preclinical",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "AMG 212",
		"indication_description" : "CANCER - SOLID TUMORS",
		"business_partner" : "",
		"portfolio_priority" : "Close Out",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 212",
		"product" : "AMG 212",
		"name" : "5309024.01",
		"trade_name" : "",
		"notepad" : "AMG 212 is an anti-prostate-specific membrane antigen (PSMA) x anti-CD3 BiTE® (bispecific T cell engager) construct. It is being investigated for the treatment of prostate cancer.",
		"modality" : "BiTE",
		"target" : "PSMA",
		"current_phase" : "Phase 1",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "AMG 212",
		"indication_description" : "CANCER - PROSTATE",
		"business_partner" : "",
		"portfolio_priority" : "Close Out",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 217",
		"product" : "AMG 217",
		"name" : "5202982.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "Pr",
		"target" : "ACT2BR",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "AMG 217",
		"indication_description" : "ONCOLOGY",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 221",
		"product" : "AMG 221",
		"name" : "5122032.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "SM",
		"target" : "11B HSD1 SG",
		"current_phase" : "",
		"medical_therapeutic_area" : "Metabolic Disorders",
		"generic_name" : "AMG 221",
		"indication_description" : "DIABETES - TYPE 2",
		"business_partner" : "Biovitrum",
		"portfolio_priority" : "",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 222",
		"product" : "AMG 222",
		"name" : "5191032.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "SM",
		"target" : "DPPIV",
		"current_phase" : "",
		"medical_therapeutic_area" : "Metabolic Disorders",
		"generic_name" : "AMG 222",
		"indication_description" : "DIABETES - TYPE 2",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 223",
		"product" : "bixalomer",
		"name" : "5190081.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "SM",
		"target" : "Phosphate Binder",
		"current_phase" : "",
		"medical_therapeutic_area" : "Nephrology",
		"generic_name" : "bixalomer",
		"indication_description" : "HYPERPHOSPHATEMIA",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 224",
		"product" : "AMG 224",
		"name" : "5322019.01",
		"trade_name" : "",
		"notepad" : "AMG 224 IS IN CLOSE OUT (per May 2018 PG decision).  AMG 224 is an antibody-drug conjugate (ADC) directed against anti- B-cell maturation antigen (BCMA) investigated for the treatment of Multiple Myeloma.",
		"modality" : "AbSM",
		"target" : "BCMA Onc",
		"current_phase" : "Phase 1",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "AMG 224",
		"indication_description" : "CANCER - MULTIPLE MYELOMA",
		"business_partner" : "",
		"portfolio_priority" : "Close Out",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 224",
		"product" : "AMG 224",
		"name" : "5322019.04",
		"trade_name" : "",
		"notepad" : "AMG 224 IS IN CLOSE OUT (per May 2018 PG decision).  AMG 224 is an antibody-drug conjugate (ADC) directed against anti- B-cell maturation antigen (BCMA) investigated for the treatment of Multiple Myeloma.",
		"modality" : "AbSM",
		"target" : "BCMA Onc",
		"current_phase" : "Phase 1",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "AMG 224",
		"indication_description" : "CANCER - MULTIPLE MYELOMA",
		"business_partner" : "",
		"portfolio_priority" : "Close Out",
		"project_type" : "New Patient Population"
	},
	{
		"amg_number" : "AMG 224",
		"product" : "AMG 224",
		"name" : "5322019.02",
		"trade_name" : "",
		"notepad" : "AMG 224 IS IN CLOSE OUT (per May 2018 PG decision).  AMG 224 is an antibody-drug conjugate (ADC) directed against anti- B-cell maturation antigen (BCMA) investigated for the treatment of Multiple Myeloma.",
		"modality" : "AbSM",
		"target" : "BCMA Onc",
		"current_phase" : "Phase 1",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "AMG 224",
		"indication_description" : "CANCER - MULTIPLE MYELOMA",
		"business_partner" : "",
		"portfolio_priority" : "Close Out",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 226",
		"product" : "AMG 226",
		"name" : "5435048.01",
		"trade_name" : "",
		"notepad" : "AMG 226 is an anti-CD70 x anti-CD3 BiTE® (bispecific T cell engager) construct. It is being investigated as a treatment for acute myeloid leukemia.",
		"modality" : "HLE BiTE",
		"target" : "CD70",
		"current_phase" : "Preclinical",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "AMG 226",
		"indication_description" : "LEUKEMIA - ACUTE MYELOID (AML)",
		"business_partner" : "",
		"portfolio_priority" : "Standard",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 227",
		"product" : "AMG 227",
		"name" : "5442028.01",
		"trade_name" : "",
		"notepad" : "AMG 227 is a PDL1-41BB AbFrab capitalizes on two clinically-proven immune mechanisms and limits 41BB agonism to PDL1-expressing tissues, with the potential to improve upon SOC anti-PD(L)1 across various indications including NSCLC, Gastric and TNBC. ",
		"modality" : "AbFrab",
		"target" : "PDL1-41BB",
		"current_phase" : "Preclinical",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "AMG 227",
		"indication_description" : "CANCER - SOLID TUMORS",
		"business_partner" : "",
		"portfolio_priority" : "Standard",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 228",
		"product" : "AMG 228",
		"name" : "5326028.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "GITR",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "AMG 228",
		"indication_description" : "CANCER - SOLID TUMORS",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 231",
		"product" : "AMG 231",
		"name" : "5476028.01",
		"trade_name" : "",
		"notepad" : "AMG 231 is an afucosylated anti-CCR8 monocloncal antibody (mAb) for the treatment of solid tumors.",
		"modality" : "mAb",
		"target" : "CCR8",
		"current_phase" : "Preclinical",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "AMG 231",
		"indication_description" : "CANCER - SOLID TUMORS",
		"business_partner" : "",
		"portfolio_priority" : "Standard",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 232",
		"product" : "AMG 232",
		"name" : "5300028.01",
		"trade_name" : "",
		"notepad" : "AMG 232 IS IN CLOSE OUT\/TRANSITION (per 2016 PG E2L decision).  AMG 232 is an MDM2 inhibitor that induces apoptosis through the p53 pathway. ",
		"modality" : "SM",
		"target" : "MDM2",
		"current_phase" : "Phase 1",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "AMG 232",
		"indication_description" : "CANCER - SOLID TUMORS",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 235",
		"product" : "AMG 235",
		"name" : "5459020.01",
		"trade_name" : "",
		"notepad" : "CD112R and TIGIT are immune inhibitory receptors that regulate T and NK cell function.  CD112R+TIGIT mAb provides immune activation through release of ligands to activate the immune costimulatory CD226 signal. In addition, the CD112R+TIGIT immune checkpoint is complementary to and non-overlapping with the PD1 checkpoint. Therefore, C112R+TIGIT mAb, when combined with anti-PD1 mAb, may result in more pronounced and durable responses in solid tumor indications.",
		"modality" : "mAb",
		"target" : "CD112R+TIGIT",
		"current_phase" : "Preclinical",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "AMG 235",
		"indication_description" : "CANCER - NON SMALL CELL LUNG",
		"business_partner" : "",
		"portfolio_priority" : "Standard",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 245",
		"product" : "AMG 245",
		"name" : "5123073.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "PepFc",
		"target" : "Myostatin",
		"current_phase" : "",
		"medical_therapeutic_area" : "Metabolic Disorders",
		"generic_name" : "AMG 245",
		"indication_description" : "SARCOPENIA - IMMOBILIZATION",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 246",
		"product" : "AMG 246",
		"name" : "5448141.01",
		"trade_name" : "",
		"notepad" : "AMG 246 is a COVID-19 neutralizing antibody. It is being investigated as a treatment or prophylactic agent for COVID-19.",
		"modality" : "mAb",
		"target" : "COVID19",
		"current_phase" : "Preclinical",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "AMG 246",
		"indication_description" : "COVID-19",
		"business_partner" : "",
		"portfolio_priority" : "Standard",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 247",
		"product" : "AMG 247",
		"name" : "5211080.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "GM-CSF #2",
		"current_phase" : "",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "AMG 247",
		"indication_description" : "MULTIPLE SCLEROSIS",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 256",
		"product" : "latikafusp",
		"name" : "5421028.01",
		"trade_name" : "",
		"notepad" : "AMG 256 (anti-PD1XIL21 mutein) is a first-in-class novel targeted IL-21 receptor agonist designed to selectively turn on the Interleukin 21 (IL-21) pathway in programmed cell death-1 (PD-1) positive cells.  It is being investigated for the treatment of solid tumors. ",
		"modality" : "AbePr",
		"target" : "PD1-IL21",
		"current_phase" : "Phase 1",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "latikafusp",
		"indication_description" : "CANCER - SOLID TUMORS",
		"business_partner" : "",
		"portfolio_priority" : "Standard",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 261",
		"product" : "AMG 261",
		"name" : "5196032.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "Pr",
		"target" : "FGF-21",
		"current_phase" : "",
		"medical_therapeutic_area" : "Metabolic Disorders",
		"generic_name" : "AMG 261",
		"indication_description" : "DIABETES - TYPE 2",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 266",
		"product" : "AMG 266",
		"name" : "5478985.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "siRNA",
		"target" : "mARC1",
		"current_phase" : "Preclinical",
		"medical_therapeutic_area" : "Metabolic Disorders",
		"generic_name" : "AMG 266",
		"indication_description" : "METABOLIC DISORDERS",
		"business_partner" : "",
		"portfolio_priority" : "Gated",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 273",
		"product" : "AMG 273",
		"name" : "5124028.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "SM",
		"target" : "VEGFR B\/U",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "AMG 273",
		"indication_description" : "CANCER - SOLID TUMORS",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 277",
		"product" : "AMG 277",
		"name" : "5180080.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "SM",
		"target" : "S1P1",
		"current_phase" : "",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "AMG 277",
		"indication_description" : "MULTIPLE SCLEROSIS",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 282",
		"product" : "AMG 282",
		"name" : "5296009.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "ST2",
		"current_phase" : "",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "AMG 282",
		"indication_description" : "ASTHMA",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 282",
		"product" : "AMG 282",
		"name" : "5296030.02",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "ST2",
		"current_phase" : "",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "AMG 282",
		"indication_description" : "CHRONIC OBSTRUCTIVE PULMONARY DISEASE",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 287",
		"product" : "AMG 287",
		"name" : "5298032.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "FGF21 #3",
		"current_phase" : "",
		"medical_therapeutic_area" : "Metabolic Disorders",
		"generic_name" : "AMG 287",
		"indication_description" : "DIABETES - TYPE 2",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 301",
		"product" : "AMG 301",
		"name" : "5325108.01",
		"trade_name" : "",
		"notepad" : "AMG 301 is a human monoclonal antibody that inhibits the pituitary adenylate cyclase-activating polypeptide type 1 (PAC1) receptor. It is being investigated for migraine prevention. AMG 301 is being developed in collaboration with Novartis Pharma AG.",
		"modality" : "mAb",
		"target" : "PAC1 Ab",
		"current_phase" : "Phase 2",
		"medical_therapeutic_area" : "Neuroscience",
		"generic_name" : "AMG 301",
		"indication_description" : "MIGRAINE",
		"business_partner" : "Novartis",
		"portfolio_priority" : "Close Out",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 303",
		"product" : "AMG 303",
		"name" : "5125045.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "OX40L",
		"current_phase" : "",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "AMG 303",
		"indication_description" : "INFLAMMATORY BOWEL DISEASE",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 305",
		"product" : "AMG 305",
		"name" : "5473028.01",
		"trade_name" : "",
		"notepad" : "CDH3-MSLN HLE dBiTE AND is a dual targeting, half-life extended BiTE molecule that targets P-cadherin (CDH3) and mesothelin (MSLN).",
		"modality" : "HLE dBiTE-AND",
		"target" : "MSLN\/CDH3",
		"current_phase" : "Preclinical",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "AMG 305",
		"indication_description" : "CANCER - SOLID TUMORS",
		"business_partner" : "",
		"portfolio_priority" : "Standard",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 309",
		"product" : "AMG 309",
		"name" : "5456141.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "SARS-COV2",
		"current_phase" : "Preclinical",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "AMG 309",
		"indication_description" : "COVID-19",
		"business_partner" : "",
		"portfolio_priority" : "Standard",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 311",
		"product" : "AMG 311",
		"name" : "5434028.01",
		"trade_name" : "",
		"notepad" : "AMG 311 is an oncolytic immunotherapy derived from herpes simplex virus type 1 (HSV-1).  It is being investigated in solid tumors.",
		"modality" : "Vir",
		"target" : "IL-12\/FLT3L",
		"current_phase" : "Preclinical",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "AMG 311",
		"indication_description" : "CANCER - SOLID TUMORS",
		"business_partner" : "",
		"portfolio_priority" : "Gated",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 317",
		"product" : "AMG 317",
		"name" : "5126009.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "IL-4R Ab",
		"current_phase" : "",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "AMG 317",
		"indication_description" : "ASTHMA",
		"business_partner" : "Medarex",
		"portfolio_priority" : "",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 319",
		"product" : "AMG 319",
		"name" : "5214984.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "SM",
		"target" : "PI3 Kinase Delta",
		"current_phase" : "",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "AMG 319",
		"indication_description" : "INFLAMMATION",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 319",
		"product" : "AMG 319",
		"name" : "5214982.02",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "SM",
		"target" : "PI3 Kinase Delta",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "AMG 319",
		"indication_description" : "ONCOLOGY",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 327",
		"product" : "AMG 327",
		"name" : "5127064.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "SM",
		"target" : "B1 (SM)",
		"current_phase" : "",
		"medical_therapeutic_area" : "Neuroscience",
		"generic_name" : "AMG 327",
		"indication_description" : "PAIN - CHRONIC INFLAMMATORY",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 330",
		"product" : "AMG 330",
		"name" : "5316048.01",
		"trade_name" : "",
		"notepad" : "AMG 330 is an anti-CD33 x anti-CD3 bispecific T cell engager (BiTE®) molecule. It is being investigated as a treatment for acute myeloid leukemia (AML).",
		"modality" : "BiTE",
		"target" : "CD33",
		"current_phase" : "Phase 1",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "AMG 330",
		"indication_description" : "LEUKEMIA - ACUTE MYELOID (AML)",
		"business_partner" : "",
		"portfolio_priority" : "Standard",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 333",
		"product" : "AMG 333",
		"name" : "5323108.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "SM",
		"target" : "TRPM8 - Onc",
		"current_phase" : "",
		"medical_therapeutic_area" : "Neuroscience",
		"generic_name" : "AMG 333",
		"indication_description" : "MIGRAINE",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 334",
		"product" : "Aimovig",
		"name" : "5220108.03",
		"trade_name" : "Aimovig",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "CGRPR",
		"current_phase" : "",
		"medical_therapeutic_area" : "Neuroscience",
		"generic_name" : "erenumab",
		"indication_description" : "MIGRAINE",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 334",
		"product" : "Aimovig",
		"name" : "5220108.02",
		"trade_name" : "Aimovig",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "CGRPR",
		"current_phase" : "",
		"medical_therapeutic_area" : "Neuroscience",
		"generic_name" : "erenumab",
		"indication_description" : "MIGRAINE",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 334",
		"product" : "Aimovig",
		"name" : "5220108.04",
		"trade_name" : "Aimovig",
		"notepad" : "Aimovig® is a monoclonal antibody that inhibits the calcitonin gene-related peptide receptor (CGRP-R). It is being investigated for prevention of chronic and episodic migraine in pediatric patients.;;ADDITIONAL INFORMATION: ;Aimovig® is developed in partnership with Novartis.",
		"modality" : "mAb",
		"target" : "CGRPR",
		"current_phase" : "Phase 3",
		"medical_therapeutic_area" : "Neuroscience",
		"generic_name" : "erenumab",
		"indication_description" : "MIGRAINE",
		"business_partner" : "",
		"portfolio_priority" : "Standard",
		"project_type" : "New Patient Population"
	},
	{
		"amg_number" : "AMG 334",
		"product" : "Aimovig",
		"name" : "5220108.01",
		"trade_name" : "Aimovig",
		"notepad" : "AIMOVIG® is a calcitonin gene-related peptide receptor antagonist indicated for the preventive treatment of migraine in adults.",
		"modality" : "mAb",
		"target" : "CGRPR",
		"current_phase" : "Launch",
		"medical_therapeutic_area" : "Neuroscience",
		"generic_name" : "erenumab",
		"indication_description" : "MIGRAINE",
		"business_partner" : "Novartis",
		"portfolio_priority" : "Standard",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 337",
		"product" : "AMG 337",
		"name" : "5216028.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "SM",
		"target" : "c-met #3",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "AMG 337",
		"indication_description" : "CANCER - SOLID TUMORS",
		"business_partner" : "",
		"portfolio_priority" : "Close Out",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 337",
		"product" : "AMG 337",
		"name" : "5216020.05",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "SM",
		"target" : "c-met #3",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "AMG 337",
		"indication_description" : "CANCER - NON SMALL CELL LUNG",
		"business_partner" : "",
		"portfolio_priority" : "Close Out",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 337",
		"product" : "AMG 337",
		"name" : "5216016.04",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "SM",
		"target" : "c-met #3",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "AMG 337",
		"indication_description" : "CANCER - COLORECTAL",
		"business_partner" : "",
		"portfolio_priority" : "Close Out",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 337",
		"product" : "AMG 337",
		"name" : "5216082.02",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "SM",
		"target" : "c-met #3",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "AMG 337",
		"indication_description" : "CANCER - GASTRIC",
		"business_partner" : "Astellas,RPharm",
		"portfolio_priority" : "Close Out",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 337",
		"product" : "AMG 337",
		"name" : "5216982.03",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "SM",
		"target" : "c-met #3",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "AMG 337",
		"indication_description" : "ONCOLOGY",
		"business_partner" : "",
		"portfolio_priority" : "Close Out",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 340",
		"product" : "AMG 340",
		"name" : "5474024.01",
		"trade_name" : "",
		"notepad" : "AMG 340 (previously TNB 585) is an anti-prostate-specific membrane antigen (PSMA) x anti-CD3 lower T cell affinity bispecific T cell engager (BiTE) molecule and is designed using the human heavy chain antibody platform. It is being investigated for the treatment of prostate cancer.",
		"modality" : "TCE FrabFc",
		"target" : "PSMA",
		"current_phase" : "Phase 1",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "AMG 340",
		"indication_description" : "CANCER - PROSTATE",
		"business_partner" : "",
		"portfolio_priority" : "Standard",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 357",
		"product" : "AMG 357",
		"name" : "5282072.03",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "SM",
		"target" : "PI3 Kinase Delta #2",
		"current_phase" : "",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "AMG 357",
		"indication_description" : "RHEUMATOID ARTHRITIS - MUSCULO-SKELETAL",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 357",
		"product" : "AMG 357",
		"name" : "5282030.02",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "SM",
		"target" : "PI3 Kinase Delta #2",
		"current_phase" : "",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "AMG 357",
		"indication_description" : "CHRONIC OBSTRUCTIVE PULMONARY DISEASE",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 357",
		"product" : "AMG 357",
		"name" : "5282051.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "SM",
		"target" : "PI3 Kinase Delta #2",
		"current_phase" : "",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "AMG 357",
		"indication_description" : "LUPUS NEPHRITIS",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 369",
		"product" : "AMG 369",
		"name" : "5203984.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "SM",
		"target" : "S1P1 #2",
		"current_phase" : "",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "AMG 369",
		"indication_description" : "INFLAMMATION",
		"business_partner" : "Epix",
		"portfolio_priority" : "",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 379",
		"product" : "AMG 379",
		"name" : "5129064.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "Pep",
		"target" : "B1 Peptide (CLOSED)",
		"current_phase" : "",
		"medical_therapeutic_area" : "Neuroscience",
		"generic_name" : "AMG 379",
		"indication_description" : "PAIN - CHRONIC INFLAMMATORY",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 386",
		"product" : "trebananib",
		"name" : "5130020.09",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "PepFc",
		"target" : "Ang2",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "trebananib",
		"indication_description" : "CANCER - NON SMALL CELL LUNG",
		"business_partner" : "",
		"portfolio_priority" : "Close Out",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 386",
		"product" : "trebananib",
		"name" : "5130016.06",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "PepFc",
		"target" : "Ang2",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "trebananib",
		"indication_description" : "CANCER - COLORECTAL",
		"business_partner" : "Takeda",
		"portfolio_priority" : "Close Out",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 386",
		"product" : "trebananib",
		"name" : "5130094.07",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "PepFc",
		"target" : "Ang2",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "trebananib",
		"indication_description" : "CANCER - HEPATOCELLULAR CARCINOMA",
		"business_partner" : "Takeda",
		"portfolio_priority" : "Close Out",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 386",
		"product" : "trebananib",
		"name" : "5130022.03",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "PepFc",
		"target" : "Ang2",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "trebananib",
		"indication_description" : "CANCER - OVARIAN",
		"business_partner" : "",
		"portfolio_priority" : "Close Out",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 386",
		"product" : "trebananib",
		"name" : "5130022.08",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "PepFc",
		"target" : "Ang2",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "trebananib",
		"indication_description" : "CANCER - OVARIAN",
		"business_partner" : "Takeda",
		"portfolio_priority" : "Close Out",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 386",
		"product" : "trebananib",
		"name" : "5130025.02",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "PepFc",
		"target" : "Ang2",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "trebananib",
		"indication_description" : "CANCER - RENAL CELL",
		"business_partner" : "",
		"portfolio_priority" : "Close Out",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 386",
		"product" : "trebananib",
		"name" : "5130015.04",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "PepFc",
		"target" : "Ang2",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "trebananib",
		"indication_description" : "CANCER - BREAST",
		"business_partner" : "",
		"portfolio_priority" : "Close Out",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 386",
		"product" : "trebananib",
		"name" : "5130082.05",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "PepFc",
		"target" : "Ang2",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "trebananib",
		"indication_description" : "CANCER - GASTRIC",
		"business_partner" : "Takeda",
		"portfolio_priority" : "Close Out",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 386",
		"product" : "trebananib",
		"name" : "5130028.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "PepFc",
		"target" : "Ang2",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "trebananib",
		"indication_description" : "CANCER - SOLID TUMORS",
		"business_partner" : "",
		"portfolio_priority" : "Close Out",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 386",
		"product" : "trebananib",
		"name" : "5130982.10",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "PepFc",
		"target" : "Ang2",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "trebananib",
		"indication_description" : "ONCOLOGY",
		"business_partner" : "",
		"portfolio_priority" : "Close Out",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 391",
		"product" : "AMG 391",
		"name" : "5185080.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "GM-CSF",
		"current_phase" : "",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "AMG 391",
		"indication_description" : "MULTIPLE SCLEROSIS",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 397",
		"product" : "murizatoclax",
		"name" : "5399019.02",
		"trade_name" : "",
		"notepad" : "AMG 397 is a small molecule inhibitor of myeloid cell leukemia 1 (MCL-1). It is being investigated for the treatment of hematologic malignancies.",
		"modality" : "SM",
		"target" : "Mcl - 1",
		"current_phase" : "Phase 1",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "murizatoclax",
		"indication_description" : "CANCER - MULTIPLE MYELOMA",
		"business_partner" : "",
		"portfolio_priority" : "Gated",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 397",
		"product" : "murizatoclax",
		"name" : "5399048.01",
		"trade_name" : "",
		"notepad" : "AMG 397 is a small molecule inhibitor of myeloid cell leukemia 1 (MCL-1). It is being investigated for the treatment of hematologic malignancies.",
		"modality" : "SM",
		"target" : "Mcl - 1",
		"current_phase" : "Phase 1",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "murizatoclax",
		"indication_description" : "LEUKEMIA - ACUTE MYELOID (AML)",
		"business_partner" : "",
		"portfolio_priority" : "Gated",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 397",
		"product" : "murizatoclax",
		"name" : "5399053.01",
		"trade_name" : "",
		"notepad" : "AMG 397 is a small molecule inhibitor of myeloid cell leukemia 1 (MCL-1). It is being investigated for the treatment of hematologic malignancies.",
		"modality" : "SM",
		"target" : "Mcl - 1",
		"current_phase" : "Phase 1",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "murizatoclax",
		"indication_description" : "LYMPHOMA - NON HODGKINS",
		"business_partner" : "",
		"portfolio_priority" : "Gated",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 397",
		"product" : "murizatoclax",
		"name" : "5399057.01",
		"trade_name" : "",
		"notepad" : "AMG 397 is a small molecule inhibitor of myeloid cell leukemia 1 (MCL-1). It is being investigated for the treatment of hematologic malignancies.",
		"modality" : "SM",
		"target" : "Mcl - 1",
		"current_phase" : "Preclinical",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "murizatoclax",
		"indication_description" : "MYELODYSPLASTIC SYNDROME (MDS)",
		"business_partner" : "",
		"portfolio_priority" : "Gated",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 399",
		"product" : "AMG 399",
		"name" : "5352108.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "SM",
		"target" : "TRPM8#2",
		"current_phase" : "",
		"medical_therapeutic_area" : "Neuroscience",
		"generic_name" : "AMG 399",
		"indication_description" : "MIGRAINE",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 399",
		"product" : "AMG 399",
		"name" : "5352900.02",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "SM",
		"target" : "TRPM8#2",
		"current_phase" : "",
		"medical_therapeutic_area" : "Neuroscience",
		"generic_name" : "AMG 399",
		"indication_description" : "GENERAL (NON-INDICATION SPECIFIC)",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 401",
		"product" : "AMG 401",
		"name" : "5313028.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "EpCAM aka MT201",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "AMG 401",
		"indication_description" : "CANCER - SOLID TUMORS",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 403",
		"product" : "AMG 403",
		"name" : "5164083.02",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "NGF Ab (PANT) backup",
		"current_phase" : "",
		"medical_therapeutic_area" : "Neuroscience",
		"generic_name" : "AMG 403",
		"indication_description" : "PAIN - OSTEOARTHRITIS",
		"business_partner" : "Medarex",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 403",
		"product" : "AMG 403",
		"name" : "5164090.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "NGF Ab (PANT) backup",
		"current_phase" : "",
		"medical_therapeutic_area" : "Neuroscience",
		"generic_name" : "AMG 403",
		"indication_description" : "POSTHERPETIC NEURALGIA",
		"business_partner" : "Medarex",
		"portfolio_priority" : "",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 403",
		"product" : "AMG 403",
		"name" : "5164089.03",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "NGF Ab (PANT) backup",
		"current_phase" : "",
		"medical_therapeutic_area" : "Neuroscience",
		"generic_name" : "AMG 403",
		"indication_description" : "PAINFUL DIABETIC NEUROPATHY",
		"business_partner" : "Medarex",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 404",
		"product" : "AMG 404",
		"name" : "5422028.05",
		"trade_name" : "",
		"notepad" : "AMG 404 is a human anti-Programmed cell death-1 (PD-1) monoclonal antibody being investigated as a treatment for patients with solid tumors. MVASI(TM) is a recombinant humanized monoclonal IgG1 antibody that binds VEGF.",
		"modality" : "mAb",
		"target" : "PD1",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "AMG 404",
		"indication_description" : "CANCER - SOLID TUMORS",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 404",
		"product" : "AMG 404",
		"name" : "5422028.01",
		"trade_name" : "",
		"notepad" : "AMG 404 is an  anti-programmed cell death-1 (PD-1) monoclonal antibody being investigated as a treatment for patients with solid tumors. It is being developed for use in combination with other Amgen oncology portfolio molecules.",
		"modality" : "mAb",
		"target" : "PD1",
		"current_phase" : "Phase 1",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "AMG 404",
		"indication_description" : "CANCER - SOLID TUMORS",
		"business_partner" : "",
		"portfolio_priority" : "Standard",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 404",
		"product" : "AMG 404",
		"name" : "5422028.04",
		"trade_name" : "",
		"notepad" : "AMG 404 is a human anti-Programmed cell death-1 (PD-1) monoclonal antibody being investigated as a treatment for patients with solid tumors. MVASI(TM) is a recombinant humanized monoclonal IgG1 antibody that binds VEGF. ;;",
		"modality" : "mAb",
		"target" : "PD1",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "AMG 404",
		"indication_description" : "CANCER - SOLID TUMORS",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 404",
		"product" : "AMG 404",
		"name" : "5422028.03",
		"trade_name" : "",
		"notepad" : "TBD",
		"modality" : "mAb",
		"target" : "PD1",
		"current_phase" : "Phase 1",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "AMG 404",
		"indication_description" : "CANCER - SOLID TUMORS",
		"business_partner" : "",
		"portfolio_priority" : "Standard",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 407",
		"product" : "Otezla",
		"name" : "5438070.01",
		"trade_name" : "Otezla",
		"notepad" : "Otezla is an oral, non-biologic PDE4 Inhibitor with a ​unique mechanism of action.  Otezla inhibits PDE4 intracellulary, elevating levels of cAMP which is thought to modulate production of both pro and anti-inflammatory mediators​. Otezla is indicated for adult patients with active psoriatic arthritis, moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy, and oral ulcers associated with Behcet s disease.",
		"modality" : "SM",
		"target" : "PDE4",
		"current_phase" : "Post-Launch",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "apremilast",
		"indication_description" : "PSORIATIC ARTHRITIS",
		"business_partner" : "",
		"portfolio_priority" : "Standard",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 407",
		"product" : "Otezla",
		"name" : "5438069.01",
		"trade_name" : "Otezla",
		"notepad" : "",
		"modality" : "SM",
		"target" : "PDE4",
		"current_phase" : "Post-Launch",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "apremilast",
		"indication_description" : "PSORIASIS",
		"business_partner" : "",
		"portfolio_priority" : "Standard",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 407",
		"product" : "Otezla",
		"name" : "5438069.06",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "SM",
		"target" : "PDE4",
		"current_phase" : "Phase 3",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "apremilast",
		"indication_description" : "PSORIASIS",
		"business_partner" : "",
		"portfolio_priority" : "Standard",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 407",
		"product" : "Otezla",
		"name" : "5438141.01",
		"trade_name" : "Otezla",
		"notepad" : "Otezla® is an oral small molecule that inhibits phosphodiesterase 4 (PDE4). It is being investigated as a potential immunomodulatory treatment in adult patients hospitalized for COVID-19 in partnership with some of the members of the COVID R&D Alliance.",
		"modality" : "SM",
		"target" : "PDE4",
		"current_phase" : "Phase 3",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "apremilast",
		"indication_description" : "COVID-19",
		"business_partner" : "",
		"portfolio_priority" : "Standard",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 407",
		"product" : "Otezla",
		"name" : "5438900.01",
		"trade_name" : "Otezla",
		"notepad" : "",
		"modality" : "SM",
		"target" : "PDE4",
		"current_phase" : "",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "apremilast",
		"indication_description" : "GENERAL (NON-INDICATION SPECIFIC)",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 407",
		"product" : "Otezla",
		"name" : "5438069.04",
		"trade_name" : "Otezla",
		"notepad" : "Otezla is an oral small molecule that inhibits phosphodiesterase 4 (PDE4). It is being investigated for the treatment of moderate to severe genital psoriasis.",
		"modality" : "SM",
		"target" : "PDE4",
		"current_phase" : "Phase 3",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "apremilast",
		"indication_description" : "PSORIASIS",
		"business_partner" : "",
		"portfolio_priority" : "Standard",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 407",
		"product" : "Otezla",
		"name" : "5438139.01",
		"trade_name" : "Otezla",
		"notepad" : "Otezla is an oral, non-biologic PDE4 Inhibitor with a ​unique mechanism of action.  Otezla inhibits PDE4 intracellulary, elevating levels of cAMP which is thought to modulate production of both pro and anti-inflammatory mediators​. Otezla is indicated for adult patients with active psoriatic arthritis, moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy, and oral ulcers associated with Behcet s disease.",
		"modality" : "SM",
		"target" : "PDE4",
		"current_phase" : "Post-Launch",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "apremilast",
		"indication_description" : "BEHCET'S DISEASE",
		"business_partner" : "",
		"portfolio_priority" : "Standard",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 407",
		"product" : "Otezla",
		"name" : "5438069.03",
		"trade_name" : "Otezla",
		"notepad" : "Otezla is an oral small molecule that inhibits phosphodiesterase 4 (PDE4). It is being investigated for the treatment of moderate to severe plaque psoriasis in pediatric patients.",
		"modality" : "SM",
		"target" : "PDE4",
		"current_phase" : "Phase 3",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "apremilast",
		"indication_description" : "PSORIASIS",
		"business_partner" : "",
		"portfolio_priority" : "Standard",
		"project_type" : "New Patient Population"
	},
	{
		"amg_number" : "AMG 407",
		"product" : "Otezla",
		"name" : "5438104.01",
		"trade_name" : "Otezla",
		"notepad" : "",
		"modality" : "SM",
		"target" : "PDE4",
		"current_phase" : "",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "apremilast",
		"indication_description" : "ULCERATIVE COLITIS",
		"business_partner" : "",
		"portfolio_priority" : "Standard",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 407",
		"product" : "Otezla",
		"name" : "5438900.02",
		"trade_name" : "Otezla",
		"notepad" : "",
		"modality" : "SM",
		"target" : "PDE4",
		"current_phase" : "",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "apremilast",
		"indication_description" : "GENERAL (NON-INDICATION SPECIFIC)",
		"business_partner" : "",
		"portfolio_priority" : "Standard",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 407",
		"product" : "Otezla",
		"name" : "5438069.02",
		"trade_name" : "Otezla",
		"notepad" : "",
		"modality" : "SM",
		"target" : "PDE4",
		"current_phase" : "Post-Launch",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "apremilast",
		"indication_description" : "PSORIASIS",
		"business_partner" : "",
		"portfolio_priority" : "Standard",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 407",
		"product" : "Otezla",
		"name" : "5438069.05",
		"trade_name" : "Otezla",
		"notepad" : "Otezla is an oral small molecule that inhibits phosphodiesterase 4 (PDE4). It is being investigated for the treatment of mild to moderate plaque psoriasis.",
		"modality" : "SM",
		"target" : "PDE4",
		"current_phase" : "Filing",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "apremilast",
		"indication_description" : "PSORIASIS",
		"business_partner" : "",
		"portfolio_priority" : "Standard",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 407",
		"product" : "Otezla",
		"name" : "5438139.02",
		"trade_name" : "Otezla",
		"notepad" : "Otezla is an oral small molecule that inhibits phosphodiesterase 4 (PDE4). It is being planned to be investigated for the treatment of Behcets disease in pediatric patients.",
		"modality" : "SM",
		"target" : "PDE4",
		"current_phase" : "Phase 3",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "apremilast",
		"indication_description" : "BEHCET'S DISEASE",
		"business_partner" : "",
		"portfolio_priority" : "Standard",
		"project_type" : "New Patient Population"
	},
	{
		"amg_number" : "AMG 407",
		"product" : "Otezla",
		"name" : "5438069.08",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "SM",
		"target" : "PDE4",
		"current_phase" : "Phase 3",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "apremilast",
		"indication_description" : "PSORIASIS",
		"business_partner" : "",
		"portfolio_priority" : "Standard",
		"project_type" : "New Dosage Form (Strength or Schedule)"
	},
	{
		"amg_number" : "AMG 407",
		"product" : "Otezla",
		"name" : "5438069.09",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "SM",
		"target" : "PDE4",
		"current_phase" : "Phase 3",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "apremilast",
		"indication_description" : "PSORIASIS",
		"business_partner" : "",
		"portfolio_priority" : "Standard",
		"project_type" : "New Patient Population"
	},
	{
		"amg_number" : "AMG 407",
		"product" : "Otezla",
		"name" : "5438070.02",
		"trade_name" : "Otezla",
		"notepad" : "Otezla is an oral small molecule that inhibits phosphodiesterase 4 (PDE4). It is being planned to be investigated for the treatment of juvenile psoriatic arthritis in pediatric patients.",
		"modality" : "SM",
		"target" : "PDE4",
		"current_phase" : "Phase 3",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "apremilast",
		"indication_description" : "PSORIATIC ARTHRITIS",
		"business_partner" : "",
		"portfolio_priority" : "Standard",
		"project_type" : "New Patient Population"
	},
	{
		"amg_number" : "AMG 412",
		"product" : "epratuzumab",
		"name" : "5175028.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "Emab",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "epratuzumab",
		"indication_description" : "CANCER - SOLID TUMORS",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 416",
		"product" : "Parsabiv",
		"name" : "5319044.01",
		"trade_name" : "Parsabiv",
		"notepad" : "Parsabiv® is a calcium-sensing receptor agonist.  It is being investigated for the treatment of secondary hyperparathyroidism (HPT) in pediatric patients.",
		"modality" : "Pep",
		"target" : "CASR",
		"current_phase" : "Launch",
		"medical_therapeutic_area" : "Nephrology",
		"generic_name" : "etelcalcetide",
		"indication_description" : "HYPERPARATHYROIDISM (HPT) - SECONDARY",
		"business_partner" : "Ono",
		"portfolio_priority" : "Standard",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 416",
		"product" : "Parsabiv",
		"name" : "5319044.02",
		"trade_name" : "Parsabiv",
		"notepad" : "Parsabiv® is a calcium-sensing receptor agonist.  It is being investigated for the treatment of secondary hyperparathyroidism (HPT) in pediatric patients.",
		"modality" : "Pep",
		"target" : "CASR",
		"current_phase" : "Phase 3",
		"medical_therapeutic_area" : "Nephrology",
		"generic_name" : "etelcalcetide",
		"indication_description" : "HYPERPARATHYROIDISM (HPT) - SECONDARY",
		"business_partner" : "Ono",
		"portfolio_priority" : "Standard",
		"project_type" : "New Patient Population"
	},
	{
		"amg_number" : "AMG 418",
		"product" : "AMG 418",
		"name" : "5466141.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "SARS-COV2",
		"current_phase" : "",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "AMG 418",
		"indication_description" : "COVID-19",
		"business_partner" : "",
		"portfolio_priority" : "Standard",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 420",
		"product" : "AMG 420",
		"name" : "5312122.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "BiTE",
		"target" : "BCMA Onc",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "AMG 420",
		"indication_description" : "CANCER - LIQUID TUMORS",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 420",
		"product" : "AMG 420",
		"name" : "5312019.02",
		"trade_name" : "",
		"notepad" : "AMG 420 is an anti-BCMA x anti-CD3 BiTE® (bispecific T cell engager) antibody construct. It is being investigated as a treatment for multiple myeloma.",
		"modality" : "BiTE",
		"target" : "BCMA Onc",
		"current_phase" : "Phase 1",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "AMG 420",
		"indication_description" : "CANCER - MULTIPLE MYELOMA",
		"business_partner" : "",
		"portfolio_priority" : "Close Out",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 423",
		"product" : "omecamtiv mecarbil",
		"name" : "5201101.03",
		"trade_name" : "",
		"notepad" : "Omecamtiv mecarbil is a small molecule selective cardiac myosin activator, or myotrope which directly targets the contractile mechanisms of the heart. It is being investigated for the treatment of heart failure in pediatric patients. Omecamtiv mecarbil is being developed under a collaboration between Amgen and Cytokinetics, with funding and strategic support from Servier.",
		"modality" : "SM",
		"target" : "Cardiac Sarcomere Activator",
		"current_phase" : "Phase 1",
		"medical_therapeutic_area" : "Cardiovascular",
		"generic_name" : "omecamtiv mecarbil",
		"indication_description" : "HEART FAILURE",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Patient Population"
	},
	{
		"amg_number" : "AMG 423",
		"product" : "omecamtiv mecarbil",
		"name" : "5201101.01",
		"trade_name" : "",
		"notepad" : "Omecamtiv mecarbil is a small molecule selective cardiac myosin activator, or myotrope which directly targets the contractile mechanisms of the heart It is being investigated for the treatment of heart failure. Omecamtiv mecarbil is being developed under a collaboration between Amgen and Cytokinetics, with funding and strategic support from Servier.",
		"modality" : "SM",
		"target" : "Cardiac Sarcomere Activator",
		"current_phase" : "Phase 3",
		"medical_therapeutic_area" : "Cardiovascular",
		"generic_name" : "omecamtiv mecarbil",
		"indication_description" : "HEART FAILURE",
		"business_partner" : "Cytokinetics,Servier",
		"portfolio_priority" : "",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 424",
		"product" : "AMG 424",
		"name" : "5395019.01",
		"trade_name" : "",
		"notepad" : "AMG 424 is a bispecific anti-CD38 x anti-CD3 T cell-recruiting antibody (XmAb® antibody). It is being investigated as a treatment for multiple myeloma.XmAb is a registered trademark of Xencor, Inc.",
		"modality" : "XmAb",
		"target" : "CD38",
		"current_phase" : "Phase 1",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "AMG 424",
		"indication_description" : "CANCER - MULTIPLE MYELOMA",
		"business_partner" : "Xencor",
		"portfolio_priority" : "Close Out",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 427",
		"product" : "AMG 427",
		"name" : "5401048.01",
		"trade_name" : "",
		"notepad" : "AMG 427 is a half-life extended (HLE) anti-fms-like tyrosine kinase 3 (FLT3) x anti-CD3 bispecific T cell engager (BiTE®) molecule. It is being investigated for the treatment of acute myeloid leukemia (AML).",
		"modality" : "HLE BiTE",
		"target" : "FLT3",
		"current_phase" : "Phase 1",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "AMG 427",
		"indication_description" : "LEUKEMIA - ACUTE MYELOID (AML)",
		"business_partner" : "",
		"portfolio_priority" : "Standard",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 429",
		"product" : "AMG 429",
		"name" : "5174028.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "SM",
		"target" : "VEGFR SG",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "AMG 429",
		"indication_description" : "CANCER - SOLID TUMORS",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 430",
		"product" : "AMG 430",
		"name" : "5415134.01",
		"trade_name" : "",
		"notepad" : "AMG 430 is an anti-Jagged-1 monoclonal antibody being investigated in respiratory diseases.",
		"modality" : "mAb",
		"target" : "JAG1",
		"current_phase" : "Phase 1",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "AMG 430",
		"indication_description" : "CYSTIC FIBROSIS",
		"business_partner" : "",
		"portfolio_priority" : "Close Out",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 430",
		"product" : "AMG 430",
		"name" : "5415030.01",
		"trade_name" : "",
		"notepad" : "AMG 430 is an anti-Jagged-1 monoclonal antibody being investigated in respiratory diseases.",
		"modality" : "mAb",
		"target" : "JAG1",
		"current_phase" : "Phase 1",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "AMG 430",
		"indication_description" : "CHRONIC OBSTRUCTIVE PULMONARY DISEASE",
		"business_partner" : "",
		"portfolio_priority" : "Close Out",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 431",
		"product" : "AMG 431",
		"name" : "5446065.01",
		"trade_name" : "",
		"notepad" : "AMG 431 is a small molecule targeting the Nav 1.7 nerve receptor channel.  It is being investigated for treatment of neuropathic, chronic, and acute pain.",
		"modality" : "SM",
		"target" : "Nav1.7",
		"current_phase" : "Preclinical",
		"medical_therapeutic_area" : "Neuroscience",
		"generic_name" : "AMG 431",
		"indication_description" : "PAIN - NEUROPATHIC",
		"business_partner" : "",
		"portfolio_priority" : "Standard",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 434",
		"product" : "AMG 434",
		"name" : "5204982.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "Pr",
		"target" : "ACT2BR #2",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "AMG 434",
		"indication_description" : "ONCOLOGY",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 442",
		"product" : "AMG 442",
		"name" : "5443116.01",
		"trade_name" : "",
		"notepad" : "AMG 442 is a monoclonal antibody that targets PDGF-D (platelet-derived growth factor D).  It is being investigated for the treatment of atherosclerosis.",
		"modality" : "mAb",
		"target" : "PDGFD",
		"current_phase" : "Preclinical",
		"medical_therapeutic_area" : "Cardiovascular",
		"generic_name" : "AMG 442",
		"indication_description" : "ATHEROSCLEROSIS",
		"business_partner" : "",
		"portfolio_priority" : "Standard",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 447",
		"product" : "AMG 447",
		"name" : "5432001.01",
		"trade_name" : "",
		"notepad" : "AMG 447 is a first-in-class Triggering Receptor Expressed on Myeloid cells 2 (TREM2) agonist monoclonal antibody.  It is being investigated for the prevention of Alzheimer s Disease.",
		"modality" : "mAb",
		"target" : "TREM2",
		"current_phase" : "Preclinical",
		"medical_therapeutic_area" : "Neuroscience",
		"generic_name" : "AMG 447",
		"indication_description" : "ALZHEIMER'S DISEASE",
		"business_partner" : "",
		"portfolio_priority" : "Gated",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 451",
		"product" : "rocatinlimab",
		"name" : "5472992.01",
		"trade_name" : "",
		"notepad" : "Rocatinlimab (formerly AMG 451\/KHK4083) is an anti-OX40 monoclonal antibody that inhibits activated OX40 expressing T cells and reduces their number.  It is being assessed for potential use in prurigo nodularis.;;;Additional Information: AMG 451 (KHK 4083) is being developed in collaboration with Kyowa Kirin Co., Ltd",
		"modality" : "mAb",
		"target" : "OX40",
		"current_phase" : "Phase 1",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "rocatinlimab",
		"indication_description" : "false",
		"business_partner" : "Kyowa Hakko Kirin",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 451",
		"product" : "rocatinlimab",
		"name" : "5472009.01",
		"trade_name" : "",
		"notepad" : ";Rocatinlimab (formerly AMG 451\/KHK4083) is an anti-OX40 monoclonal antibody that inhibits activated OX40 expressing T cells and reduces their number.  It is being assessed for potential use in asthma. ;;;Additional Information: AMG 451 (KHK 4083) is being developed in collaboration with Kyowa Kirin Co., Ltd",
		"modality" : "mAb",
		"target" : "OX40",
		"current_phase" : "Phase 1",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "rocatinlimab",
		"indication_description" : "ASTHMA",
		"business_partner" : "Kyowa Hakko Kirin",
		"portfolio_priority" : "",
		"project_type" : "New Patient Population"
	},
	{
		"amg_number" : "AMG 451",
		"product" : "rocatinlimab",
		"name" : "5472109.01",
		"trade_name" : "",
		"notepad" : ";Rocatinlimab (formerly AMG 451\/KHK4083) is an anti-OX40 monoclonal antibody that inhibits activated OX40 expressing T cells and reduces their number.  It is being investigated for the treatment of moderate-to-severe atopic dermatitis.;;; Additional Information: AMG 451 (KHK 4083) is being developed in collaboration with Kyowa Kirin Co., Ltd",
		"modality" : "mAb",
		"target" : "OX40",
		"current_phase" : "Phase 3",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "rocatinlimab",
		"indication_description" : "ATOPIC DERMATITIS",
		"business_partner" : "Kyowa Hakko Kirin",
		"portfolio_priority" : "Fastlane",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 454",
		"product" : "AMG 454",
		"name" : "5479030.01",
		"trade_name" : "",
		"notepad" : "AMG 454 is the back-up molecule for AMG 430. This asset provides Amgen the opportunity to develop a first-in-class therapeutic for the lasting reduction of mucus production through the transformation of mucus-producing goblet cells into long-lived mucus-clearing ciliated cells in the airways. It is anticipated to have broad applicability across a wide spectrum of respiratory diseases characterized by pathological mucus production. The 2 lead indications proposed by the team are chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF).",
		"modality" : "mAb",
		"target" : "JAG1",
		"current_phase" : "Preclinical",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "AMG 454",
		"indication_description" : "CHRONIC OBSTRUCTIVE PULMONARY DISEASE",
		"business_partner" : "",
		"portfolio_priority" : "Fastlane",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 456",
		"product" : "AMG 456",
		"name" : "5132032.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "SM",
		"target" : "11bHSD1 #3",
		"current_phase" : "",
		"medical_therapeutic_area" : "Metabolic Disorders",
		"generic_name" : "AMG 456",
		"indication_description" : "DIABETES - TYPE 2",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 458",
		"product" : "AMG 458",
		"name" : "5177028.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "SM",
		"target" : "cMET",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "AMG 458",
		"indication_description" : "CANCER - SOLID TUMORS",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 476",
		"product" : "AMG 476",
		"name" : "5133072.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "SM",
		"target" : "P38 2nd Gen",
		"current_phase" : "",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "AMG 476",
		"indication_description" : "RHEUMATOID ARTHRITIS - MUSCULO-SKELETAL",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 476",
		"product" : "AMG 476",
		"name" : "5133016.03",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "SM",
		"target" : "P38 2nd Gen",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "AMG 476",
		"indication_description" : "CANCER - COLORECTAL",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 476",
		"product" : "AMG 476",
		"name" : "5133016.02",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "SM",
		"target" : "P38 2nd Gen",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "AMG 476",
		"indication_description" : "CANCER - COLORECTAL",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 477",
		"product" : "AMG 477",
		"name" : "5170032.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "GlucagonR Ab",
		"current_phase" : "",
		"medical_therapeutic_area" : "Metabolic Disorders",
		"generic_name" : "AMG 477",
		"indication_description" : "DIABETES - TYPE 2",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 479",
		"product" : "ganitumab",
		"name" : "5134096.10",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "IGF- 1R (CLOSED)",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "ganitumab",
		"indication_description" : "CARCINOID",
		"business_partner" : "Takeda",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 479",
		"product" : "ganitumab",
		"name" : "5134028.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "IGF- 1R (CLOSED)",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "ganitumab",
		"indication_description" : "CANCER - SOLID TUMORS",
		"business_partner" : "Takeda",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 479",
		"product" : "ganitumab",
		"name" : "5134023.05",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "IGF- 1R (CLOSED)",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "ganitumab",
		"indication_description" : "CANCER - PANCREAS",
		"business_partner" : "Takeda",
		"portfolio_priority" : "",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 479",
		"product" : "ganitumab",
		"name" : "5134026.02",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "IGF- 1R (CLOSED)",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "ganitumab",
		"indication_description" : "CANCER - SARCOMA",
		"business_partner" : "Takeda",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 479",
		"product" : "ganitumab",
		"name" : "5134016.12",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "IGF- 1R (CLOSED)",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "ganitumab",
		"indication_description" : "CANCER - COLORECTAL",
		"business_partner" : "Takeda",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 479",
		"product" : "ganitumab",
		"name" : "5134016.11",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "IGF- 1R (CLOSED)",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "ganitumab",
		"indication_description" : "CANCER - COLORECTAL",
		"business_partner" : "Takeda",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 479",
		"product" : "ganitumab",
		"name" : "5134027.09",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "IGF- 1R (CLOSED)",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "ganitumab",
		"indication_description" : "CANCER - SMALL CELL LUNG",
		"business_partner" : "Takeda",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 479",
		"product" : "ganitumab",
		"name" : "5134016.06",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "IGF- 1R (CLOSED)",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "ganitumab",
		"indication_description" : "CANCER - COLORECTAL",
		"business_partner" : "Takeda",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 479",
		"product" : "ganitumab",
		"name" : "5134015.03",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "IGF- 1R (CLOSED)",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "ganitumab",
		"indication_description" : "CANCER - BREAST",
		"business_partner" : "Takeda",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 479",
		"product" : "ganitumab",
		"name" : "5134020.14",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "IGF- 1R (CLOSED)",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "ganitumab",
		"indication_description" : "CANCER - NON SMALL CELL LUNG",
		"business_partner" : "Takeda",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 479",
		"product" : "ganitumab",
		"name" : "5134082.07",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "IGF- 1R (CLOSED)",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "ganitumab",
		"indication_description" : "CANCER - GASTRIC",
		"business_partner" : "Takeda",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 479",
		"product" : "ganitumab",
		"name" : "5134018.16",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "IGF- 1R (CLOSED)",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "ganitumab",
		"indication_description" : "CANCER - HEAD AND NECK",
		"business_partner" : "Takeda",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 479",
		"product" : "ganitumab",
		"name" : "5134018.15",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "IGF- 1R (CLOSED)",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "ganitumab",
		"indication_description" : "CANCER - HEAD AND NECK",
		"business_partner" : "Takeda",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 479",
		"product" : "ganitumab",
		"name" : "5134022.04",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "IGF- 1R (CLOSED)",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "ganitumab",
		"indication_description" : "CANCER - OVARIAN",
		"business_partner" : "Takeda",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 479",
		"product" : "ganitumab",
		"name" : "5134020.13",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "IGF- 1R (CLOSED)",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "ganitumab",
		"indication_description" : "CANCER - NON SMALL CELL LUNG",
		"business_partner" : "Takeda",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 479",
		"product" : "ganitumab",
		"name" : "5134024.08",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "IGF- 1R (CLOSED)",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "ganitumab",
		"indication_description" : "CANCER - PROSTATE",
		"business_partner" : "Takeda",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 488",
		"product" : "AMG 488",
		"name" : "5386028.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "BiTE",
		"target" : "MSLN",
		"current_phase" : "Preclinical",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "AMG 488",
		"indication_description" : "CANCER - SOLID TUMORS",
		"business_partner" : "",
		"portfolio_priority" : "Close Out",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 492",
		"product" : "AMG 492",
		"name" : "5284088.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "PCSK9 #2",
		"current_phase" : "",
		"medical_therapeutic_area" : "Metabolic Disorders",
		"generic_name" : "AMG 492",
		"indication_description" : "HYPERCHOLESTEROLEMIA",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 498",
		"product" : "AMG 498",
		"name" : "5454109.01",
		"trade_name" : "",
		"notepad" : "AMG 498 is a human monoclonal antibody that inhibits IL-13. It is being investigated for the treatment of atopic dermatitis.",
		"modality" : "mAb",
		"target" : "IL-13",
		"current_phase" : "Preclinical",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "AMG 498",
		"indication_description" : "ATOPIC DERMATITIS",
		"business_partner" : "",
		"portfolio_priority" : "Standard",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 506",
		"product" : "AMG 506",
		"name" : "5433028.01",
		"trade_name" : "",
		"notepad" : "AMG 506 is a multi-specific FAP x 4-1BB-targeting DARPin biologic under investigation as a treatment for patients with solid tumors. It is being developed for use in combination with other Amgen oncology portfolio molecules.ADDITIONAL INFORMATION:AMG 506 (also known as MP0310) is being developed in collaboration  with Molecular Partners AG. DARPin is a registered trademark owned by Molecular Partners AG.",
		"modality" : "ePr",
		"target" : "Anti-FAP x 4-188 agonist",
		"current_phase" : "Phase 1",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "AMG 506",
		"indication_description" : "CANCER - SOLID TUMORS",
		"business_partner" : "",
		"portfolio_priority" : "Gated",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 507",
		"product" : "AMG 507",
		"name" : "5288116.02",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "PrFc",
		"target" : "rLCAT",
		"current_phase" : "",
		"medical_therapeutic_area" : "Cardiovascular",
		"generic_name" : "AMG 507",
		"indication_description" : "ATHEROSCLEROSIS",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 507",
		"product" : "AMG 507",
		"name" : "5288088.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "PrFc",
		"target" : "rLCAT",
		"current_phase" : "",
		"medical_therapeutic_area" : "Cardiovascular",
		"generic_name" : "AMG 507",
		"indication_description" : "HYPERCHOLESTEROLEMIA",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 509",
		"product" : "AMG 509",
		"name" : "5420026.01",
		"trade_name" : "",
		"notepad" : "AMG 509 (STEAP1 XmAb antibody) is a bivalent T cell engager and is designed using XmAb 2+1 technology. ;;ADDITIONAL INFORMATION;XmAb is a registered trademark of Xencor, Inc.",
		"modality" : "XmAb",
		"target" : "STEAP1",
		"current_phase" : "Preclinical",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "AMG 509",
		"indication_description" : "CANCER - SARCOMA",
		"business_partner" : "",
		"portfolio_priority" : "Gated",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 509",
		"product" : "AMG 509",
		"name" : "5420024.01",
		"trade_name" : "",
		"notepad" : "AMG 509 (STEAP1 XmAb antibody) is a bivalent T cell engager and is designed using XmAb 2+1 technology. It is being investigated for the treatment of prostate cancer.;;ADDITIONAL INFORMATION;XmAb is a registered trademark of Xencor, Inc.",
		"modality" : "XmAb",
		"target" : "STEAP1",
		"current_phase" : "Phase 1",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "AMG 509",
		"indication_description" : "CANCER - PROSTATE",
		"business_partner" : "",
		"portfolio_priority" : "Fastlane",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 510",
		"product" : "LUMAKRAS",
		"name" : "5407028.05",
		"trade_name" : "",
		"notepad" : "LUMAKRAS is a KRASG12C small molecule inhibitor under investigation for the treatment of advanced non-small cell lung cancer.",
		"modality" : "SM",
		"target" : "KRAS",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "sotorasib",
		"indication_description" : "CANCER - SOLID TUMORS",
		"business_partner" : "",
		"portfolio_priority" : "Standard",
		"project_type" : "New Patient Population"
	},
	{
		"amg_number" : "AMG 510",
		"product" : "LUMAKRAS",
		"name" : "5407028.07",
		"trade_name" : "",
		"notepad" : "LUMAKRAS is a KRASG12C small molecule inhibitor under investigation for the treatment of advanced non-small cell lung cancer.",
		"modality" : "SM",
		"target" : "KRAS",
		"current_phase" : "Phase 1",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "sotorasib",
		"indication_description" : "CANCER - SOLID TUMORS",
		"business_partner" : "",
		"portfolio_priority" : "Standard",
		"project_type" : "New Combination of a Marketed Active Substance"
	},
	{
		"amg_number" : "AMG 510",
		"product" : "LUMAKRAS",
		"name" : "5407016.05",
		"trade_name" : "",
		"notepad" : "LUMAKRAS is a KRASG12C small molecule inhibitor under investigation for the treatment of advanced colorectal cancer.",
		"modality" : "SM",
		"target" : "KRAS",
		"current_phase" : "Phase 3",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "sotorasib",
		"indication_description" : "CANCER - COLORECTAL",
		"business_partner" : "",
		"portfolio_priority" : "Standard",
		"project_type" : "New Combination of a Marketed Active Substance"
	},
	{
		"amg_number" : "AMG 510",
		"product" : "LUMAKRAS",
		"name" : "5407028.03",
		"trade_name" : "",
		"notepad" : "LUMAKRAS is a KRASG12C small molecule inhibitor under investigation for the treatment of advanced solid tumors other than non-small cell lung cancer or advanced colorectal cancer.",
		"modality" : "SM",
		"target" : "KRAS",
		"current_phase" : "Phase 2",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "sotorasib",
		"indication_description" : "CANCER - SOLID TUMORS",
		"business_partner" : "",
		"portfolio_priority" : "Standard",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 510",
		"product" : "LUMAKRAS",
		"name" : "5407028.06",
		"trade_name" : "",
		"notepad" : "LUMAKRAS is a KRASG12C small molecule inhibitor under investigation for the treatment of advanced non-small cell lung cancer.",
		"modality" : "SM",
		"target" : "KRAS",
		"current_phase" : "Phase 1",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "sotorasib",
		"indication_description" : "CANCER - SOLID TUMORS",
		"business_partner" : "",
		"portfolio_priority" : "Standard",
		"project_type" : "New Combination of a Marketed Active Substance"
	},
	{
		"amg_number" : "AMG 510",
		"product" : "LUMAKRAS",
		"name" : "5407028.02",
		"trade_name" : "",
		"notepad" : "LUMAKRAS is a KRASG12C small molecule inhibitor under investigation for the treatment of advanced colorectal cancer.",
		"modality" : "SM",
		"target" : "KRAS",
		"current_phase" : "Phase 2",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "sotorasib",
		"indication_description" : "CANCER - SOLID TUMORS",
		"business_partner" : "",
		"portfolio_priority" : "Standard",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 510",
		"product" : "LUMAKRAS",
		"name" : "5407028.04",
		"trade_name" : "",
		"notepad" : "LUMAKRAS is a KRASG12C small molecule inhibitor under investigation for the treatment of advanced non-small cell lung cancer.",
		"modality" : "SM",
		"target" : "KRAS",
		"current_phase" : "Phase 2",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "sotorasib",
		"indication_description" : "CANCER - SOLID TUMORS",
		"business_partner" : "",
		"portfolio_priority" : "Standard",
		"project_type" : "New Combination of a Marketed Active Substance"
	},
	{
		"amg_number" : "AMG 510",
		"product" : "LUMAKRAS",
		"name" : "5407028.08",
		"trade_name" : "",
		"notepad" : "LUMAKRAS is a KRASG12C small molecule inhibitor under investigation for the treatment of advanced non-small cell lung cancer.",
		"modality" : "SM",
		"target" : "KRAS",
		"current_phase" : "Phase 2",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "sotorasib",
		"indication_description" : "CANCER - SOLID TUMORS",
		"business_partner" : "",
		"portfolio_priority" : "Standard",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 510",
		"product" : "LUMAKRAS",
		"name" : "5407028.01",
		"trade_name" : "LUMAKRAS",
		"notepad" : "LUMAKRAS is a KRASG12C small molecule inhibitor under investigation for the treatment of advanced non-small cell lung cancer. ;;",
		"modality" : "SM",
		"target" : "KRAS",
		"current_phase" : "Launch",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "sotorasib",
		"indication_description" : "CANCER - SOLID TUMORS",
		"business_partner" : "",
		"portfolio_priority" : "Fastlane",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 511",
		"product" : "AMG 511",
		"name" : "5281028.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "SM",
		"target" : "PI3 Kinase Alpha",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "AMG 511",
		"indication_description" : "CANCER - SOLID TUMORS",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 517",
		"product" : "AMG 517",
		"name" : "5136064.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "SM",
		"target" : "VR1",
		"current_phase" : "",
		"medical_therapeutic_area" : "Neuroscience",
		"generic_name" : "AMG 517",
		"indication_description" : "PAIN - CHRONIC INFLAMMATORY",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 520",
		"product" : "AMG 520",
		"name" : "5385001.01",
		"trade_name" : "",
		"notepad" : "AMG 520 (CNP520) is a small molecule inhibitor of beta-site amyloid precursor protein (APP) cleaving enzyme-1 (BACE).  It is being investigated for the prevention of Alzheimer s Disease.  AMG 520 (CNP520) is being developed in collaboration with Novartis Pharma AG.",
		"modality" : "SM",
		"target" : "BACE Inhibitor",
		"current_phase" : "Phase 3",
		"medical_therapeutic_area" : "Neuroscience",
		"generic_name" : "AMG 520",
		"indication_description" : "ALZHEIMER'S DISEASE",
		"business_partner" : "Novartis",
		"portfolio_priority" : "Close Out",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 529",
		"product" : "AMG 529",
		"name" : "5393127.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "ASGR1",
		"current_phase" : "Phase 1",
		"medical_therapeutic_area" : "Cardiovascular",
		"generic_name" : "AMG 529",
		"indication_description" : "CORONARY ARTERY DISEASE",
		"business_partner" : "",
		"portfolio_priority" : "Close Out",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 531",
		"product" : "Nplate",
		"name" : "5137130.02",
		"trade_name" : "",
		"notepad" : "Nplate® is a thrombopoietin receptor agonist (TPO-RA). Nplate is being investigated in Acute Radiation Syndrome (ARS).",
		"modality" : "PepFc",
		"target" : "TPO-R",
		"current_phase" : "Post-Launch",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "romiplostim",
		"indication_description" : "ACUTE RADIATION SYNDROME (ARS)",
		"business_partner" : "Kyowa Hakko Kirin",
		"portfolio_priority" : "Standard",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 531",
		"product" : "Nplate",
		"name" : "5137046.03",
		"trade_name" : "",
		"notepad" : "Nplate® is a thrombopoietin receptor agonist (TPO-RA). . It is being investigated in early immune (idiopathic) -thrombocytopenia purpura (ITP).",
		"modality" : "PepFc",
		"target" : "TPO-R",
		"current_phase" : "Launch",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "romiplostim",
		"indication_description" : "IDIOPATHIC THROMBOCYTOPENIA PURPURA-ITP",
		"business_partner" : "Kyowa Hakko Kirin",
		"portfolio_priority" : "Standard",
		"project_type" : "New Patient Population"
	},
	{
		"amg_number" : "AMG 531",
		"product" : "Nplate",
		"name" : "5137057.02",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "PepFc",
		"target" : "TPO-R",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "romiplostim",
		"indication_description" : "MYELODYSPLASTIC SYNDROME (MDS)",
		"business_partner" : "Kyowa Hakko Kirin",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 531",
		"product" : "Nplate",
		"name" : "5137041.04",
		"trade_name" : "",
		"notepad" : "Nplate® is a thrombopoietin receptor agonist (TPO-RA).  Nplate is approved immune (idiopathic) thrombocytopenic purpura (ITP).  Nplate is being investigated in chemotherapy-induced thrombocyopenia (CIT) and Acute Radiation Syndrome (ARS).",
		"modality" : "PepFc",
		"target" : "TPO-R",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "romiplostim",
		"indication_description" : "HEPATITIS C",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 531",
		"product" : "Nplate",
		"name" : "5137076.03",
		"trade_name" : "",
		"notepad" : "Nplate® is a thrombopoietin receptor agonist (TPO-RA). It is being investigated for the treatment of in chemotherapy-induced thrombocytopenia (CIT).",
		"modality" : "PepFc",
		"target" : "TPO-R",
		"current_phase" : "Phase 3",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "romiplostim",
		"indication_description" : "THROMBOCYTOPENIA - CHEMOTHERAPY INDUCED",
		"business_partner" : "Kyowa Hakko Kirin",
		"portfolio_priority" : "Standard",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 531",
		"product" : "Nplate",
		"name" : "5137003.01",
		"trade_name" : "",
		"notepad" : "Nplate® is a thrombopoietin receptor agonist (TPO-RA). It is being investigated for the treatment of patients in R\/R and 1L Severe Aplastic Anemia",
		"modality" : "PepFc",
		"target" : "TPO-R",
		"current_phase" : "Phase 3",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "romiplostim",
		"indication_description" : "ANEMIA - APLASTIC",
		"business_partner" : "",
		"portfolio_priority" : "Standard",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 531",
		"product" : "Nplate",
		"name" : "5137076.04",
		"trade_name" : "",
		"notepad" : "Nplate® is a thrombopoietin receptor agonist (TPO-RA). It is being investigated for the treatment of in chemotherapy-induced thrombocytopenia (CIT).",
		"modality" : "PepFc",
		"target" : "TPO-R",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "romiplostim",
		"indication_description" : "THROMBOCYTOPENIA - CHEMOTHERAPY INDUCED",
		"business_partner" : "Kyowa Hakko Kirin",
		"portfolio_priority" : "Standard",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 531",
		"product" : "Nplate",
		"name" : "5137046.02",
		"trade_name" : "",
		"notepad" : "Nplate® is a thrombopoietin receptor agonist (TPO-RA) that stimulates bone marrow megakaryocytes to produce platelets. Nplate is approved for subcutaneous injection for the treatment of chronic immune (idiopathic) thrombocytopenic purpura (ITP) in patients who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.",
		"modality" : "PepFc",
		"target" : "TPO-R",
		"current_phase" : "Filing",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "romiplostim",
		"indication_description" : "IDIOPATHIC THROMBOCYTOPENIA PURPURA-ITP",
		"business_partner" : "Kyowa Hakko Kirin",
		"portfolio_priority" : "",
		"project_type" : "New Patient Population"
	},
	{
		"amg_number" : "AMG 531",
		"product" : "Nplate",
		"name" : "5137003.02",
		"trade_name" : "",
		"notepad" : "Nplate® is a thrombopoietin receptor agonist (TPO-RA). It is being investigated for the treatment of patients in R\/R and 1L Severe Aplastic Anemia",
		"modality" : "PepFc",
		"target" : "TPO-R",
		"current_phase" : "Phase 3",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "romiplostim",
		"indication_description" : "ANEMIA - APLASTIC",
		"business_partner" : "",
		"portfolio_priority" : "Standard",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 531",
		"product" : "Nplate",
		"name" : "5137046.01",
		"trade_name" : "",
		"notepad" : "Nplate® is a thrombopoietin receptor agonist (TPO-RA).  Nplate is approved immune (idiopathic) thrombocytopenic purpura (ITP).  Nplate is being investigated in chemotherapy-induced thrombocyopenia (CIT) and Acute Radiation Syndrome (ARS).",
		"modality" : "PepFc",
		"target" : "TPO-R",
		"current_phase" : "Post-Launch",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "romiplostim",
		"indication_description" : "IDIOPATHIC THROMBOCYTOPENIA PURPURA-ITP",
		"business_partner" : "Kyowa Hakko Kirin",
		"portfolio_priority" : "Standard",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 531",
		"product" : "Nplate",
		"name" : "5137046.04",
		"trade_name" : "",
		"notepad" : "Nplate® is a thrombopoietin receptor agonist (TPO-RA).  Nplate is approved immune (idiopathic) thrombocytopenic purpura (ITP).  Nplate is being investigated in chemotherapy-induced thrombocyopenia (CIT) and Acute Radiation Syndrome (ARS).",
		"modality" : "PepFc",
		"target" : "TPO-R",
		"current_phase" : "Phase 3",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "romiplostim",
		"indication_description" : "IDIOPATHIC THROMBOCYTOPENIA PURPURA-ITP",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Patient Population"
	},
	{
		"amg_number" : "AMG 534",
		"product" : "AMG 534",
		"name" : "5441019.01",
		"trade_name" : "",
		"notepad" : "AMG 534 is a half-life extended anti-BCMA x anti-CS-1 multispecific T cell engager construct.",
		"modality" : "HLE dBiTE-OR",
		"target" : "BCMA-CS1",
		"current_phase" : "Preclinical",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "AMG 534",
		"indication_description" : "CANCER - MULTIPLE MYELOMA",
		"business_partner" : "",
		"portfolio_priority" : "Gated",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 548",
		"product" : "AMG 548",
		"name" : "5138072.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "SM",
		"target" : "P38",
		"current_phase" : "",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "AMG 548",
		"indication_description" : "RHEUMATOID ARTHRITIS - MUSCULO-SKELETAL",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 552",
		"product" : "bemarituzumab",
		"name" : "5465028.02",
		"trade_name" : "",
		"notepad" : "Bemarituzumab is a monoclonal antibody that inhibits fibroblast growth factor receptor 2b (FGFR2b). It is being investigated for the treatment of advanced solid tumors other than advanced squamous non-small cell lung cancer.",
		"modality" : "mAb",
		"target" : "FGFR2b",
		"current_phase" : "Phase 1",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "bemarituzumab",
		"indication_description" : "CANCER - SOLID TUMORS",
		"business_partner" : "",
		"portfolio_priority" : "Fastlane",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 552",
		"product" : "bemarituzumab",
		"name" : "5465082.02",
		"trade_name" : "",
		"notepad" : "Bemarituzumab is a monoclonal antibody that inhibits fibroblast growth factor receptor 2b (FGFR2b). It is being investigated for the treatment of advanced Gastric Cancer and Gastroesophageal Junction (GEJ) cancers.;;ADDITIONAL INFORMATION;In April 2021, Amgen announced that the U.S. Food and Drug Administration (FDA), granted Breakthrough Therapy Designation for bemarituzumab.",
		"modality" : "mAb",
		"target" : "FGFR2b",
		"current_phase" : "Phase 3",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "bemarituzumab",
		"indication_description" : "CANCER - GASTRIC",
		"business_partner" : "",
		"portfolio_priority" : "Fastlane",
		"project_type" : "New Combination of a Pipeline Active Substance"
	},
	{
		"amg_number" : "AMG 552",
		"product" : "bemarituzumab",
		"name" : "5465082.03",
		"trade_name" : "",
		"notepad" : "Bemarituzumab is a monoclonal antibody that inhibits fibroblast growth factor receptor 2b (FGFR2b). It is being investigated for the treatment of advanced Gastric Cancer and Gastroesophageal Junction (GEJ) cancers.;;ADDITIONAL INFORMATION;In April 2021, Amgen announced that the U.S. Food and Drug Administration (FDA), granted Breakthrough Therapy Designation for bemarituzumab.",
		"modality" : "mAb",
		"target" : "FGFR2b",
		"current_phase" : "Phase 1",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "bemarituzumab",
		"indication_description" : "CANCER - GASTRIC",
		"business_partner" : "",
		"portfolio_priority" : "Fastlane",
		"project_type" : "New Combination of a Pipeline Active Substance"
	},
	{
		"amg_number" : "AMG 552",
		"product" : "bemarituzumab",
		"name" : "5465082.01",
		"trade_name" : "",
		"notepad" : "Bemarituzumab is a monoclonal antibody that inhibits fibroblast growth factor receptor 2b (FGFR2b). It is being investigated for the treatment of advanced Gastric Cancer and Gastroesophageal Junction (GEJ) cancers.;;ADDITIONAL INFORMATION;In April 2021, Amgen announced that the U.S. Food and Drug Administration (FDA), granted Breakthrough Therapy Designation for bemarituzumab.",
		"modality" : "mAb",
		"target" : "FGFR2b",
		"current_phase" : "Phase 3",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "bemarituzumab",
		"indication_description" : "CANCER - GASTRIC",
		"business_partner" : "",
		"portfolio_priority" : "Fastlane",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 552",
		"product" : "bemarituzumab",
		"name" : "5465082.04",
		"trade_name" : "",
		"notepad" : "Bemarituzumab is a monoclonal antibody that inhibits fibroblast growth factor receptor 2b (FGFR2b). It is being investigated for the treatment of advanced Gastric Cancer and Gastroesophageal Junction (GEJ) Adenocarcinoma.;;ADDITIONAL INFORMATION;In April 2021, Amgen announced that the FDA granted Breakthrough Therapy Designation for bemarituzumab.",
		"modality" : "mAb",
		"target" : "FGFR2b",
		"current_phase" : "Phase 1",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "bemarituzumab",
		"indication_description" : "CANCER - GASTRIC",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 552",
		"product" : "bemarituzumab",
		"name" : "5465028.03",
		"trade_name" : "",
		"notepad" : "Bemarituzumab is a monoclonal antibody that inhibits fibroblast growth factor receptor 2b (FGFR2b). It is being investigated for the treatment of advanced squamous non-small cell lung cancer.",
		"modality" : "mAb",
		"target" : "FGFR2b",
		"current_phase" : "Phase 1",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "bemarituzumab",
		"indication_description" : "CANCER - SOLID TUMORS",
		"business_partner" : "",
		"portfolio_priority" : "Fastlane",
		"project_type" : "New Combination of a Pipeline Active Substance"
	},
	{
		"amg_number" : "AMG 552",
		"product" : "bemarituzumab",
		"name" : "5465028.01",
		"trade_name" : "",
		"notepad" : "Bemarituzumab is a monoclonal antibody that inhibits fibroblast growth factor receptor 2b (FGFR2b). It is being investigated for the treatment of advanced squamous non-small cell lung cancer.",
		"modality" : "mAb",
		"target" : "FGFR2b",
		"current_phase" : "Phase 1",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "bemarituzumab",
		"indication_description" : "CANCER - SOLID TUMORS",
		"business_partner" : "",
		"portfolio_priority" : "Fastlane",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 553",
		"product" : "AMG 553",
		"name" : "5412048.01",
		"trade_name" : "",
		"notepad" : "AMG 553 is an anti-FLT3 Chimeric Antigen Receptor (CAR)-T cell therapy.  It is being investigated for the treatment of Relapsed\/Refractory Acute Myeloid Leukemia. It is partnered with Kite.",
		"modality" : "CAR-T",
		"target" : "FLT3",
		"current_phase" : "Preclinical",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "AMG 553",
		"indication_description" : "LEUKEMIA - ACUTE MYELOID (AML)",
		"business_partner" : "",
		"portfolio_priority" : "Gated",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 557",
		"product" : "AMG 557",
		"name" : "5139074.01",
		"trade_name" : "",
		"notepad" : "AMG 557 is a human monoclonal antibody that inhibits the action of the ICOS ligand.  It is being investigated as a treatment for primary Sjögren s syndrome.  AMG 557 is being developed in collaboration with AstraZeneca plc.",
		"modality" : "mAb",
		"target" : "B7RP1",
		"current_phase" : "",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "AMG 557",
		"indication_description" : "SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)",
		"business_partner" : "Medarex",
		"portfolio_priority" : "Close Out",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 562",
		"product" : "AMG 562",
		"name" : "5400053.02",
		"trade_name" : "",
		"notepad" : "AMG 562 is a half-life extended (HLE) BiTE® (bispecific T cell engager) construct directed against CD19 and CD3.  It is being investigated as a treatment for B-cell Non-Hodgkin s Lymphoma (B-NHL).",
		"modality" : "HLE BiTE",
		"target" : "CD19",
		"current_phase" : "Phase 1",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "AMG 562",
		"indication_description" : "LYMPHOMA - NON HODGKINS",
		"business_partner" : "",
		"portfolio_priority" : "Close Out",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 562",
		"product" : "AMG 562",
		"name" : "5400053.01",
		"trade_name" : "",
		"notepad" : "AMG 562 is a half-life extended (HLE) BiTE® (bispecific T cell engager) construct directed against CD19 (Cluster of Differentiation 19) and CD3.  It is being investigated as a treatment for B-cell Non-Hodgkin s Lymphoma (B-NHL).",
		"modality" : "HLE BiTE",
		"target" : "CD19",
		"current_phase" : "Phase 1",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "AMG 562",
		"indication_description" : "LYMPHOMA - NON HODGKINS",
		"business_partner" : "",
		"portfolio_priority" : "Close Out",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 562",
		"product" : "AMG 562",
		"name" : "5400053.03",
		"trade_name" : "",
		"notepad" : "AMG 562 is a half-life extended (HLE) BiTE® (bispecific T cell engager) construct directed against CD19 and CD3.  It is being investigated as a treatment for B-cell Non-Hodgkin s Lymphoma (B-NHL).",
		"modality" : "HLE BiTE",
		"target" : "CD19",
		"current_phase" : "Phase 1",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "AMG 562",
		"indication_description" : "LYMPHOMA - NON HODGKINS",
		"business_partner" : "",
		"portfolio_priority" : "Close Out",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 563",
		"product" : "AMG 563",
		"name" : "5140074.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "CD30L",
		"current_phase" : "",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "AMG 563",
		"indication_description" : "SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)",
		"business_partner" : "UCB",
		"portfolio_priority" : "",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 570",
		"product" : "rozibafusp alfa",
		"name" : "5349072.01",
		"trade_name" : "",
		"notepad" : "Rozibafusp alfa (AMG 570) is a novel bispecific peptide-antibody conjugate that simultaneously blocks ICOSL and BAFF activity.  It is being investigated for systemic lupus erythematosus.;; ;; ",
		"modality" : "AbPep",
		"target" : "B7RP1\/BAFF",
		"current_phase" : "Phase 1",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "rozibafusp alfa",
		"indication_description" : "RHEUMATOID ARTHRITIS - MUSCULO-SKELETAL",
		"business_partner" : "",
		"portfolio_priority" : "Standard",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 570",
		"product" : "rozibafusp alfa",
		"name" : "5349984.01",
		"trade_name" : "",
		"notepad" : "Rozibafusp alfa (AMG 570) is a novel bispecific peptide-antibody conjugate that simultaneously blocks ICOSL and BAFF activity.  It is being investigated for systemic lupus erythematosus.;;",
		"modality" : "AbPep",
		"target" : "B7RP1\/BAFF",
		"current_phase" : "Phase 2",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "rozibafusp alfa",
		"indication_description" : "INFLAMMATION",
		"business_partner" : "",
		"portfolio_priority" : "Standard",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 575",
		"product" : "AMG 575",
		"name" : "5141072.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "p55",
		"current_phase" : "",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "AMG 575",
		"indication_description" : "RHEUMATOID ARTHRITIS - MUSCULO-SKELETAL",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 579",
		"product" : "AMG 579",
		"name" : "5221091.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "SM",
		"target" : "PDE10",
		"current_phase" : "",
		"medical_therapeutic_area" : "Neuroscience",
		"generic_name" : "AMG 579",
		"indication_description" : "SCHIZOPHRENIA",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 581",
		"product" : "AMG 581",
		"name" : "5321091.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "SM",
		"target" : "PDE10",
		"current_phase" : "",
		"medical_therapeutic_area" : "Neuroscience",
		"generic_name" : "AMG 581",
		"indication_description" : "SCHIZOPHRENIA",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 584",
		"product" : "AMG 584",
		"name" : "5418028.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "SM",
		"target" : "KRAS G12C",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "AMG 584",
		"indication_description" : "CANCER - SOLID TUMORS",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 589",
		"product" : "AMG 589",
		"name" : "5215108.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "CGRP-alpha Ab",
		"current_phase" : "",
		"medical_therapeutic_area" : "Neuroscience",
		"generic_name" : "AMG 589",
		"indication_description" : "MIGRAINE",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 592",
		"product" : "efavaleukin alfa",
		"name" : "5350133.06",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "ePrFc",
		"target" : "IL-2 Mutein",
		"current_phase" : "",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "efavaleukin alfa",
		"indication_description" : "KIDNEY ANTIBODY – MEDIATED REJECTIONS",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 592",
		"product" : "efavaleukin alfa",
		"name" : "5350104.01",
		"trade_name" : "",
		"notepad" : "Efavaleukin alfa is an IL-2 mutein Fc fusion protein.  It is being investigated for the treatment of Ulcerative Colitis.",
		"modality" : "ePrFc",
		"target" : "IL-2 Mutein",
		"current_phase" : "Phase 2",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "efavaleukin alfa",
		"indication_description" : "ULCERATIVE COLITIS",
		"business_partner" : "",
		"portfolio_priority" : "Standard",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 592",
		"product" : "efavaleukin alfa",
		"name" : "5350991.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "ePrFc",
		"target" : "IL-2 Mutein",
		"current_phase" : "Phase 2",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "efavaleukin alfa",
		"indication_description" : "991",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 592",
		"product" : "efavaleukin alfa",
		"name" : "5350080.05",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "ePrFc",
		"target" : "IL-2 Mutein",
		"current_phase" : "",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "efavaleukin alfa",
		"indication_description" : "MULTIPLE SCLEROSIS",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 592",
		"product" : "efavaleukin alfa",
		"name" : "5350038.01",
		"trade_name" : "",
		"notepad" : "Efavaleukin alfa is an IL-2 mutein Fc fusion protein.  It is being investigated for the treatment of Graph Versus Host Disease.",
		"modality" : "ePrFc",
		"target" : "IL-2 Mutein",
		"current_phase" : "Phase 1",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "efavaleukin alfa",
		"indication_description" : "GRAFT VS HOST DISEASE",
		"business_partner" : "",
		"portfolio_priority" : "Standard",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 592",
		"product" : "efavaleukin alfa",
		"name" : "5350074.01",
		"trade_name" : "",
		"notepad" : "Efavaleukin alfa is an IL-2 mutein Fc fusion protein.  It is being investigated for the treatment of systemic lupus erythematosus.",
		"modality" : "ePrFc",
		"target" : "IL-2 Mutein",
		"current_phase" : "Phase 2",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "efavaleukin alfa",
		"indication_description" : "SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)",
		"business_partner" : "",
		"portfolio_priority" : "Fastlane",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 592",
		"product" : "efavaleukin alfa",
		"name" : "5350072.02",
		"trade_name" : "",
		"notepad" : "Efavaleukin alfa is an IL-2 mutein Fc fusion protein.  It is being investigated for the treatment of inflammatory diseases.",
		"modality" : "ePrFc",
		"target" : "IL-2 Mutein",
		"current_phase" : "Phase 1",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "efavaleukin alfa",
		"indication_description" : "RHEUMATOID ARTHRITIS - MUSCULO-SKELETAL",
		"business_partner" : "",
		"portfolio_priority" : "Close Out",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 594",
		"product" : "AMG 594",
		"name" : "5416101.01",
		"trade_name" : "",
		"notepad" : "AMG 594 is a selective small molecule cardiac troponin activator being developed to improve muscle function, directly targeting the loss of contractility.;;ADDITIONAL INFORMATION;;AMG 594 was discovered under a joint research program conducted between Amgen and Cytokinetics.",
		"modality" : "SM",
		"target" : "Cardiac Troponin (CTM)",
		"current_phase" : "Phase 1",
		"medical_therapeutic_area" : "Cardiovascular",
		"generic_name" : "AMG 594",
		"indication_description" : "HEART FAILURE",
		"business_partner" : "Cytokinetics",
		"portfolio_priority" : "Gated",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 595",
		"product" : "AMG 595",
		"name" : "5210982.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "AbSM",
		"target" : "EGFRvlll",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "AMG 595",
		"indication_description" : "ONCOLOGY",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 596",
		"product" : "AMG 596",
		"name" : "5378037.01",
		"trade_name" : "",
		"notepad" : "AMG 596 is an anti-EGFRvIII x anti-CD3 BiTE® (bispecific T cell engager) molecule. AMG 596  is being investigated for glioblastoma.",
		"modality" : "BiTE",
		"target" : "EGFRvlll",
		"current_phase" : "Phase 1",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "AMG 596",
		"indication_description" : "GLIOBLASTOMA",
		"business_partner" : "",
		"portfolio_priority" : "Close Out",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 598",
		"product" : "AMG 598",
		"name" : "5394985.01",
		"trade_name" : "",
		"notepad" : "AMG 598 is a first-in-class human monoclonal antibody being investigated as a treatment for obesity.",
		"modality" : "mAb",
		"target" : "GIPR",
		"current_phase" : "Phase 1",
		"medical_therapeutic_area" : "Metabolic Disorders",
		"generic_name" : "AMG 598",
		"indication_description" : "METABOLIC DISORDERS",
		"business_partner" : "",
		"portfolio_priority" : "Close Out",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 601",
		"product" : "AMG 601",
		"name" : "5142069.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "IL-18R",
		"current_phase" : "",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "AMG 601",
		"indication_description" : "PSORIASIS",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 604",
		"product" : "AMG 604",
		"name" : "5171032.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "SM",
		"target" : "BVT 11BHSD1 B\/U",
		"current_phase" : "",
		"medical_therapeutic_area" : "Metabolic Disorders",
		"generic_name" : "AMG 604",
		"indication_description" : "DIABETES - TYPE 2",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 609",
		"product" : "AMG 609",
		"name" : "5439985.02",
		"trade_name" : "",
		"notepad" : "AMG 609 is a small interfering RNA (siRNA) that selectively targets a variant allele of patatin like phospholipase domain containing 3, also known as PNPLA3 I148M. It is being investigated for the treatment of nonalcoholic steatohepatitis (NASH).",
		"modality" : "siRNASM",
		"target" : "PNPLA3",
		"current_phase" : "Phase 1",
		"medical_therapeutic_area" : "Metabolic Disorders",
		"generic_name" : "AMG 609",
		"indication_description" : "METABOLIC DISORDERS",
		"business_partner" : "",
		"portfolio_priority" : "Gated",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 623",
		"product" : "AMG 623",
		"name" : "5144074.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "PepFc",
		"target" : "AGP3 (CLOSED)",
		"current_phase" : "",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "AMG 623",
		"indication_description" : "SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 623",
		"product" : "AMG 623",
		"name" : "5144049.02",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "PepFc",
		"target" : "AGP3 (CLOSED)",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "AMG 623",
		"indication_description" : "LEUKEMIA - CHRONIC LYMPHOCYTIC (CLL)",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 624",
		"product" : "AMG 624",
		"name" : "5463020.01",
		"trade_name" : "",
		"notepad" : "TIGIT is an immune inhibitory receptor that regulates T and NK cell function. TIGIT mAb provides checkpoint blockade that is complementary to and non-overlapping with the PD1 mAb. Therefore, TIGIT mAb, when combined with AMG 404 will reinvigorate anti-tumor immune responses and has the potential to deepen and achieve durable responses in multiple solid tumor indications. AMG 624 could become part of a new standard of care platform if TIGIT + PD1 becomes a new I\/O backbone.",
		"modality" : "mAb",
		"target" : "TIGIT",
		"current_phase" : "Preclinical",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "AMG 624",
		"indication_description" : "CANCER - NON SMALL CELL LUNG",
		"business_partner" : "",
		"portfolio_priority" : "Standard",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 628",
		"product" : "AMG 628",
		"name" : "5145064.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "SM",
		"target" : "VR1 SG",
		"current_phase" : "",
		"medical_therapeutic_area" : "Neuroscience",
		"generic_name" : "AMG 628",
		"indication_description" : "PAIN - CHRONIC INFLAMMATORY",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 634",
		"product" : "AMG 634",
		"name" : "5444984.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "SM",
		"target" : "PDE4",
		"current_phase" : "Phase 2",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "AMG 634",
		"indication_description" : "INFLAMMATION",
		"business_partner" : "",
		"portfolio_priority" : "Gated",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 643",
		"product" : "AMG 643",
		"name" : "5477028.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "AbFrab",
		"target" : "CD40xFAP",
		"current_phase" : "Preclinical",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "AMG 643",
		"indication_description" : "CANCER - SOLID TUMORS",
		"business_partner" : "",
		"portfolio_priority" : "Standard",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 650",
		"product" : "AMG 650",
		"name" : "5429022.01",
		"trade_name" : "",
		"notepad" : "AMG 650 is a small molecule KIF18A inhibitor, which is being evaluated as an oral treatment for advanced solid tumors.",
		"modality" : "SM",
		"target" : "KIF18A",
		"current_phase" : "Phase 1",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "AMG 650",
		"indication_description" : "CANCER - OVARIAN",
		"business_partner" : "",
		"portfolio_priority" : "Standard",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 650",
		"product" : "AMG 650",
		"name" : "5429015.01",
		"trade_name" : "",
		"notepad" : "AMG 650 is an orally-administrated small molecule being evaluated in advanced solid tumors.",
		"modality" : "SM",
		"target" : "KIF18A",
		"current_phase" : "Preclinical",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "AMG 650",
		"indication_description" : "CANCER - BREAST",
		"business_partner" : "",
		"portfolio_priority" : "Standard",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 650",
		"product" : "AMG 650",
		"name" : "5429022.02",
		"trade_name" : "",
		"notepad" : "AMG 650 is an orally-administrated small molecule being evaluated in advanced solid tumors.",
		"modality" : "SM",
		"target" : "KIF18A",
		"current_phase" : "Preclinical",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "AMG 650",
		"indication_description" : "CANCER - OVARIAN",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 651",
		"product" : "AMG 651",
		"name" : "5449016.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "TCE FrabFc",
		"target" : "EGFR",
		"current_phase" : "Phase 1",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "AMG 651",
		"indication_description" : "CANCER - COLORECTAL",
		"business_partner" : "",
		"portfolio_priority" : "Standard",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 655",
		"product" : "conatumumab",
		"name" : "5147023.02",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "TRAIL R2 (CLOSED)",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "conatumumab",
		"indication_description" : "CANCER - PANCREAS",
		"business_partner" : "Takeda",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 655",
		"product" : "conatumumab",
		"name" : "5147016.13",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "TRAIL R2 (CLOSED)",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "conatumumab",
		"indication_description" : "CANCER - COLORECTAL",
		"business_partner" : "Takeda",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 655",
		"product" : "conatumumab",
		"name" : "5147015.05",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "TRAIL R2 (CLOSED)",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "conatumumab",
		"indication_description" : "CANCER - BREAST",
		"business_partner" : "Takeda",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 655",
		"product" : "conatumumab",
		"name" : "5147020.03",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "TRAIL R2 (CLOSED)",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "conatumumab",
		"indication_description" : "CANCER - NON SMALL CELL LUNG",
		"business_partner" : "Takeda",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 655",
		"product" : "conatumumab",
		"name" : "5147020.09",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "TRAIL R2 (CLOSED)",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "conatumumab",
		"indication_description" : "CANCER - NON SMALL CELL LUNG",
		"business_partner" : "Takeda",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 655",
		"product" : "conatumumab",
		"name" : "5147028.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "TRAIL R2 (CLOSED)",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "conatumumab",
		"indication_description" : "CANCER - SOLID TUMORS",
		"business_partner" : "Takeda",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 655",
		"product" : "conatumumab",
		"name" : "5147020.10",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "TRAIL R2 (CLOSED)",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "conatumumab",
		"indication_description" : "CANCER - NON SMALL CELL LUNG",
		"business_partner" : "Takeda",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 655",
		"product" : "conatumumab",
		"name" : "5147053.06",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "TRAIL R2 (CLOSED)",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "conatumumab",
		"indication_description" : "LYMPHOMA - NON HODGKINS",
		"business_partner" : "Takeda",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 655",
		"product" : "conatumumab",
		"name" : "5147016.11",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "TRAIL R2 (CLOSED)",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "conatumumab",
		"indication_description" : "CANCER - COLORECTAL",
		"business_partner" : "Takeda",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 655",
		"product" : "conatumumab",
		"name" : "5147026.08",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "TRAIL R2 (CLOSED)",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "conatumumab",
		"indication_description" : "CANCER - SARCOMA",
		"business_partner" : "Takeda",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 655",
		"product" : "conatumumab",
		"name" : "5147016.12",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "TRAIL R2 (CLOSED)",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "conatumumab",
		"indication_description" : "CANCER - COLORECTAL",
		"business_partner" : "Takeda",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 655",
		"product" : "conatumumab",
		"name" : "5147016.04",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "TRAIL R2 (CLOSED)",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "conatumumab",
		"indication_description" : "CANCER - COLORECTAL",
		"business_partner" : "Takeda",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 658",
		"product" : "AMG 658",
		"name" : "5176074.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "SM",
		"target" : "p38 SG BU",
		"current_phase" : "",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "AMG 658",
		"indication_description" : "SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 673",
		"product" : "emerfetamab",
		"name" : "5387048.01",
		"trade_name" : "",
		"notepad" : "AMG 673 is a half-life extended (HLE) anti-CD33 x anti-CD3 BiTE® (bispecific T cell engager) construct. It is being investigated for the treatment of acute myeloid leukemia.",
		"modality" : "HLE BiTE",
		"target" : "CD33-HLE",
		"current_phase" : "Phase 1",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "emerfetamab",
		"indication_description" : "LEUKEMIA - ACUTE MYELOID (AML)",
		"business_partner" : "",
		"portfolio_priority" : "Gated",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 676",
		"product" : "AMG 676",
		"name" : "5391982.01",
		"trade_name" : "",
		"notepad" : "ON HOLD. AMG 676 CDH19 HLE BiTE is a bi-specific T cell engager with 2 arms: CDH19 and CD3. The HLE BiTE will bind CD3 on T cells and be targeted to CDH19 on tumor\/tissue cells. The binding of the HLE BiTE to both CD3 and CDH19 will induce T cell activation cytokine production and cytolytic lysis of CDH19 positive target cells. per PG decision Q3 2019, the program was terminated.",
		"modality" : "HLE BiTE",
		"target" : "CDH19 BiTE",
		"current_phase" : "Preclinical",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "AMG 676",
		"indication_description" : "ONCOLOGY",
		"business_partner" : "",
		"portfolio_priority" : "Close Out",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 678",
		"product" : "IMLYGIC",
		"name" : "5291094.05",
		"trade_name" : "Imlygic",
		"notepad" : "",
		"modality" : "Vir",
		"target" : "GM-CSF",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "talimogene laherparepvec",
		"indication_description" : "CANCER - HEPATOCELLULAR CARCINOMA",
		"business_partner" : "",
		"portfolio_priority" : "Standard",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 678",
		"product" : "IMLYGIC",
		"name" : "5291900.03",
		"trade_name" : "Imlygic",
		"notepad" : "",
		"modality" : "Vir",
		"target" : "GM-CSF",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "talimogene laherparepvec",
		"indication_description" : "GENERAL (NON-INDICATION SPECIFIC)",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 678",
		"product" : "IMLYGIC",
		"name" : "5291095.02",
		"trade_name" : "Imlygic",
		"notepad" : "IMLYGIC® is an oncolytic immunotherapy derived from herpes simplex virus type 1 (HSV-1). It is approved in melanoma monotherapy in advanced melanoma patients.",
		"modality" : "Vir",
		"target" : "GM-CSF",
		"current_phase" : "Post-Launch",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "talimogene laherparepvec",
		"indication_description" : "CANCER - MELANOMA",
		"business_partner" : "",
		"portfolio_priority" : "Standard",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 678",
		"product" : "IMLYGIC",
		"name" : "5291018.01",
		"trade_name" : "Imlygic",
		"notepad" : "IMLYGIC® is an oncolytic immunotherapy derived from herpes simplex virus type 1 (HSV-1). It is being investigated in SCCHN as a combination treatment with pembrolizumab.",
		"modality" : "Vir",
		"target" : "GM-CSF",
		"current_phase" : "Phase 1",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "talimogene laherparepvec",
		"indication_description" : "CANCER - HEAD AND NECK",
		"business_partner" : "Merck",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 678",
		"product" : "IMLYGIC",
		"name" : "5291094.06",
		"trade_name" : "",
		"notepad" : "IMLYGIC® is an oncolytic immunotherapy derived from herpes simplex virus type 1 (HSV-1). It is being investigated for the treatment of solid tumors in combination with pembrolizumab.",
		"modality" : "Vir",
		"target" : "GM-CSF",
		"current_phase" : "Phase 2",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "talimogene laherparepvec",
		"indication_description" : "CANCER - HEPATOCELLULAR CARCINOMA",
		"business_partner" : "Merck",
		"portfolio_priority" : "Standard",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 678",
		"product" : "IMLYGIC",
		"name" : "5291015.04",
		"trade_name" : "Imlygic",
		"notepad" : "",
		"modality" : "Vir",
		"target" : "GM-CSF",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "talimogene laherparepvec",
		"indication_description" : "CANCER - BREAST",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 678",
		"product" : "IMLYGIC",
		"name" : "5291095.07",
		"trade_name" : "Imlygic",
		"notepad" : "IMLYGIC® is an oncolytic immunotherapy derived from herpes simplex virus type 1 (HSV-1). It is being investigated in melanoma as a combination treatment with pembrolizumab.",
		"modality" : "Vir",
		"target" : "GM-CSF",
		"current_phase" : "Preclinical",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "talimogene laherparepvec",
		"indication_description" : "CANCER - MELANOMA",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Formulation \/ Delivery System for a Marketed Active Substance"
	},
	{
		"amg_number" : "AMG 678",
		"product" : "IMLYGIC",
		"name" : "5291095.06",
		"trade_name" : "Imlygic",
		"notepad" : "IMLYGIC® is an oncolytic immunotherapy derived from herpes simplex virus type 1 (HSV-1). It is being investigated for the treatment of melanoma in combination with pembrolizumab.",
		"modality" : "Vir",
		"target" : "GM-CSF",
		"current_phase" : "Phase 3",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "talimogene laherparepvec",
		"indication_description" : "CANCER - MELANOMA",
		"business_partner" : "Merck,Nuvelution",
		"portfolio_priority" : "Standard",
		"project_type" : "New Combination of a Marketed Active Substance"
	},
	{
		"amg_number" : "AMG 682",
		"product" : "AMG 682",
		"name" : "5437047.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "HLE dBiTE",
		"target" : "CD20 x CD22",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "AMG 682",
		"indication_description" : "LEUKEMIA - ACUTE LYMPHOBLASTIC (ALL)",
		"business_partner" : "",
		"portfolio_priority" : "Standard",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 700",
		"product" : "AMG 700",
		"name" : "5280001.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "SM",
		"target" : "BACE",
		"current_phase" : "",
		"medical_therapeutic_area" : "Neuroscience",
		"generic_name" : "AMG 700",
		"indication_description" : "ALZHEIMER'S DISEASE",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 701",
		"product" : "pavurutamab",
		"name" : "5398019.01",
		"trade_name" : "",
		"notepad" : "AMG 701 is a half-life extended (HLE) anti-B-cell maturation antigen (BCMA) x anti-CD3 BiTE® (bispecific T cell engager) construct. It is being investigated for the treatment of multiple myeloma.",
		"modality" : "HLE BiTE",
		"target" : "BCMA",
		"current_phase" : "Phase 1",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "pavurutamab",
		"indication_description" : "CANCER - MULTIPLE MYELOMA",
		"business_partner" : "",
		"portfolio_priority" : "Standard",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 706",
		"product" : "motesanib diphosphate",
		"name" : "5149020.07",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "SM",
		"target" : "VEGFR",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "motesanib diphosphate",
		"indication_description" : "CANCER - NON SMALL CELL LUNG",
		"business_partner" : "Abbott Laboratories,Millennium Pharmaceuticals,Takeda",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 706",
		"product" : "motesanib diphosphate",
		"name" : "5149982.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "SM",
		"target" : "VEGFR",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "motesanib diphosphate",
		"indication_description" : "ONCOLOGY",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 706",
		"product" : "motesanib diphosphate",
		"name" : "5149016.05",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "SM",
		"target" : "VEGFR",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "motesanib diphosphate",
		"indication_description" : "CANCER - COLORECTAL",
		"business_partner" : "Takeda",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 706",
		"product" : "motesanib diphosphate",
		"name" : "5149015.08",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "SM",
		"target" : "VEGFR",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "motesanib diphosphate",
		"indication_description" : "CANCER - BREAST",
		"business_partner" : "Takeda",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 706",
		"product" : "motesanib diphosphate",
		"name" : "5149017.03",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "SM",
		"target" : "VEGFR",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "motesanib diphosphate",
		"indication_description" : "CANCER - GASTROINTESTINAL STROMAL TUMORS",
		"business_partner" : "Takeda",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 706",
		"product" : "motesanib diphosphate",
		"name" : "5149015.06",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "SM",
		"target" : "VEGFR",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "motesanib diphosphate",
		"indication_description" : "CANCER - BREAST",
		"business_partner" : "Takeda",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 706",
		"product" : "motesanib diphosphate",
		"name" : "5149028.09",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "SM",
		"target" : "VEGFR",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "motesanib diphosphate",
		"indication_description" : "CANCER - SOLID TUMORS",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 706",
		"product" : "motesanib diphosphate",
		"name" : "5149028.10",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "SM",
		"target" : "VEGFR",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "motesanib diphosphate",
		"indication_description" : "CANCER - SOLID TUMORS",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 706",
		"product" : "motesanib diphosphate",
		"name" : "5149023.05",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "SM",
		"target" : "VEGFR",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "motesanib diphosphate",
		"indication_description" : "CANCER - PANCREAS",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 706",
		"product" : "motesanib diphosphate",
		"name" : "5149029.04",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "SM",
		"target" : "VEGFR",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "motesanib diphosphate",
		"indication_description" : "CANCER - THYROID",
		"business_partner" : "Takeda",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 706",
		"product" : "motesanib diphosphate",
		"name" : "5149017.02",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "SM",
		"target" : "VEGFR",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "motesanib diphosphate",
		"indication_description" : "CANCER - GASTROINTESTINAL STROMAL TUMORS",
		"business_partner" : "Takeda",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 706-Combo",
		"product" : "AMG 706-Combo",
		"name" : "5167020.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "SM",
		"target" : "VEGFR",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "AMG 706-Combo",
		"indication_description" : "CANCER - NON SMALL CELL LUNG",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 706-Combo",
		"product" : "AMG 706-Combo",
		"name" : "5167016.02",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "SM",
		"target" : "VEGFR",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "AMG 706-Combo",
		"indication_description" : "CANCER - COLORECTAL",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 706-Combo",
		"product" : "AMG 706-Combo",
		"name" : "5167018.03",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "SM",
		"target" : "VEGFR",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "AMG 706-Combo",
		"indication_description" : "CANCER - HEAD AND NECK",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 714",
		"product" : "ordesekimab",
		"name" : "5150105.03",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "IL-15",
		"current_phase" : "",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "ordesekimab",
		"indication_description" : "REFRACTORY CELIAC DISEASE (RCD)",
		"business_partner" : "Celimmune",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 714",
		"product" : "ordesekimab",
		"name" : "5150072.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "IL-15",
		"current_phase" : "",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "ordesekimab",
		"indication_description" : "RHEUMATOID ARTHRITIS - MUSCULO-SKELETAL",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 714",
		"product" : "ordesekimab",
		"name" : "5150105.05",
		"trade_name" : "",
		"notepad" : "AMG 714 is a human monoclonal antibody that binds to Interleukin-15 (IL-15). It is being investigated for the treatment of celiac disease.;;ADDITIONAL INFORMATION;Amgen reacquired the AMG 714 program from Celimmune LLC and entered into a collaboration with Provention Bio.",
		"modality" : "mAb",
		"target" : "IL-15",
		"current_phase" : "Phase 2",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "ordesekimab",
		"indication_description" : "REFRACTORY CELIAC DISEASE (RCD)",
		"business_partner" : "ProventionBio",
		"portfolio_priority" : "Gated",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 714",
		"product" : "ordesekimab",
		"name" : "5150069.02",
		"trade_name" : "",
		"notepad" : "AMG 714 is a human monoclonal antibody that binds to Interleukin-15 (IL-15). It is being investigated for the treatment of celiac disease. In November 2017 Amgen reacquired the AMG 714 program from Celimmune LLC and entered into a collaboration with Provention Bio in 2018 for non-responsive celiac disease.",
		"modality" : "mAb",
		"target" : "IL-15",
		"current_phase" : "",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "ordesekimab",
		"indication_description" : "PSORIASIS",
		"business_partner" : "Genmab",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 720",
		"product" : "AMG 720",
		"name" : "5388001.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "SM",
		"target" : "BACE #3",
		"current_phase" : "",
		"medical_therapeutic_area" : "Neuroscience",
		"generic_name" : "AMG 720",
		"indication_description" : "ALZHEIMER'S DISEASE",
		"business_partner" : "",
		"portfolio_priority" : "Close Out",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 729",
		"product" : "AMG 729",
		"name" : "5290074.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "XmAb",
		"target" : "CDH19",
		"current_phase" : "",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "AMG 729",
		"indication_description" : "SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)",
		"business_partner" : "Xencor",
		"portfolio_priority" : "",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 745",
		"product" : "AMG 745",
		"name" : "5151982.04",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "PepFc",
		"target" : "Myostatin #2",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "AMG 745",
		"indication_description" : "ONCOLOGY",
		"business_partner" : "Takeda",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 745",
		"product" : "AMG 745",
		"name" : "5151014.03",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "PepFc",
		"target" : "Myostatin #2",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "AMG 745",
		"indication_description" : "CACHEXIA - CANCER",
		"business_partner" : "Takeda",
		"portfolio_priority" : "",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 745",
		"product" : "AMG 745",
		"name" : "5151073.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "PepFc",
		"target" : "Myostatin #2",
		"current_phase" : "",
		"medical_therapeutic_area" : "Metabolic Disorders",
		"generic_name" : "AMG 745",
		"indication_description" : "SARCOPENIA - IMMOBILIZATION",
		"business_partner" : "Takeda",
		"portfolio_priority" : "",
		"project_type" : "New Patient Population"
	},
	{
		"amg_number" : "AMG 745",
		"product" : "AMG 745",
		"name" : "5151099.02",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "PepFc",
		"target" : "Myostatin #2",
		"current_phase" : "",
		"medical_therapeutic_area" : "Metabolic Disorders",
		"generic_name" : "AMG 745",
		"indication_description" : "MUSCULAR DYSTROPHY",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 747",
		"product" : "AMG 747",
		"name" : "5192091.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "SM",
		"target" : "GlyT-1",
		"current_phase" : "",
		"medical_therapeutic_area" : "Neuroscience",
		"generic_name" : "AMG 747",
		"indication_description" : "SCHIZOPHRENIA",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 753",
		"product" : "AMG 753",
		"name" : "5152028.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "PrFc",
		"target" : "Tek Delta",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "AMG 753",
		"indication_description" : "CANCER - SOLID TUMORS",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 757",
		"product" : "tarlatamab",
		"name" : "5392982.05",
		"trade_name" : "",
		"notepad" : "Tarlatamab (formerly AMG 757) is a half-life extended (HLE) anti -delta-like ligand 3 (DLL3) x anti-CD3 BiTE (bispecific T cell engager) molecule. It is being investigated for the treatment of small cell lung cancer.",
		"modality" : "HLE BiTE",
		"target" : "DLL3 BiTE",
		"current_phase" : "Phase 1",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "tarlatamab",
		"indication_description" : "ONCOLOGY",
		"business_partner" : "",
		"portfolio_priority" : "Fastlane",
		"project_type" : "New Patient Population"
	},
	{
		"amg_number" : "AMG 757",
		"product" : "tarlatamab",
		"name" : "5392982.06",
		"trade_name" : "",
		"notepad" : "Tarlatamab (formerly AMG 757) is a half-life extended (HLE) anti- delta-like ligand 3 (DLL3) x anti-CD3 BiTE (bispecific T cell engager) molecule. It is being investigated for the treatment of small cell lung cancer.",
		"modality" : "HLE BiTE",
		"target" : "DLL3 BiTE",
		"current_phase" : "Phase 1",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "tarlatamab",
		"indication_description" : "ONCOLOGY",
		"business_partner" : "",
		"portfolio_priority" : "Fastlane",
		"project_type" : "New Patient Population"
	},
	{
		"amg_number" : "AMG 757",
		"product" : "tarlatamab",
		"name" : "5392982.01",
		"trade_name" : "",
		"notepad" : "Tarlatamab (formerly AMG 757) is a half-life extended (HLE) anti- delta-like ligand 3 (DLL3) x anti-CD3 BiTE (bispecific T cell engager) molecule. It is being investigated for the treatment of small cell lung cancer.",
		"modality" : "HLE BiTE",
		"target" : "DLL3 BiTE",
		"current_phase" : "Phase 2",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "tarlatamab",
		"indication_description" : "ONCOLOGY",
		"business_partner" : "",
		"portfolio_priority" : "Fastlane",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 757",
		"product" : "tarlatamab",
		"name" : "5392982.03",
		"trade_name" : "",
		"notepad" : "AMG 757 is an extended half-life anti-DLL3 x anti-CD3 BiTE® (bispecific T cell engager) construct. It is being investigated as a treatment for small-cell lung cancer.",
		"modality" : "HLE BiTE",
		"target" : "DLL3 BiTE",
		"current_phase" : "Phase 1",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "tarlatamab",
		"indication_description" : "ONCOLOGY",
		"business_partner" : "",
		"portfolio_priority" : "Gated",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 757",
		"product" : "tarlatamab",
		"name" : "5392982.04",
		"trade_name" : "",
		"notepad" : "Tarlatamab (formerly AMG 757) is a half-life extended (HLE) anti- delta-like ligand 3 (DLL3) x anti-CD3 BiTE (bispecific T cell engager) molecule. It is being investigated for the treatment of neuroendocrine prostate cancer.",
		"modality" : "HLE BiTE",
		"target" : "DLL3 BiTE",
		"current_phase" : "Phase 1",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "tarlatamab",
		"indication_description" : "ONCOLOGY",
		"business_partner" : "",
		"portfolio_priority" : "Fastlane",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 761",
		"product" : "AMG 761",
		"name" : "5200009.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "Anti-CCR4",
		"current_phase" : "",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "AMG 761",
		"indication_description" : "ASTHMA",
		"business_partner" : "Kyowa Hakko Kirin",
		"portfolio_priority" : "",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 763",
		"product" : "AMG 763",
		"name" : "5299074.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "IL-21R",
		"current_phase" : "",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "AMG 763",
		"indication_description" : "SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 777",
		"product" : "AMG 777",
		"name" : "5178014.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "Anti-Activin A",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "AMG 777",
		"indication_description" : "CACHEXIA - CANCER",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 780",
		"product" : "AMG 780",
		"name" : "5187028.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "Angiopoietin b\/u",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "AMG 780",
		"indication_description" : "CANCER - SOLID TUMORS",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 785",
		"product" : "EVENITY",
		"name" : "5153102.03",
		"trade_name" : "Evenity",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "Sclerostin",
		"current_phase" : "",
		"medical_therapeutic_area" : "Bone",
		"generic_name" : "romosozumab",
		"indication_description" : "FRACTURE HEALING",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 785",
		"product" : "EVENITY",
		"name" : "5153062.02",
		"trade_name" : "Evenity",
		"notepad" : "EVENITY  is a humanized monoclonal antibody that inhibits the action of sclerostin and has been evaluated as a treatment for osteoporosis.  EVENITY  has received marketing approval in major markets, including Japan, US and EU.  Additional country approvals are forthcoming.",
		"modality" : "mAb",
		"target" : "Sclerostin",
		"current_phase" : "Launch",
		"medical_therapeutic_area" : "Bone",
		"generic_name" : "romosozumab",
		"indication_description" : "OSTEOPOROSIS",
		"business_partner" : "Astellas,UCB",
		"portfolio_priority" : "Standard",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 785",
		"product" : "romosozumab",
		"name" : "5153062.05",
		"trade_name" : "",
		"notepad" : "EVENITY  is a humanized monoclonal antibody that inhibits the action of sclerostin and has been evaluated as a treatment for osteoporosis.  EVENITY  has received marketing approval in major markets, including Japan, US and EU.  Additional country approvals are forthcoming.  It is being investigated for the  treatment of glucocorticoid-induced osteoporosis (GIOP) in pediatric patients.;;TEAM NOTE: Per regulatory agency agreement; the Pediatric GIOP commitment has been released",
		"modality" : "mAb",
		"target" : "Sclerostin",
		"current_phase" : "",
		"medical_therapeutic_area" : "",
		"generic_name" : "romosozumab",
		"indication_description" : "OSTEOPOROSIS",
		"business_partner" : "",
		"portfolio_priority" : "Standard",
		"project_type" : "New Patient Population"
	},
	{
		"amg_number" : "AMG 785",
		"product" : "EVENITY",
		"name" : "5153062.03",
		"trade_name" : "Evenity",
		"notepad" : "EVENITY® is a humanized monoclonal antibody that inhibits the action of sclerostin. It is being investigated for the treatment of male osteoporosis.",
		"modality" : "mAb",
		"target" : "Sclerostin",
		"current_phase" : "Phase 3",
		"medical_therapeutic_area" : "Bone",
		"generic_name" : "romosozumab",
		"indication_description" : "OSTEOPOROSIS",
		"business_partner" : "Astellas,UCB",
		"portfolio_priority" : "Standard",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 785",
		"product" : "EVENITY",
		"name" : "5153019.01",
		"trade_name" : "Evenity",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "Sclerostin",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "romosozumab",
		"indication_description" : "CANCER - MULTIPLE MYELOMA",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 785",
		"product" : "EVENITY",
		"name" : "5153062.04",
		"trade_name" : "",
		"notepad" : "EVENITY® is a humanized monoclonal antibody that inhibits the action of sclerostin. It is being investigated for the treatment of osteogenesis imperfecta in pediatric patients.",
		"modality" : "mAb",
		"target" : "Sclerostin",
		"current_phase" : "Phase 1",
		"medical_therapeutic_area" : "Bone",
		"generic_name" : "romosozumab",
		"indication_description" : "OSTEOPOROSIS",
		"business_partner" : "",
		"portfolio_priority" : "Standard",
		"project_type" : "New Patient Population"
	},
	{
		"amg_number" : "AMG 786",
		"product" : "AMG 786",
		"name" : "5458060.01",
		"trade_name" : "",
		"notepad" : "AMG 786 is a small molecule being investigated for the treatment of obesity.",
		"modality" : "SM",
		"target" : "FADS1",
		"current_phase" : "Phase 1",
		"medical_therapeutic_area" : "Metabolic Disorders",
		"generic_name" : "AMG 786",
		"indication_description" : "OBESITY",
		"business_partner" : "",
		"portfolio_priority" : "Standard",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 794",
		"product" : "AMG 794",
		"name" : "5445028.01",
		"trade_name" : "",
		"notepad" : "AMG 794 is a half-life extended BiTE® (bispecific T-cell engager) targeting oncofetal antigen claudin 6 (CLDN6) on tumor cells and CD3 on T-cells.  AMG 794 is planning for development in non-small cell lung and ovarian cancers.",
		"modality" : "HLE BiTE",
		"target" : "CLDN6",
		"current_phase" : "Preclinical",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "AMG 794",
		"indication_description" : "CANCER - SOLID TUMORS",
		"business_partner" : "",
		"portfolio_priority" : "Standard",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 795",
		"product" : "AMG 795",
		"name" : "5453141.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "Vaccine_TBD",
		"target" : "SARS-COV2",
		"current_phase" : "Preclinical",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "AMG 795",
		"indication_description" : "COVID-19",
		"business_partner" : "",
		"portfolio_priority" : "Standard",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 797",
		"product" : "AMG 797",
		"name" : "5461028.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "TCR-T Payload",
		"target" : "MAGE B2\/A4",
		"current_phase" : "Preclinical",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "AMG 797",
		"indication_description" : "CANCER - SOLID TUMORS",
		"business_partner" : "",
		"portfolio_priority" : "Gated",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 811",
		"product" : "AMG 811",
		"name" : "5154074.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "IFNg Ab",
		"current_phase" : "",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "AMG 811",
		"indication_description" : "SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)",
		"business_partner" : "Medarex",
		"portfolio_priority" : "",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 819",
		"product" : "AMG 819",
		"name" : "5155065.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "PepFc",
		"target" : "NGF Pb",
		"current_phase" : "",
		"medical_therapeutic_area" : "Neuroscience",
		"generic_name" : "AMG 819",
		"indication_description" : "PAIN - NEUROPATHIC",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 820",
		"product" : "AMG 820",
		"name" : "5173028.01",
		"trade_name" : "",
		"notepad" : "AMG 820 is an investigational fully human immunoglobulin G2 mAb directed against human colony stimulating factor-1 receptor (CSF1R) that inhibits binding of the ligands CSF1 and IL34 and subsequent ligand induced receptor activation.  In combination with Keytruda AMG 820 is being investigated for solid tumors including Pancreatic cancer and Non Small Cell Lung cancer (NSCLC) and Colorectal cancer. ;;AMG 820 was discontinued per PG Core decision on Jan 22, 2018 with no rationale provided.   GPGM was Dirk Nagorsen. Amgen signed the agreement with AmMax to out license AMG820 on March 26, 2020. The AmMax press release was announced on March 30, 2020 (press release ).",
		"modality" : "mAb",
		"target" : "C-FMS Ab",
		"current_phase" : "Phase 1",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "AMG 820",
		"indication_description" : "CANCER - SOLID TUMORS",
		"business_partner" : "",
		"portfolio_priority" : "Close Out",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 827",
		"product" : "brodalumab",
		"name" : "5163070.07",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "IL-17R (CLOSED)",
		"current_phase" : "",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "brodalumab",
		"indication_description" : "PSORIATIC ARTHRITIS",
		"business_partner" : "",
		"portfolio_priority" : "Close Out",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 827",
		"product" : "brodalumab",
		"name" : "5163009.05",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "IL-17R (CLOSED)",
		"current_phase" : "",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "brodalumab",
		"indication_description" : "ASTHMA",
		"business_partner" : "Kirin-Amgen JV",
		"portfolio_priority" : "Close Out",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 827",
		"product" : "brodalumab",
		"name" : "5163030.09",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "IL-17R (CLOSED)",
		"current_phase" : "",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "brodalumab",
		"indication_description" : "CHRONIC OBSTRUCTIVE PULMONARY DISEASE",
		"business_partner" : "AstraZeneca\/MedImmune",
		"portfolio_priority" : "Close Out",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 827",
		"product" : "brodalumab",
		"name" : "5163069.02",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "IL-17R (CLOSED)",
		"current_phase" : "",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "brodalumab",
		"indication_description" : "PSORIASIS",
		"business_partner" : "",
		"portfolio_priority" : "Close Out",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 827",
		"product" : "brodalumab",
		"name" : "5163072.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "IL-17R (CLOSED)",
		"current_phase" : "",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "brodalumab",
		"indication_description" : "RHEUMATOID ARTHRITIS - MUSCULO-SKELETAL",
		"business_partner" : "Kirin-Amgen JV",
		"portfolio_priority" : "Close Out",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 827",
		"product" : "brodalumab",
		"name" : "5163984.04",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "IL-17R (CLOSED)",
		"current_phase" : "",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "brodalumab",
		"indication_description" : "INFLAMMATION",
		"business_partner" : "Kirin-Amgen JV",
		"portfolio_priority" : "Close Out",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 827",
		"product" : "brodalumab",
		"name" : "5163008.08",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "IL-17R (CLOSED)",
		"current_phase" : "",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "brodalumab",
		"indication_description" : "ANKYLOSING SPONDYLITIS",
		"business_partner" : "Kirin-Amgen JV",
		"portfolio_priority" : "Close Out",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 827",
		"product" : "brodalumab",
		"name" : "5163045.03",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "IL-17R (CLOSED)",
		"current_phase" : "",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "brodalumab",
		"indication_description" : "INFLAMMATORY BOWEL DISEASE",
		"business_partner" : "Kirin-Amgen JV",
		"portfolio_priority" : "Close Out",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 827",
		"product" : "brodalumab",
		"name" : "5163115.06",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "IL-17R (CLOSED)",
		"current_phase" : "",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "brodalumab",
		"indication_description" : "SPONDYLOARTHROPATHY",
		"business_partner" : "Kirin-Amgen JV",
		"portfolio_priority" : "Close Out",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 833",
		"product" : "AMG 833",
		"name" : "5156072.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "SM",
		"target" : "P38 2nd Gen",
		"current_phase" : "",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "AMG 833",
		"indication_description" : "RHEUMATOID ARTHRITIS - MUSCULO-SKELETAL",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 837",
		"product" : "AMG 837",
		"name" : "5157032.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "SM",
		"target" : "GPR40 - T.O;",
		"current_phase" : "",
		"medical_therapeutic_area" : "Metabolic Disorders",
		"generic_name" : "AMG 837",
		"indication_description" : "DIABETES - TYPE 2",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 844",
		"product" : "AMG 844",
		"name" : "5462028.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "AbFrab",
		"target" : "PDL1-41BB",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "AMG 844",
		"indication_description" : "CANCER - SOLID TUMORS",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 847",
		"product" : "AMG 847",
		"name" : "5283091.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "SM",
		"target" : "GlyT-1 #2",
		"current_phase" : "",
		"medical_therapeutic_area" : "Neuroscience",
		"generic_name" : "AMG 847",
		"indication_description" : "SCHIZOPHRENIA",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 853",
		"product" : "vidupiprant",
		"name" : "5181106.06",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "SM",
		"target" : "CRTH2 B\/U",
		"current_phase" : "",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "vidupiprant",
		"indication_description" : "ALLERGIC RHINITIS",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 853",
		"product" : "vidupiprant",
		"name" : "5181107.08",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "SM",
		"target" : "CRTH2 B\/U",
		"current_phase" : "",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "vidupiprant",
		"indication_description" : "URTICARIA",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 853",
		"product" : "vidupiprant",
		"name" : "5181009.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "SM",
		"target" : "CRTH2 B\/U",
		"current_phase" : "",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "vidupiprant",
		"indication_description" : "ASTHMA",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 853",
		"product" : "vidupiprant",
		"name" : "5181030.07",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "SM",
		"target" : "CRTH2 B\/U",
		"current_phase" : "",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "vidupiprant",
		"indication_description" : "CHRONIC OBSTRUCTIVE PULMONARY DISEASE",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 864",
		"product" : "AMG 864",
		"name" : "5158001.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "Anti-Amyloid Ab #1",
		"current_phase" : "",
		"medical_therapeutic_area" : "Neuroscience",
		"generic_name" : "AMG 864",
		"indication_description" : "ALZHEIMER'S DISEASE",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 873",
		"product" : "AMG 873",
		"name" : "5389069.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "SM",
		"target" : "RORg",
		"current_phase" : "",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "AMG 873",
		"indication_description" : "PSORIASIS",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 875",
		"product" : "AMG 875",
		"name" : "5212032.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "PrFc",
		"target" : "FGF21 #2",
		"current_phase" : "",
		"medical_therapeutic_area" : "Metabolic Disorders",
		"generic_name" : "AMG 875",
		"indication_description" : "DIABETES - TYPE 2",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 876",
		"product" : "AMG 876",
		"name" : "5217032.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "PrFc",
		"target" : "FGF21 #2 (RGE)",
		"current_phase" : "",
		"medical_therapeutic_area" : "Metabolic Disorders",
		"generic_name" : "AMG 876",
		"indication_description" : "DIABETES - TYPE 2",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 876",
		"product" : "AMG 876",
		"name" : "5217985.02",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "PrFc",
		"target" : "FGF21 #2 (RGE)",
		"current_phase" : "",
		"medical_therapeutic_area" : "Metabolic Disorders",
		"generic_name" : "AMG 876",
		"indication_description" : "METABOLIC DISORDERS",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Dosage Form"
	},
	{
		"amg_number" : "AMG 888",
		"product" : "AMG 888",
		"name" : "5182028.02",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "her3",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "AMG 888",
		"indication_description" : "CANCER - SOLID TUMORS",
		"business_partner" : "Daiichi Sankyo",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 888",
		"product" : "AMG 888",
		"name" : "5182028.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "her3",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "AMG 888",
		"indication_description" : "CANCER - SOLID TUMORS",
		"business_partner" : "Daiichi Sankyo",
		"portfolio_priority" : "",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 888",
		"product" : "AMG 888",
		"name" : "5182028.03",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "her3",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "AMG 888",
		"indication_description" : "CANCER - SOLID TUMORS",
		"business_partner" : "Daiichi Sankyo",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 890",
		"product" : "olpasiran",
		"name" : "5404989.01",
		"trade_name" : "",
		"notepad" : "Olpasiran (formerly known as AMG 890) is a small interfering RNA (siRNA) that lowers lipoprotein(a), also known as Lp(a). It is being investigated for the treatment of atherosclerotic cardiovascular disease. ",
		"modality" : "siRNA",
		"target" : "Lp(a)",
		"current_phase" : "Phase 2",
		"medical_therapeutic_area" : "Cardiovascular",
		"generic_name" : "olpasiran",
		"indication_description" : "CARDIOVASCULAR",
		"business_partner" : "",
		"portfolio_priority" : "Standard",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 891",
		"product" : "AMG 891",
		"name" : "5183086.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "Hepcidin",
		"current_phase" : "",
		"medical_therapeutic_area" : "Nephrology",
		"generic_name" : "AMG 891",
		"indication_description" : "ANEMIA",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 898",
		"product" : "AMG 898",
		"name" : "5470028.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "PrFc",
		"target" : "CD80",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "AMG 898",
		"indication_description" : "CANCER - SOLID TUMORS",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 899",
		"product" : "AMG 899",
		"name" : "5380088.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "SM",
		"target" : "CETP",
		"current_phase" : "",
		"medical_therapeutic_area" : "Cardiovascular",
		"generic_name" : "AMG 899",
		"indication_description" : "HYPERCHOLESTEROLEMIA",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 900",
		"product" : "AMG 900",
		"name" : "5197982.02",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "SM",
		"target" : "Aurora",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "AMG 900",
		"indication_description" : "ONCOLOGY",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 900",
		"product" : "AMG 900",
		"name" : "5197028.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "SM",
		"target" : "Aurora",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "AMG 900",
		"indication_description" : "CANCER - SOLID TUMORS",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 910",
		"product" : "AMG 910",
		"name" : "5424082.03",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "HLE BiTE",
		"target" : "CLDN18.2",
		"current_phase" : "Preclinical",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "AMG 910",
		"indication_description" : "CANCER - GASTRIC",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Combination of a Pipeline Active Substance"
	},
	{
		"amg_number" : "AMG 910",
		"product" : "AMG 910",
		"name" : "5424082.01",
		"trade_name" : "",
		"notepad" : "AMG 910 is a half-life extended (HLE) anti-CLDN18.2 x anti-CD3 bispecific T cell engager (BiTE) molecule. It is being investigated for the treatment of gastric and gastroesophageal junction cancer.",
		"modality" : "HLE BiTE",
		"target" : "CLDN18.2",
		"current_phase" : "Phase 1",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "AMG 910",
		"indication_description" : "CANCER - GASTRIC",
		"business_partner" : "",
		"portfolio_priority" : "Standard",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 916",
		"product" : "Enbrel",
		"name" : "5109072.04",
		"trade_name" : "Enbrel",
		"notepad" : "ENBREL is a fusion protein that inhibits tumor necrosis factor. It is being investigated as a monotherapy for psoriatic arthritis treatment and as a monotherapy in maintaining remission of rheumatoid arthritis.",
		"modality" : "PrFc",
		"target" : "TNF",
		"current_phase" : "Post-Launch",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "etanercept",
		"indication_description" : "RHEUMATOID ARTHRITIS - MUSCULO-SKELETAL",
		"business_partner" : "Pfizer",
		"portfolio_priority" : "",
		"project_type" : "New Combination of a Marketed Active Substance"
	},
	{
		"amg_number" : "AMG 916",
		"product" : "Enbrel",
		"name" : "5109007.09",
		"trade_name" : "Enbrel",
		"notepad" : "",
		"modality" : "PrFc",
		"target" : "TNF",
		"current_phase" : "",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "etanercept",
		"indication_description" : "ANEMIA - HEART FAILURE",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 916",
		"product" : "Enbrel",
		"name" : "5109069.05",
		"trade_name" : "Enbrel",
		"notepad" : "",
		"modality" : "PrFc",
		"target" : "TNF",
		"current_phase" : "",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "etanercept",
		"indication_description" : "PSORIASIS",
		"business_partner" : "Pfizer",
		"portfolio_priority" : "",
		"project_type" : "New Patient Population"
	},
	{
		"amg_number" : "AMG 916",
		"product" : "Enbrel",
		"name" : "5109072.05",
		"trade_name" : "Enbrel",
		"notepad" : "ENBREL is a fusion protein that inhibits tumor necrosis factor. It is being investigated as a monotherapy for psoriatic arthritis treatment and as a monotherapy in maintaining remission of rheumatoid arthritis.",
		"modality" : "PrFc",
		"target" : "TNF",
		"current_phase" : "Post-Launch",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "etanercept",
		"indication_description" : "RHEUMATOID ARTHRITIS - MUSCULO-SKELETAL",
		"business_partner" : "Pfizer",
		"portfolio_priority" : "",
		"project_type" : "New Combination of a Marketed Active Substance"
	},
	{
		"amg_number" : "AMG 916",
		"product" : "Enbrel",
		"name" : "5109977.17",
		"trade_name" : "Enbrel",
		"notepad" : "",
		"modality" : "PrFc",
		"target" : "TNF",
		"current_phase" : "",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "etanercept",
		"indication_description" : "NON RECOVERABLE",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 916",
		"product" : "Enbrel",
		"name" : "5109071.03",
		"trade_name" : "Enbrel",
		"notepad" : "",
		"modality" : "PrFc",
		"target" : "TNF",
		"current_phase" : "",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "etanercept",
		"indication_description" : "RHEUMATOID ARTHRITIS - JUVENILE",
		"business_partner" : "Pfizer",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 916",
		"product" : "Enbrel",
		"name" : "5109070.08",
		"trade_name" : "Enbrel",
		"notepad" : "ENBREL is a fusion protein that inhibits tumor necrosis factor. It is being investigated as a monotherapy for psoriatic arthritis treatment and as a monotherapy in maintaining remission of rheumatoid arthritis.",
		"modality" : "PrFc",
		"target" : "TNF",
		"current_phase" : "Post-Launch",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "etanercept",
		"indication_description" : "PSORIATIC ARTHRITIS",
		"business_partner" : "Pfizer",
		"portfolio_priority" : "Standard",
		"project_type" : "New Combination of a Marketed Active Substance"
	},
	{
		"amg_number" : "AMG 916",
		"product" : "Enbrel",
		"name" : "5109984.16",
		"trade_name" : "Enbrel",
		"notepad" : "",
		"modality" : "PrFc",
		"target" : "TNF",
		"current_phase" : "",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "etanercept",
		"indication_description" : "INFLAMMATION",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 916",
		"product" : "Enbrel",
		"name" : "5109812.13",
		"trade_name" : "Enbrel",
		"notepad" : "",
		"modality" : "PrFc",
		"target" : "TNF",
		"current_phase" : "",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "etanercept",
		"indication_description" : "DEVICES AND FORMULATIONS",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Formulation \/ Delivery System for a Marketed Active Substance"
	},
	{
		"amg_number" : "AMG 916",
		"product" : "Enbrel",
		"name" : "5109812.18",
		"trade_name" : "Enbrel",
		"notepad" : "",
		"modality" : "PrFc",
		"target" : "TNF",
		"current_phase" : "",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "etanercept",
		"indication_description" : "DEVICES AND FORMULATIONS",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Formulation \/ Delivery System for a Marketed Active Substance"
	},
	{
		"amg_number" : "AMG 916",
		"product" : "Enbrel",
		"name" : "5109812.14",
		"trade_name" : "Enbrel",
		"notepad" : "",
		"modality" : "PrFc",
		"target" : "TNF",
		"current_phase" : "",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "etanercept",
		"indication_description" : "DEVICES AND FORMULATIONS",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Formulation \/ Delivery System for a Marketed Active Substance"
	},
	{
		"amg_number" : "AMG 916",
		"product" : "Enbrel",
		"name" : "5109072.10",
		"trade_name" : "Enbrel",
		"notepad" : "ENBREL is a fusion protein that inhibits tumor necrosis factor. It is being investigated as a monotherapy for psoriatic arthritis treatment and as a monotherapy in maintaining remission of rheumatoid arthritis.",
		"modality" : "PrFc",
		"target" : "TNF",
		"current_phase" : "Post-Launch",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "etanercept",
		"indication_description" : "RHEUMATOID ARTHRITIS - MUSCULO-SKELETAL",
		"business_partner" : "Pfizer",
		"portfolio_priority" : "",
		"project_type" : "New Combination of a Marketed Active Substance"
	},
	{
		"amg_number" : "AMG 916",
		"product" : "Enbrel",
		"name" : "5109085.10",
		"trade_name" : "Enbrel",
		"notepad" : "",
		"modality" : "PrFc",
		"target" : "TNF",
		"current_phase" : "",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "etanercept",
		"indication_description" : "IDIOPATHIC PULMONARY FIBROSIS",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 916",
		"product" : "Enbrel",
		"name" : "5109982.15",
		"trade_name" : "Enbrel",
		"notepad" : "",
		"modality" : "PrFc",
		"target" : "TNF",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "etanercept",
		"indication_description" : "ONCOLOGY",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 916",
		"product" : "Enbrel",
		"name" : "5109072.03",
		"trade_name" : "Enbrel",
		"notepad" : "ENBREL is a fusion protein that inhibits tumor necrosis factor. It is being investigated as a monotherapy for psoriatic arthritis treatment and as a monotherapy in maintaining remission of rheumatoid arthritis.",
		"modality" : "PrFc",
		"target" : "TNF",
		"current_phase" : "Post-Launch",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "etanercept",
		"indication_description" : "RHEUMATOID ARTHRITIS - MUSCULO-SKELETAL",
		"business_partner" : "Pfizer",
		"portfolio_priority" : "",
		"project_type" : "New Combination of a Marketed Active Substance"
	},
	{
		"amg_number" : "AMG 916",
		"product" : "Enbrel",
		"name" : "5109072.09",
		"trade_name" : "Enbrel",
		"notepad" : "ENBREL is a fusion protein that inhibits tumor necrosis factor. It is being investigated as a monotherapy for psoriatic arthritis treatment and as a monotherapy in maintaining remission of rheumatoid arthritis.",
		"modality" : "PrFc",
		"target" : "TNF",
		"current_phase" : "Post-Launch",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "etanercept",
		"indication_description" : "RHEUMATOID ARTHRITIS - MUSCULO-SKELETAL",
		"business_partner" : "Pfizer",
		"portfolio_priority" : "",
		"project_type" : "New Combination of a Marketed Active Substance"
	},
	{
		"amg_number" : "AMG 916",
		"product" : "Enbrel",
		"name" : "5109815.12",
		"trade_name" : "Enbrel",
		"notepad" : "",
		"modality" : "PrFc",
		"target" : "TNF",
		"current_phase" : "Filing",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "etanercept",
		"indication_description" : "SFP DEVELOPMENT - 1ST GENERATION",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Formulation \/ Delivery System for a Marketed Active Substance"
	},
	{
		"amg_number" : "AMG 916",
		"product" : "Enbrel",
		"name" : "5109008.06",
		"trade_name" : "Enbrel",
		"notepad" : "",
		"modality" : "PrFc",
		"target" : "TNF",
		"current_phase" : "",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "etanercept",
		"indication_description" : "ANKYLOSING SPONDYLITIS",
		"business_partner" : "Pfizer",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 916",
		"product" : "Enbrel",
		"name" : "5109069.04",
		"trade_name" : "Enbrel",
		"notepad" : "ENBREL is a fusion protein that inhibits tumor necrosis factor. It is being investigated as a monotherapy for psoriatic arthritis treatment and as a monotherapy in maintaining remission of rheumatoid arthritis.",
		"modality" : "PrFc",
		"target" : "TNF",
		"current_phase" : "Post-Launch",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "etanercept",
		"indication_description" : "PSORIASIS",
		"business_partner" : "Pfizer",
		"portfolio_priority" : "Standard",
		"project_type" : "New Combination of a Marketed Active Substance"
	},
	{
		"amg_number" : "AMG 916",
		"product" : "Enbrel",
		"name" : "5109812.12",
		"trade_name" : "Enbrel",
		"notepad" : "",
		"modality" : "PrFc",
		"target" : "TNF",
		"current_phase" : "",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "etanercept",
		"indication_description" : "DEVICES AND FORMULATIONS",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Formulation \/ Delivery System for a Marketed Active Substance"
	},
	{
		"amg_number" : "AMG 916",
		"product" : "Enbrel",
		"name" : "5109072.13",
		"trade_name" : "Enbrel",
		"notepad" : "ENBREL is a fusion protein that inhibits tumor necrosis factor. It is being investigated as a monotherapy for psoriatic arthritis treatment and as a monotherapy in maintaining remission of rheumatoid arthritis.",
		"modality" : "PrFc",
		"target" : "TNF",
		"current_phase" : "Post-Launch",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "etanercept",
		"indication_description" : "RHEUMATOID ARTHRITIS - MUSCULO-SKELETAL",
		"business_partner" : "Pfizer",
		"portfolio_priority" : "",
		"project_type" : "New Combination of a Marketed Active Substance"
	},
	{
		"amg_number" : "AMG 916",
		"product" : "Enbrel",
		"name" : "5109072.06",
		"trade_name" : "Enbrel",
		"notepad" : "ENBREL is a fusion protein that inhibits tumor necrosis factor. It is being investigated as a monotherapy for psoriatic arthritis treatment and as a monotherapy in maintaining remission of rheumatoid arthritis.",
		"modality" : "PrFc",
		"target" : "TNF",
		"current_phase" : "Post-Launch",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "etanercept",
		"indication_description" : "RHEUMATOID ARTHRITIS - MUSCULO-SKELETAL",
		"business_partner" : "Pfizer",
		"portfolio_priority" : "",
		"project_type" : "New Combination of a Marketed Active Substance"
	},
	{
		"amg_number" : "AMG 916",
		"product" : "Enbrel",
		"name" : "5109072.01",
		"trade_name" : "Enbrel",
		"notepad" : "ENBREL is a fusion protein that inhibits tumor necrosis factor. It is being investigated as a monotherapy for psoriatic arthritis treatment and as a monotherapy in maintaining remission of rheumatoid arthritis.",
		"modality" : "PrFc",
		"target" : "TNF",
		"current_phase" : "Post-Launch",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "etanercept",
		"indication_description" : "RHEUMATOID ARTHRITIS - MUSCULO-SKELETAL",
		"business_partner" : "Pfizer",
		"portfolio_priority" : "Standard",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 916",
		"product" : "Enbrel",
		"name" : "5109812.11",
		"trade_name" : "Enbrel",
		"notepad" : "",
		"modality" : "PrFc",
		"target" : "TNF",
		"current_phase" : "",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "etanercept",
		"indication_description" : "DEVICES AND FORMULATIONS",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Formulation \/ Delivery System for a Marketed Active Substance"
	},
	{
		"amg_number" : "AMG 916",
		"product" : "Enbrel",
		"name" : "5109069.07",
		"trade_name" : "Enbrel",
		"notepad" : "",
		"modality" : "PrFc",
		"target" : "TNF",
		"current_phase" : "",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "etanercept",
		"indication_description" : "PSORIASIS",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Formulation \/ Delivery System for a Marketed Active Substance"
	},
	{
		"amg_number" : "AMG 916",
		"product" : "Enbrel",
		"name" : "5109984.17",
		"trade_name" : "Enbrel",
		"notepad" : "",
		"modality" : "PrFc",
		"target" : "TNF",
		"current_phase" : "",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "etanercept",
		"indication_description" : "INFLAMMATION",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Patient Population"
	},
	{
		"amg_number" : "AMG 916",
		"product" : "Enbrel",
		"name" : "5109072.11",
		"trade_name" : "Enbrel",
		"notepad" : "ENBREL is a fusion protein that inhibits tumor necrosis factor. It is being investigated as a monotherapy for psoriatic arthritis treatment and as a monotherapy in maintaining remission of rheumatoid arthritis.",
		"modality" : "PrFc",
		"target" : "TNF",
		"current_phase" : "Post-Launch",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "etanercept",
		"indication_description" : "RHEUMATOID ARTHRITIS - MUSCULO-SKELETAL",
		"business_partner" : "Pfizer",
		"portfolio_priority" : "",
		"project_type" : "New Combination of a Marketed Active Substance"
	},
	{
		"amg_number" : "AMG 916",
		"product" : "Enbrel",
		"name" : "5109812.02",
		"trade_name" : "Enbrel",
		"notepad" : "",
		"modality" : "PrFc",
		"target" : "TNF",
		"current_phase" : "",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "etanercept",
		"indication_description" : "DEVICES AND FORMULATIONS",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Formulation \/ Delivery System for a Marketed Active Substance"
	},
	{
		"amg_number" : "AMG 925",
		"product" : "AMG 925",
		"name" : "5285048.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "SM",
		"target" : "CDK 4\/6",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "AMG 925",
		"indication_description" : "LEUKEMIA - ACUTE MYELOID (AML)",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 949",
		"product" : "AMG 949",
		"name" : "5160028.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "Pr",
		"target" : "Immx - FLT3L",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "AMG 949",
		"indication_description" : "CANCER - SOLID TUMORS",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 951",
		"product" : "dulanermin",
		"name" : "5161028.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "Pr",
		"target" : "Immx - TRAIL\/Apo2L",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "dulanermin",
		"indication_description" : "CANCER - SOLID TUMORS",
		"business_partner" : "Genentech",
		"portfolio_priority" : "",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 951",
		"product" : "dulanermin",
		"name" : "5161016.03",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "Pr",
		"target" : "Immx - TRAIL\/Apo2L",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "dulanermin",
		"indication_description" : "CANCER - COLORECTAL",
		"business_partner" : "Genentech",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 951",
		"product" : "dulanermin",
		"name" : "5161053.02",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "Pr",
		"target" : "Immx - TRAIL\/Apo2L",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "dulanermin",
		"indication_description" : "LYMPHOMA - NON HODGKINS",
		"business_partner" : "Genentech",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 951",
		"product" : "dulanermin",
		"name" : "5161020.04",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "Pr",
		"target" : "Immx - TRAIL\/Apo2L",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "dulanermin",
		"indication_description" : "CANCER - NON SMALL CELL LUNG",
		"business_partner" : "Genentech",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 951",
		"product" : "dulanermin",
		"name" : "5161016.05",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "Pr",
		"target" : "Immx - TRAIL\/Apo2L",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "dulanermin",
		"indication_description" : "CANCER - COLORECTAL",
		"business_partner" : "Genentech",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 951",
		"product" : "dulanermin",
		"name" : "5161020.06",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "Pr",
		"target" : "Immx - TRAIL\/Apo2L",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "dulanermin",
		"indication_description" : "CANCER - NON SMALL CELL LUNG",
		"business_partner" : "Genentech",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 951",
		"product" : "dulanermin",
		"name" : "5161110.07",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "Pr",
		"target" : "Immx - TRAIL\/Apo2L",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "dulanermin",
		"indication_description" : "CHONDRO SARCOMA",
		"business_partner" : "Roche",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 952",
		"product" : "AMG 952",
		"name" : "5162073.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "Pr",
		"target" : "Immx - IL-1R type II",
		"current_phase" : "",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "AMG 952",
		"indication_description" : "SARCOPENIA - IMMOBILIZATION",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 954",
		"product" : "Vectibix",
		"name" : "5112018.07",
		"trade_name" : "Vectibix",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "Immx - ABX-EGF",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "panitumumab",
		"indication_description" : "CANCER - HEAD AND NECK",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Formulation \/ Delivery System for a Marketed Active Substance"
	},
	{
		"amg_number" : "AMG 954",
		"product" : "Vectibix",
		"name" : "5112982.03",
		"trade_name" : "Vectibix",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "Immx - ABX-EGF",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "panitumumab",
		"indication_description" : "ONCOLOGY",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 954",
		"product" : "Vectibix",
		"name" : "5112029.08",
		"trade_name" : "Vectibix",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "Immx - ABX-EGF",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "panitumumab",
		"indication_description" : "CANCER - THYROID",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 954",
		"product" : "Vectibix",
		"name" : "5112016.11",
		"trade_name" : "Vectibix",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "Immx - ABX-EGF",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "panitumumab",
		"indication_description" : "CANCER - COLORECTAL",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 954",
		"product" : "Vectibix",
		"name" : "5112016.10",
		"trade_name" : "Vectibix",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "Immx - ABX-EGF",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "panitumumab",
		"indication_description" : "CANCER - COLORECTAL",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 954",
		"product" : "Vectibix",
		"name" : "5112018.09",
		"trade_name" : "Vectibix",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "Immx - ABX-EGF",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "panitumumab",
		"indication_description" : "CANCER - HEAD AND NECK",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 954",
		"product" : "Vectibix",
		"name" : "5112016.12",
		"trade_name" : "Vectibix",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "Immx - ABX-EGF",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "panitumumab",
		"indication_description" : "CANCER - COLORECTAL",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 954",
		"product" : "Vectibix",
		"name" : "5112016.04",
		"trade_name" : "Vectibix",
		"notepad" : "Vectibix® (panitumumab) is for treating patients with wild-type RAS metastatic colorectal cancer (cancer that has spread outside of the colon and rectum). RAS status is determined by an FDA-approved test. Wild-type RAS is a cancer without mutations in the KRAS and NRAS genes.",
		"modality" : "mAb",
		"target" : "Immx - ABX-EGF",
		"current_phase" : "Post-Launch",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "panitumumab",
		"indication_description" : "CANCER - COLORECTAL",
		"business_partner" : "Betta Pharma JV,Biocartis,Takeda",
		"portfolio_priority" : "Standard",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 954",
		"product" : "Vectibix",
		"name" : "5112020.02",
		"trade_name" : "Vectibix",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "Immx - ABX-EGF",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "panitumumab",
		"indication_description" : "CANCER - NON SMALL CELL LUNG",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 954",
		"product" : "Vectibix",
		"name" : "5112016.06",
		"trade_name" : "Vectibix",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "Immx - ABX-EGF",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "panitumumab",
		"indication_description" : "CANCER - COLORECTAL",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 954",
		"product" : "Vectibix",
		"name" : "5112016.05",
		"trade_name" : "Vectibix",
		"notepad" : "",
		"modality" : "mAb",
		"target" : "Immx - ABX-EGF",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "panitumumab",
		"indication_description" : "CANCER - COLORECTAL",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 966",
		"product" : "AMG 966",
		"name" : "5390031.03",
		"trade_name" : "",
		"notepad" : "AMG 966 is a monoclonal antibody being investigated for the treatment of inflammatory bowel diseases (Crohn’s disease and ulcerative colitis).",
		"modality" : "hIgG",
		"target" : "TL1A Ab",
		"current_phase" : "Phase 1",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "AMG 966",
		"indication_description" : "CROHN'S DISEASE",
		"business_partner" : "",
		"portfolio_priority" : "Close Out",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 978",
		"product" : "AMG 978",
		"name" : "5364001.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "SM",
		"target" : "BACE # 2",
		"current_phase" : "",
		"medical_therapeutic_area" : "Neuroscience",
		"generic_name" : "AMG 978",
		"indication_description" : "ALZHEIMER'S DISEASE",
		"business_partner" : "Novartis",
		"portfolio_priority" : "",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 981",
		"product" : "Kyprolis",
		"name" : "5340019.17",
		"trade_name" : "Kyprolis",
		"notepad" : "KYPROLIS® is a proteasome inhibitor. It is being investigated in a variety of combinations and patient populations for multiple myeloma (Phase 3)",
		"modality" : "SM",
		"target" : "proteasome 26S subunit; non-ATPase 14",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "carfilzomib",
		"indication_description" : "CANCER - MULTIPLE MYELOMA",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Dosage Form (Strength or Schedule)"
	},
	{
		"amg_number" : "AMG 981",
		"product" : "Kyprolis",
		"name" : "5340019.09",
		"trade_name" : "Kyprolis",
		"notepad" : "KYPROLIS® is a proteasome inhibitor. It is being investigated in a variety of combinations and patient populations for multiple myeloma (Phase 3)",
		"modality" : "SM",
		"target" : "proteasome 26S subunit; non-ATPase 14",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "carfilzomib",
		"indication_description" : "CANCER - MULTIPLE MYELOMA",
		"business_partner" : "Ono",
		"portfolio_priority" : "",
		"project_type" : "New Formulation \/ Delivery System for a Marketed Active Substance"
	},
	{
		"amg_number" : "AMG 981",
		"product" : "Kyprolis",
		"name" : "5340019.07",
		"trade_name" : "Kyprolis",
		"notepad" : "KYPROLIS® is a small molecule proteasome inhibitor (PI). It is being investigated in the CANDOR study in combination with dexamethasone and DARZALEX® (daratumumab) compared to KYPROLIS® and dexamethasone alone.;;ADDITIONAL INFORMATION;DARZALEX is a registered trademark of Janssen Biotech, Inc.",
		"modality" : "SM",
		"target" : "proteasome 26S subunit; non-ATPase 14",
		"current_phase" : "Post-Launch",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "carfilzomib",
		"indication_description" : "CANCER - MULTIPLE MYELOMA",
		"business_partner" : "Ono",
		"portfolio_priority" : "Standard",
		"project_type" : "New Combination of a Marketed Active Substance"
	},
	{
		"amg_number" : "AMG 981",
		"product" : "Kyprolis",
		"name" : "5340027.02",
		"trade_name" : "Kyprolis",
		"notepad" : "KYPROLIS® is a proteasome inhibitor. It is being investigated in a variety of combinations and patient populations for multiple myeloma (Phase 3)",
		"modality" : "SM",
		"target" : "proteasome 26S subunit; non-ATPase 14",
		"current_phase" : "Phase 2",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "carfilzomib",
		"indication_description" : "CANCER - SMALL CELL LUNG",
		"business_partner" : "Ono",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 981",
		"product" : "Kyprolis",
		"name" : "5340019.05",
		"trade_name" : "Kyprolis",
		"notepad" : "KYPROLIS® is a proteasome inhibitor. It is being investigated in a variety of combinations and patient populations for multiple myeloma (Phase 3)",
		"modality" : "SM",
		"target" : "proteasome 26S subunit; non-ATPase 14",
		"current_phase" : "Filing",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "carfilzomib",
		"indication_description" : "CANCER - MULTIPLE MYELOMA",
		"business_partner" : "Ono",
		"portfolio_priority" : "",
		"project_type" : "New Combination of a Marketed Active Substance"
	},
	{
		"amg_number" : "AMG 981",
		"product" : "Kyprolis",
		"name" : "5340019.08",
		"trade_name" : "Kyprolis",
		"notepad" : "KYPROLIS® is a proteasome inhibitor. It is being investigated in a variety of combinations and patient populations for multiple myeloma (Phase 3)",
		"modality" : "SM",
		"target" : "proteasome 26S subunit; non-ATPase 14",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "carfilzomib",
		"indication_description" : "CANCER - MULTIPLE MYELOMA",
		"business_partner" : "",
		"portfolio_priority" : "Close Out",
		"project_type" : "New Formulation \/ Delivery System for a Marketed Active Substance"
	},
	{
		"amg_number" : "AMG 981",
		"product" : "Kyprolis",
		"name" : "5340019.13",
		"trade_name" : "Kyprolis",
		"notepad" : "KYPROLIS® is a proteasome inhibitor. It is being investigated in a variety of combinations and patient populations for multiple myeloma (Phase 3)",
		"modality" : "SM",
		"target" : "proteasome 26S subunit; non-ATPase 14",
		"current_phase" : "Post-Launch",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "carfilzomib",
		"indication_description" : "CANCER - MULTIPLE MYELOMA",
		"business_partner" : "Ono",
		"portfolio_priority" : "",
		"project_type" : "New Combination of a Marketed Active Substance"
	},
	{
		"amg_number" : "AMG 981",
		"product" : "Kyprolis",
		"name" : "5340019.12",
		"trade_name" : "Kyprolis",
		"notepad" : "KYPROLIS® is a proteasome inhibitor. It is being investigated in a variety of combinations and patient populations for multiple myeloma (Phase 3)",
		"modality" : "SM",
		"target" : "proteasome 26S subunit; non-ATPase 14",
		"current_phase" : "Post-Launch",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "carfilzomib",
		"indication_description" : "CANCER - MULTIPLE MYELOMA",
		"business_partner" : "Ono",
		"portfolio_priority" : "",
		"project_type" : "New Combination of a Marketed Active Substance"
	},
	{
		"amg_number" : "AMG 981",
		"product" : "Kyprolis",
		"name" : "5340019.16",
		"trade_name" : "Kyprolis",
		"notepad" : "KYPROLIS® is a proteasome inhibitor. It is being investigated in a variety of combinations and patient populations for multiple myeloma (Phase 3)",
		"modality" : "SM",
		"target" : "proteasome 26S subunit; non-ATPase 14",
		"current_phase" : "Phase 3",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "carfilzomib",
		"indication_description" : "CANCER - MULTIPLE MYELOMA",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Combination of a Marketed Active Substance"
	},
	{
		"amg_number" : "AMG 981",
		"product" : "Kyprolis",
		"name" : "5340047.03",
		"trade_name" : "Kyprolis",
		"notepad" : "KYPROLIS is a small molecule proteasome inhibitor (PI). It is being investigated for acute lymphoblastic leukemia (ALL) in pediatric patients.",
		"modality" : "SM",
		"target" : "proteasome 26S subunit; non-ATPase 14",
		"current_phase" : "Phase 2",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "carfilzomib",
		"indication_description" : "LEUKEMIA - ACUTE LYMPHOBLASTIC (ALL)",
		"business_partner" : "Ono",
		"portfolio_priority" : "Standard",
		"project_type" : "New Patient Population"
	},
	{
		"amg_number" : "AMG 981",
		"product" : "Kyprolis",
		"name" : "5340900.06",
		"trade_name" : "Kyprolis",
		"notepad" : "",
		"modality" : "SM",
		"target" : "proteasome 26S subunit; non-ATPase 14",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "carfilzomib",
		"indication_description" : "GENERAL (NON-INDICATION SPECIFIC)",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 981",
		"product" : "Kyprolis",
		"name" : "5340019.11",
		"trade_name" : "Kyprolis",
		"notepad" : "KYPROLIS® is a proteasome inhibitor. It is being investigated in a variety of combinations and patient populations for multiple myeloma (Phase 3)",
		"modality" : "SM",
		"target" : "proteasome 26S subunit; non-ATPase 14",
		"current_phase" : "Phase 3",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "carfilzomib",
		"indication_description" : "CANCER - MULTIPLE MYELOMA",
		"business_partner" : "Ono",
		"portfolio_priority" : "",
		"project_type" : "New Combination of a Marketed Active Substance"
	},
	{
		"amg_number" : "AMG 981",
		"product" : "Kyprolis",
		"name" : "5340019.10",
		"trade_name" : "Kyprolis",
		"notepad" : "KYPROLIS® is a proteasome inhibitor. It is being investigated in a variety of combinations and patient populations for multiple myeloma (Phase 3)",
		"modality" : "SM",
		"target" : "proteasome 26S subunit; non-ATPase 14",
		"current_phase" : "Phase 3",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "carfilzomib",
		"indication_description" : "CANCER - MULTIPLE MYELOMA",
		"business_partner" : "Ono",
		"portfolio_priority" : "",
		"project_type" : "New Combination of a Marketed Active Substance"
	},
	{
		"amg_number" : "AMG 981",
		"product" : "Kyprolis",
		"name" : "5340019.15",
		"trade_name" : "Kyprolis",
		"notepad" : "KYPROLIS is a small molecule proteasome inhibitor (PI). It is being investigated for weekly dosing in combinations with lenalidomide and dexamethasone for the treatment of relapsed multiple myeloma.",
		"modality" : "SM",
		"target" : "proteasome 26S subunit; non-ATPase 14",
		"current_phase" : "Phase 3",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "carfilzomib",
		"indication_description" : "CANCER - MULTIPLE MYELOMA",
		"business_partner" : "Ono",
		"portfolio_priority" : "Standard",
		"project_type" : "New Dosage Form (Strength or Schedule)"
	},
	{
		"amg_number" : "AMG 981",
		"product" : "Kyprolis",
		"name" : "5340019.01",
		"trade_name" : "Kyprolis",
		"notepad" : "KYPROLIS® is a proteasome inhibitor (PI). KYPROLIS is approved for relapsed or refractory multiple myeloma (RRMM).  KYPROLIS is being investigated in a variety of combinations and patient populations for multiple myeloma and for Pediatric acute lymphoblastic leukemia (ALL).",
		"modality" : "SM",
		"target" : "proteasome 26S subunit; non-ATPase 14",
		"current_phase" : "Post-Launch",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "carfilzomib",
		"indication_description" : "CANCER - MULTIPLE MYELOMA",
		"business_partner" : "Ono",
		"portfolio_priority" : "Standard",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 981",
		"product" : "Kyprolis",
		"name" : "5340019.14",
		"trade_name" : "Kyprolis",
		"notepad" : "KYPROLIS® is a proteasome inhibitor. It is being investigated in a variety of combinations and patient populations for multiple myeloma (Phase 3)",
		"modality" : "SM",
		"target" : "proteasome 26S subunit; non-ATPase 14",
		"current_phase" : "Phase 3",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "carfilzomib",
		"indication_description" : "CANCER - MULTIPLE MYELOMA",
		"business_partner" : "Ono",
		"portfolio_priority" : "",
		"project_type" : "New Combination of a Marketed Active Substance"
	},
	{
		"amg_number" : "AMG 981",
		"product" : "Kyprolis",
		"name" : "5340019.06",
		"trade_name" : "Kyprolis",
		"notepad" : "KYPROLIS® is a proteasome inhibitor (PI). KYPROLIS is approved for relapsed or refractory multiple myeloma (RRMM).  KYPROLIS is being investigated in a variety of combinations and patient populations for multiple myeloma and for Pediatric acute lymphoblastic leukemia (ALL).",
		"modality" : "SM",
		"target" : "proteasome 26S subunit; non-ATPase 14",
		"current_phase" : "Post-Launch",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "carfilzomib",
		"indication_description" : "CANCER - MULTIPLE MYELOMA",
		"business_partner" : "Ono",
		"portfolio_priority" : "Standard",
		"project_type" : "New Combination of a Marketed Active Substance"
	},
	{
		"amg_number" : "AMG 982",
		"product" : "oprozomib",
		"name" : "5341900.05",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "Pep",
		"target" : "Proteasome Inhibitor",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "oprozomib",
		"indication_description" : "GENERAL (NON-INDICATION SPECIFIC)",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 982",
		"product" : "oprozomib",
		"name" : "5341019.03",
		"trade_name" : "",
		"notepad" : "TRANSITION TO DISCONTINUED - Oprozomib is an oral proteasome inhibitor. It is being investigated for the treatment of multiple myeloma.",
		"modality" : "Pep",
		"target" : "Proteasome Inhibitor",
		"current_phase" : "Preclinical",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "oprozomib",
		"indication_description" : "CANCER - MULTIPLE MYELOMA",
		"business_partner" : "",
		"portfolio_priority" : "Close Out",
		"project_type" : "New Patient Population"
	},
	{
		"amg_number" : "AMG 982",
		"product" : "oprozomib",
		"name" : "5341019.01",
		"trade_name" : "",
		"notepad" : "TRANSITION TO DISCONTINUED - Oprozomib is an oral proteasome inhibitor. It is being investigated for the treatment of multiple myeloma.",
		"modality" : "Pep",
		"target" : "Proteasome Inhibitor",
		"current_phase" : "Phase 1",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "oprozomib",
		"indication_description" : "CANCER - MULTIPLE MYELOMA",
		"business_partner" : "Ono",
		"portfolio_priority" : "Close Out",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 982",
		"product" : "oprozomib",
		"name" : "5341053.02",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "Pep",
		"target" : "Proteasome Inhibitor",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "oprozomib",
		"indication_description" : "LYMPHOMA - NON HODGKINS",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 982",
		"product" : "oprozomib",
		"name" : "5341053.04",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "Pep",
		"target" : "Proteasome Inhibitor",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "oprozomib",
		"indication_description" : "LYMPHOMA - NON HODGKINS",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 982",
		"product" : "oprozomib",
		"name" : "5341019.02",
		"trade_name" : "",
		"notepad" : "TRANSITION TO DISCONTINUED - Oprozomib is an oral proteasome inhibitor. It is being investigated for the treatment of multiple myeloma.",
		"modality" : "Pep",
		"target" : "Proteasome Inhibitor",
		"current_phase" : "Preclinical",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "oprozomib",
		"indication_description" : "CANCER - MULTIPLE MYELOMA",
		"business_partner" : "",
		"portfolio_priority" : "Close Out",
		"project_type" : "New Patient Population"
	},
	{
		"amg_number" : "AMG 982",
		"product" : "oprozomib",
		"name" : "5341094.03",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "Pep",
		"target" : "Proteasome Inhibitor",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "oprozomib",
		"indication_description" : "CANCER - HEPATOCELLULAR CARCINOMA",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 983",
		"product" : "Nexavar",
		"name" : "5342025.02",
		"trade_name" : "Nexavar",
		"notepad" : "",
		"modality" : "SM",
		"target" : "Tyrosine kinase inhibitor",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "sorafenib",
		"indication_description" : "CANCER - RENAL CELL",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 983",
		"product" : "Nexavar",
		"name" : "5342015.01",
		"trade_name" : "Nexavar",
		"notepad" : "",
		"modality" : "SM",
		"target" : "Tyrosine kinase inhibitor",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "sorafenib",
		"indication_description" : "CANCER - BREAST",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 983",
		"product" : "Nexavar",
		"name" : "5342094.04",
		"trade_name" : "Nexavar",
		"notepad" : "",
		"modality" : "SM",
		"target" : "Tyrosine kinase inhibitor",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "sorafenib",
		"indication_description" : "CANCER - HEPATOCELLULAR CARCINOMA",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 983",
		"product" : "Nexavar",
		"name" : "5342029.03",
		"trade_name" : "Nexavar",
		"notepad" : "",
		"modality" : "SM",
		"target" : "Tyrosine kinase inhibitor",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "sorafenib",
		"indication_description" : "CANCER - THYROID",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 984",
		"product" : "Stivarga",
		"name" : "5343016.01",
		"trade_name" : "Stivarga",
		"notepad" : "",
		"modality" : "SM",
		"target" : "Protein Kinases",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "regorafenib",
		"indication_description" : "CANCER - COLORECTAL",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 984",
		"product" : "Stivarga",
		"name" : "5343017.02",
		"trade_name" : "Stivarga",
		"notepad" : "",
		"modality" : "SM",
		"target" : "Protein Kinases",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "regorafenib",
		"indication_description" : "CANCER - GASTROINTESTINAL STROMAL TUMORS",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 985",
		"product" : "AMG 985",
		"name" : "5345022.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "Pep",
		"target" : "Alpha-Folate",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "AMG 985",
		"indication_description" : "CANCER - OVARIAN",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 986",
		"product" : "AMG 986",
		"name" : "5377101.01",
		"trade_name" : "",
		"notepad" : "AMG 986 is a small molecule agonist of the Apelin receptor (APJ). It is being investigated for the treatment of heart failure.",
		"modality" : "SM",
		"target" : "Apelin\/APJ Agonist SM",
		"current_phase" : "Phase 1",
		"medical_therapeutic_area" : "Cardiovascular",
		"generic_name" : "AMG 986",
		"indication_description" : "HEART FAILURE",
		"business_partner" : "",
		"portfolio_priority" : "Close Out",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 992",
		"product" : "AMG 992",
		"name" : "5431984.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "ePrFc",
		"target" : "IL-2 Mutein",
		"current_phase" : "",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "AMG 992",
		"indication_description" : "INFLAMMATION",
		"business_partner" : "",
		"portfolio_priority" : "Gated",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 994",
		"product" : "AMG 994",
		"name" : "5430028.01",
		"trade_name" : "",
		"notepad" : "AMG 994 is a bispecific antibody. It is being investigated for the treatment of non-small cell lung cancer, mesothelioma, pancreatic cancer and ovarian cancer.",
		"modality" : "AbFrab",
		"target" : "CD40-MSLN",
		"current_phase" : "Phase 1",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "AMG 994",
		"indication_description" : "CANCER - SOLID TUMORS",
		"business_partner" : "",
		"portfolio_priority" : "Standard",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG 998",
		"product" : "Corlanor",
		"name" : "5324900.01",
		"trade_name" : "Corlanor",
		"notepad" : "",
		"modality" : "SM",
		"target" : "If Ion Current",
		"current_phase" : "",
		"medical_therapeutic_area" : "Cardiovascular",
		"generic_name" : "ivabradine",
		"indication_description" : "GENERAL (NON-INDICATION SPECIFIC)",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 998",
		"product" : "Corlanor",
		"name" : "5324007.02",
		"trade_name" : "Corlanor",
		"notepad" : "",
		"modality" : "SM",
		"target" : "If Ion Current",
		"current_phase" : "",
		"medical_therapeutic_area" : "Cardiovascular",
		"generic_name" : "ivabradine",
		"indication_description" : "ANEMIA - HEART FAILURE",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG 998",
		"product" : "Corlanor",
		"name" : "5324101.03",
		"trade_name" : "Corlanor",
		"notepad" : "Corlanor® is a prescription medicine that is used to reduce the risk of hospitalization due to worsening heart failure. Corlanor® is used in certain people who have persistent (chronic) heart failure caused by the lower-left part of their heart not contracting well.",
		"modality" : "SM",
		"target" : "If Ion Current",
		"current_phase" : "Post-Launch",
		"medical_therapeutic_area" : "Cardiovascular",
		"generic_name" : "ivabradine",
		"indication_description" : "HEART FAILURE",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG_5168",
		"product" : "AMG_5168",
		"name" : "5168060.06",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "",
		"target" : "",
		"current_phase" : "",
		"medical_therapeutic_area" : "Metabolic Disorders",
		"generic_name" : "",
		"indication_description" : "OBESITY",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG_5168",
		"product" : "AMG_5168",
		"name" : "5168060.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "",
		"target" : "",
		"current_phase" : "",
		"medical_therapeutic_area" : "Metabolic Disorders",
		"generic_name" : "",
		"indication_description" : "OBESITY",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AMG_5168",
		"product" : "AMG_5168",
		"name" : "5168060.04",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "",
		"target" : "",
		"current_phase" : "",
		"medical_therapeutic_area" : "Metabolic Disorders",
		"generic_name" : "",
		"indication_description" : "OBESITY",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG_5168",
		"product" : "AMG_5168",
		"name" : "5168060.03",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "",
		"target" : "",
		"current_phase" : "",
		"medical_therapeutic_area" : "Metabolic Disorders",
		"generic_name" : "",
		"indication_description" : "OBESITY",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG_5168",
		"product" : "AMG_5168",
		"name" : "5168060.02",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "",
		"target" : "",
		"current_phase" : "",
		"medical_therapeutic_area" : "Metabolic Disorders",
		"generic_name" : "",
		"indication_description" : "OBESITY",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AMG_5168",
		"product" : "AMG_5168",
		"name" : "5168060.05",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "",
		"target" : "",
		"current_phase" : "",
		"medical_therapeutic_area" : "Metabolic Disorders",
		"generic_name" : "",
		"indication_description" : "OBESITY",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "AXP 1001",
		"product" : "Acetato de ciproterona",
		"name" : "5330024.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "SM",
		"target" : "",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "cyproterone acetate",
		"indication_description" : "CANCER - PROSTATE",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : ""
	},
	{
		"amg_number" : "AXP 1002",
		"product" : "Acetato de desmopressina",
		"name" : "5335900.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "SM",
		"target" : "",
		"current_phase" : "",
		"medical_therapeutic_area" : "Metabolic Disorders",
		"generic_name" : "desmopressin acetate",
		"indication_description" : "GENERAL (NON-INDICATION SPECIFIC)",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AXP 1003",
		"product" : "Botulift",
		"name" : "5346900.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "Pr",
		"target" : "",
		"current_phase" : "",
		"medical_therapeutic_area" : "Neuroscience",
		"generic_name" : "botulinum toxin type a",
		"indication_description" : "GENERAL (NON-INDICATION SPECIFIC)",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : ""
	},
	{
		"amg_number" : "AXP 1004",
		"product" : "Femigestrol",
		"name" : "5337015.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "SM",
		"target" : "",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "megestrol acetate",
		"indication_description" : "CANCER - BREAST",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : ""
	},
	{
		"amg_number" : "AXP 1005",
		"product" : "Gonadopin",
		"name" : "5332900.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "Pr",
		"target" : "",
		"current_phase" : "",
		"medical_therapeutic_area" : "Exploratory",
		"generic_name" : "follitropin alfa",
		"indication_description" : "GENERAL (NON-INDICATION SPECIFIC)",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : ""
	},
	{
		"amg_number" : "AXP 1006",
		"product" : "Hormotrop",
		"name" : "5292985.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "Pr",
		"target" : "",
		"current_phase" : "",
		"medical_therapeutic_area" : "Metabolic Disorders",
		"generic_name" : "somatropin",
		"indication_description" : "METABOLIC DISORDERS",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : ""
	},
	{
		"amg_number" : "AXP 1007",
		"product" : "Lorelin",
		"name" : "5295900.02",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "SM",
		"target" : "",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "leuprorelin acetate",
		"indication_description" : "GENERAL (NON-INDICATION SPECIFIC)",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : ""
	},
	{
		"amg_number" : "AXP 1007",
		"product" : "Lorelin",
		"name" : "5295034.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "SM",
		"target" : "",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "leuprorelin acetate",
		"indication_description" : "ENDOMETRIOSIS",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : ""
	},
	{
		"amg_number" : "AXP 1008",
		"product" : "Plaquemax",
		"name" : "5336059.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "Pr",
		"target" : "",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "oprelvekine",
		"indication_description" : "NEUTROPENIA - CHEMOTHERAPY INDUCED",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : ""
	},
	{
		"amg_number" : "AXP 1009",
		"product" : "Seacalcit",
		"name" : "5331062.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "SM",
		"target" : "",
		"current_phase" : "",
		"medical_therapeutic_area" : "Bone",
		"generic_name" : "salmon calcitonin",
		"indication_description" : "OSTEOPOROSIS",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : ""
	},
	{
		"amg_number" : "AXP 1010",
		"product" : "Solupren",
		"name" : "5327984.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "SM",
		"target" : "",
		"current_phase" : "",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "methylprednisone sodium succinate",
		"indication_description" : "INFLAMMATION",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : ""
	},
	{
		"amg_number" : "AXP 1011",
		"product" : "Solustrep",
		"name" : "5333900.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "Pr",
		"target" : "",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "streptokinase",
		"indication_description" : "GENERAL (NON-INDICATION SPECIFIC)",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : ""
	},
	{
		"amg_number" : "AXP 1012",
		"product" : "Hemoprex",
		"name" : "5329001.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "SM",
		"target" : "",
		"current_phase" : "",
		"medical_therapeutic_area" : "Neuroscience",
		"generic_name" : "rivastigmine tartrate",
		"indication_description" : "ALZHEIMER'S DISEASE",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : ""
	},
	{
		"amg_number" : "AXP 1013",
		"product" : "Inofungin",
		"name" : "5356900.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "SM",
		"target" : "",
		"current_phase" : "",
		"medical_therapeutic_area" : "Exploratory",
		"generic_name" : "nystatin",
		"indication_description" : "GENERAL (NON-INDICATION SPECIFIC)",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : ""
	},
	{
		"amg_number" : "AXP 1014",
		"product" : "Cefalexina",
		"name" : "5294900.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "SM",
		"target" : "",
		"current_phase" : "",
		"medical_therapeutic_area" : "Exploratory",
		"generic_name" : "cephalexin monohydrate",
		"indication_description" : "GENERAL (NON-INDICATION SPECIFIC)",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : ""
	},
	{
		"amg_number" : "AXP 1015",
		"product" : "Citoplax",
		"name" : "5347900.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "SM",
		"target" : "",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "cisplatin",
		"indication_description" : "GENERAL (NON-INDICATION SPECIFIC)",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : ""
	},
	{
		"amg_number" : "AXP 1016",
		"product" : "Dacarbazina",
		"name" : "5339095.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "SM",
		"target" : "",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "dacarbazine",
		"indication_description" : "CANCER - MELANOMA",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : ""
	},
	{
		"amg_number" : "AXP 1017",
		"product" : "Fluoruracila",
		"name" : "5338900.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "SM",
		"target" : "",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "fluorouracil",
		"indication_description" : "GENERAL (NON-INDICATION SPECIFIC)",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : ""
	},
	{
		"amg_number" : "AXP 1018",
		"product" : "Nuovodox",
		"name" : "5334900.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "SM",
		"target" : "",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "epirubicin hydrochloride",
		"indication_description" : "GENERAL (NON-INDICATION SPECIFIC)",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : ""
	},
	{
		"amg_number" : "AXP 1020",
		"product" : "TAXILAN",
		"name" : "5348900.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "SM",
		"target" : "",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "paclitaxel",
		"indication_description" : "GENERAL (NON-INDICATION SPECIFIC)",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : ""
	},
	{
		"amg_number" : "AXP 1021",
		"product" : "Trebyxan",
		"name" : "5359900.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "SM",
		"target" : "",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "irinotecan hydrochloride trihydrate",
		"indication_description" : "GENERAL (NON-INDICATION SPECIFIC)",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : ""
	},
	{
		"amg_number" : "AXP 1022",
		"product" : "Gencix",
		"name" : "5354900.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "SM",
		"target" : "",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "gemcitabine hydrochloride",
		"indication_description" : "GENERAL (NON-INDICATION SPECIFIC)",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : ""
	},
	{
		"amg_number" : "AXP 1038",
		"product" : "Actiparin",
		"name" : "5293981.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "Pr",
		"target" : "",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "heparin sodium",
		"indication_description" : "EXPLORATORY",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : ""
	},
	{
		"amg_number" : "AXP 1039",
		"product" : "Hemoprex",
		"name" : "5355006.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "Pr",
		"target" : "",
		"current_phase" : "",
		"medical_therapeutic_area" : "Nephrology",
		"generic_name" : "epoetin alfa biosimilar",
		"indication_description" : "ANEMIA - CHRONIC RENAL FAILURE",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : ""
	},
	{
		"amg_number" : "AXP 1040",
		"product" : "Pamigraf",
		"name" : "5358900.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "SM",
		"target" : "",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "lopamidol",
		"indication_description" : "GENERAL (NON-INDICATION SPECIFIC)",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : ""
	},
	{
		"amg_number" : "AXP 1041",
		"product" : "Zydena",
		"name" : "5360900.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "SM",
		"target" : "",
		"current_phase" : "",
		"medical_therapeutic_area" : "Exploratory",
		"generic_name" : "udenafila",
		"indication_description" : "GENERAL (NON-INDICATION SPECIFIC)",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : ""
	},
	{
		"amg_number" : "AXP 1042",
		"product" : "Myograf",
		"name" : "5357900.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "Pr",
		"target" : "G-CSF",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "filgrastim biosimilar",
		"indication_description" : "GENERAL (NON-INDICATION SPECIFIC)",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : ""
	},
	{
		"amg_number" : "AXP 1043",
		"product" : "Capecitabine",
		"name" : "5366015.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "SM",
		"target" : "",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "capecitabine",
		"indication_description" : "CANCER - BREAST",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : ""
	},
	{
		"amg_number" : "AXP 1043",
		"product" : "Capecitabine",
		"name" : "5366016.02",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "SM",
		"target" : "",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "capecitabine",
		"indication_description" : "CANCER - COLORECTAL",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : ""
	},
	{
		"amg_number" : "AXP 1043",
		"product" : "Capecitabine",
		"name" : "5366082.03",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "SM",
		"target" : "",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "capecitabine",
		"indication_description" : "CANCER - GASTRIC",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : ""
	},
	{
		"amg_number" : "AXP 1044",
		"product" : "Erlotinib Hydrochloride",
		"name" : "5367023.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "SM",
		"target" : "",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "erlotinib hydrochloride",
		"indication_description" : "CANCER - PANCREAS",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : ""
	},
	{
		"amg_number" : "AXP 1044",
		"product" : "Erlotinib Hydrochloride",
		"name" : "5367027.02",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "SM",
		"target" : "",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "erlotinib hydrochloride",
		"indication_description" : "CANCER - SMALL CELL LUNG",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : ""
	},
	{
		"amg_number" : "AXP 1045",
		"product" : "Cabergoline",
		"name" : "5368900.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "SM",
		"target" : "",
		"current_phase" : "",
		"medical_therapeutic_area" : "Exploratory",
		"generic_name" : "cabergoline",
		"indication_description" : "GENERAL (NON-INDICATION SPECIFIC)",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : ""
	},
	{
		"amg_number" : "AXP 1046",
		"product" : "Oncoplatin",
		"name" : "5369900.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "SM",
		"target" : "",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "carboplatin",
		"indication_description" : "GENERAL (NON-INDICATION SPECIFIC)",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : ""
	},
	{
		"amg_number" : "AXP 1046",
		"product" : "Oncoplatin",
		"name" : "5369022.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "SM",
		"target" : "",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "carboplatin",
		"indication_description" : "CANCER - OVARIAN",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "AXP 1047",
		"product" : "Cloridrato de remifentanila",
		"name" : "5371900.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "SM",
		"target" : "",
		"current_phase" : "",
		"medical_therapeutic_area" : "Neuroscience",
		"generic_name" : "remifentanil hydrochloride",
		"indication_description" : "GENERAL (NON-INDICATION SPECIFIC)",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : ""
	},
	{
		"amg_number" : "AXP 1048",
		"product" : "Decitabina",
		"name" : "5372057.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "SM",
		"target" : "",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "decitabine",
		"indication_description" : "MYELODYSPLASTIC SYNDROME (MDS)",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : ""
	},
	{
		"amg_number" : "AXP 1049",
		"product" : "Leucin",
		"name" : "5373059.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "Pr",
		"target" : "G-CSF",
		"current_phase" : "",
		"medical_therapeutic_area" : "Hematology\/Oncology",
		"generic_name" : "filgrastim biosimilar",
		"indication_description" : "NEUTROPENIA - CHEMOTHERAPY INDUCED",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : ""
	},
	{
		"amg_number" : "AXP 1050",
		"product" : "Bromovent",
		"name" : "5374030.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "SM",
		"target" : "",
		"current_phase" : "",
		"medical_therapeutic_area" : "Inflammation",
		"generic_name" : "ipratropium bromide",
		"indication_description" : "CHRONIC OBSTRUCTIVE PULMONARY DISEASE",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : ""
	},
	{
		"amg_number" : "AXP 1051",
		"product" : "Fideine",
		"name" : "5375988.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "SM",
		"target" : "",
		"current_phase" : "",
		"medical_therapeutic_area" : "Metabolic Disorders",
		"generic_name" : "bisacodyl",
		"indication_description" : "LAXATIVE",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : ""
	},
	{
		"amg_number" : "Non-Product 5020",
		"product" : "Non-Product 5020",
		"name" : "5020900.02",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "",
		"target" : "",
		"current_phase" : "",
		"medical_therapeutic_area" : "Non-Product",
		"generic_name" : "Non-Product 5020",
		"indication_description" : "GENERAL (NON-INDICATION SPECIFIC)",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Route of Administration "
	},
	{
		"amg_number" : "Non-Product 5020",
		"product" : "Non-Product 5020",
		"name" : "5020900.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "",
		"target" : "",
		"current_phase" : "",
		"medical_therapeutic_area" : "Non-Product",
		"generic_name" : "Non-Product 5020",
		"indication_description" : "GENERAL (NON-INDICATION SPECIFIC)",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Route of Administration "
	},
	{
		"amg_number" : "Phase 0",
		"product" : "phase 0 – exploratory",
		"name" : "5999986.04",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "",
		"target" : "",
		"current_phase" : "",
		"medical_therapeutic_area" : "Exploratory",
		"generic_name" : "phase 0 – exploratory",
		"indication_description" : "NEUROSCIENCE",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "Phase 0",
		"product" : "phase 0 – exploratory",
		"name" : "5999984.03",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "",
		"target" : "",
		"current_phase" : "",
		"medical_therapeutic_area" : "Exploratory",
		"generic_name" : "phase 0 – exploratory",
		"indication_description" : "INFLAMMATION",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	},
	{
		"amg_number" : "Phase 0",
		"product" : "phase 0 – exploratory",
		"name" : "5999900.01",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "",
		"target" : "",
		"current_phase" : "",
		"medical_therapeutic_area" : "Exploratory",
		"generic_name" : "phase 0 – exploratory",
		"indication_description" : "GENERAL (NON-INDICATION SPECIFIC)",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "Lead"
	},
	{
		"amg_number" : "Phase 0",
		"product" : "phase 0 – exploratory",
		"name" : "5999982.02",
		"trade_name" : "",
		"notepad" : "",
		"modality" : "",
		"target" : "",
		"current_phase" : "",
		"medical_therapeutic_area" : "Exploratory",
		"generic_name" : "phase 0 – exploratory",
		"indication_description" : "ONCOLOGY",
		"business_partner" : "",
		"portfolio_priority" : "",
		"project_type" : "New Indication \/ Disease State"
	}
]
